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Summary
Asthma is a chronic inflammatory disease of the airways and viral infections account for 
the majority of exacerbations and may play a role in its pathogenesis. Bradykinin levels 
are increased in the lungs of asthmatics and inhaled bradykinin produces 
bronchoconstriction in asthmatic but not in normal patients. In this study, guinea-pigs 
were inoculated with parainfluenza and influenza virus to establish airways inflammation 
and hyperreactivity. The role of bradykinin in the parainfluenza model was examined by 
using the tissue kallikrein inhibitor, FE999024, and the bradykinin B2 receptor antagonist, 
MEN16132. Firstly, the effects of bradykinin inhalation in conscious guinea-pigs were 
characterized by using inhibitors of its breakdown and selective antagonists. Inhaled 
bradykinin produced a bronchoconstriction only after treatment with the inhibitors of 
angiotensin converting enzyme and/or neutral endopeptidase, captopril and 
phosphoramidon respectively. Inhaled bradykinin also increased inflammatory cell influx 
to the lungs when its breakdown was inhibited with both drugs. Cell influx and 
bronchoconstriction were blocked by the B2 receptor antagonists icatibant and 
MEN16132. These responses were therefore B2 receptor-mediated. In ovalbumin 
sensitized guinea-pigs, inhaled ovalbumin produced early and late asthmatic responses, 
inflammatory cell influx and airway hyperreactivity to histamine. These were inhibited 
by dexamethasone. Bradykinin caused bronchoconstriction without using metabolism 
inhibitors, indicating airways hyperreactivity to bradykinin. Parainfluenza-3 and 
influenza caused inflammatory cell influx and airways hyperreactivity to histamine.
These were inhibited by FE999024, MEN16132 and dexamethasone. Parainfluenza-3 
virus inoculated into sensitized guinea-pigs exacerbated the response to inhaled
ovalbumin, with a prolonged bronchconstriction replacing early and late phases. This was 
resistant to dexamethasone. This study supports a role for bradykinin in virus-induced 
lung inflammation and the use of inhibitors of bradykinin for potential treatment of 
airway inflammation.
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Chapter 1
Introduction
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1.1 Asthma
Asthma is a chronic inflammatory disease of the airways. It is characterized by bronchial 
hyperresponsiveness, an influx of inflammatory cells, epithelial cells damage and 
bronchiolar fibrosis (Cohn et al 2005).
1.2 Clinical Categories
Atopic asthma is triggered by allergens and is usually diagnosed early in life. Atopic 
asthma is caused by an inappropriate Immunoglobulin-E (Ig-E)-mediated immune 
response in certain individuals (Lopez and Salvaggio 1987). Non-atopic asthma is caused 
by respiratory infection, exercise and drugs including aspirin and develops later in life. In 
non-atopic asthma there is no antibody or hyper-sensitivity reaction and IgE levels are 
normal. There is a third type of asthma caused by exposure to specific proteins or small 
chemicals at work and is called occupational asthma.
13 Inflammation
Asthma is a complex inflammatory disease of the airway which involves the release of a 
wide range of inflammatory mediators from a wide range of inflammatory and structural 
cells. Subjects who suffer from atopic or allergic asthma become sensitive to a specific 
allergen. When they are subsequently exposed to that allergen, asthmatic symptoms will 
occur. Sensitization occurs when allergens, such as those associated with house dust 
mites or pollens, are recognized by antigen presenting cells (APCs), such as 
macrophages, B cells and dentritic cells. IgE on the surface of APCs binds the antigen 
and causes it to be internalized by endocytosis. The antigen is processed and then
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transferred to the cell surface as membrane bound histocompatibility complex class II 
(Banchereau and Steinman, 1998). The antigen is recognised by naive T cells which are 
activated and differentiate into T helper type 1 (Thl) or T helper type 2 (Th2) cells. This 
differentiation is triggered by interleukin (IL)-2 which is released from nai've T cells. IL-2 
has an autocrine function, causing proliferation of the cells that release it, giving rise to a 
clone of activated T cells. Whether T cells become Thl or Th2 is dependent upon the 
presence of cytokines IL-12 and IL-4, respectively (Romagnani 1997). Thl cells are 
responsible for killing intracellular parasites and are involved in autoimmune responses 
(Berger 2000). They secrete macrophage-activating cytokines and other cytokines such as 
interferon (IFN)-y activate cluster of differentiation (CD)8 + T cells to become cytotoxic 
cells (Tc) that kill virally infected host cells. IFN-y derived from Thl cells inhibits Th2 
cell function. Th2 cells are responsible for the development of antibody-mediated 
immune responses. Th2 cells cooperate with and activate B cells to proliferate and give 
rise to memory B cells (MB) and plasma cells (P) that secrete antibody and IL-4 from 
Th2 cells inhibit Thl cell function. Antigen is taken in and processed by APCs, such as 
dendritic cells, that migrate to the lymph nodes and present antigen to the naive T helper 
cells which are activated to Th2 cells (Fig. 1.1). These then release cytokines IL-4 and II- 
13 which stimulate the production of allergen-specific IgE from B cells. These then bind 
to the surface of mast cells. IL-4 also induces the expression of high affinity allergen- 
specific IgE receptors (FceRI) on the surface of mast cells. Monovalent binding of IgE 
causes increased FceRI expression, increases mast cell resistance to apoptosis and can 
induce cytokine release (Knol 2006). Binding of the allergen-specific IgE to these
3
receptors marks the establishment of sensitization -  subsequent exposure to that allergen 
leads to the allergic response.
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Figure 1.1
The allergic cascade in asthma: a Th2-immune response. Eosinophil cationic protein 
(ECP). Taken from Hendeles et al (2004).
There are two phases of the allergic response to allergen exposure -  the immediate or 
early asthmatic response (EAR) and the late asthmatic response (LAR) which occurs 
about 7 hours later (Fig. 1.2). These responses arise as a result of re-exposure to the 
allergen which binds to the membrane-bound IgE on sensitized mast cells or basophils. 
The bound IgE interact and cross-link with the IgE that bound to the mast cell during the
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sensitization phase. Cross-linking of bound IgE leads to clustering of surface receptors 
which promotes a cascade of tyrosine phosphorylation resulting in activation of 
phospholipase Cy and mast cell degranulation (Knol, 2006). The mast cell releases a wide 
range of inflammatory mediators, including histamine, tryptase, prostaglandins, 
leukotrienes and cytokines. The histamine release mainly explains the EAR since it acts 
locally on airways smooth muscle to cause contraction and bronchoconstriction. IL-5 
released from mast cells and from activated Th2 cells during the sensitization process 
recruits eosinophils and activates them to release mediators of inflammation and 
bronchospasm, including leukotrienes. They also release eosinophilic cationic protein and 
major basic protein (MBP) which may cause epithelial damage and thereby promote 
airways hyperreactivity (see later). Eosinophils also release fibrinolytic growth factors 
and matrix metalloproteinases (MMPs) which are involved in airways remodelling in 
asthma (Elias et al 1999). IL-4 also enhances the migration of eosinophils from the blood 
to the lungs via upregulation of endothelial vascular-cell adhesion molecule expression 
(VCAM-1). The LAR is caused by the attraction of inflammatory cells such as 
macrophages, eosinophils, lymphocytes and neutrophils into the lungs where they release 
mediators to cause bronchoconstriction (leukotrienes), bronchoconstriction and 
vasodilatation and vascular leakage of protein to cause oedema (Durham and Kay 1985).
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Figure 1.2
Induction of the immediate or early and late asthmatic responses after allergen challenge 
in atopic asthma. Major basic protein (MBP); eosinophil cationic protein (ECP); allergen 
(Ag). (From Biaze et al 2003).
1.4 N eurogenic inflam m ation
Inflammatory mediators such as bradykinin, histamine and prostaglandins released from 
mast cells act on sensory nerve endings to release the neuropeptides substance P (SP), 
neurokinin (NK) A and calcitonin gene-related peptide (CGRP) (Fig 1.3.) (Maggi 1991). 
These peptides exert inflammatory effects and the process is therefore referred to as 
neurogenic inflammation. They interact with tachykinin receptors which are classified as
NKi, NK2 and NK3 receptors (Brain and Cox 2006). The rank orders o f potency for the 
naturally occurring neuropeptides are SP>NKA>NKB for NKi receptors, 
NKA>NKB>SP for NK2  receptors and NKB>NKA>SP for NK3 receptors (Alexander et
6
al 2009). SP and NKA cause raised vascular permeability (NKi receptors), vasodilatation 
(NKi receptors), bronchconstriction (NK2 receptors), mast cell degranulation, 
inflammatory cell recruitment, and mucus secretion (NKI receptors) (Maggi 1991). The 
epithelial shedding that occurs in asthma exposes the sensory neurones to the excitation 
by inflammatory mediators. Neurokinin antagonists have now been developed but are not 
currently used in the treatment of asthma, because they do not show sufficient efficacy.
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Figure 1.3
Neurogenic inflammation. Release of neuropeptides from sensory nerve endings.
1.5 Cells and mediators in asthma pathology
Mast cells
The numbers of mast cells in the bronchoalveolar lavage fluid of asthmatics is up to six­
fold higher than in non-asthmatics (Hamid et al 2003).The fraction of mast cells that 
produce cytokines IL-4, IL-5 and tumour necrosis factor (TNF)-a is also increased in
7
asthmatics (Bradding et al 1994). The cytoplasmic granules of mast cells contain 
mediators o f the asthmatic response, including histamine, tryptase, prostaglandin D2 and 
leukotrienes C4 . Degranulation by the binding of allergen to the allergen-specific IgE 
bound to the mast cell releases these mediators to trigger the inflammatory cascade and 
bronchoconstriction, increased vascular permeability and leukocyte influx and activation. 
Also contained in mast cells is the glycosaminoglycan, heparin (Rose and Page 2004). 
There is clinical and experimental evidence that unfractioned and low molecular weight 
heparins may be benefical in airway inflammation (Diamant and Page 2000). The anionic 
nature of heparin allows rapid and spontaneous binding to cationic proteins (Motojima et 
al 1989), potentially neutralising the effects of damaging cationic species within the lung 
(Diamant and Page 2000). Heparin can bind to, and inhibit the effect of, a number of 
cytotoxic eosinophil-specific granule proteins including major basic protein, eosinophil 
cationic protein, and eosinophil peroxidase (Nilsson et al 1995). Heparin has been shown 
to affect various aspects of the immune response such as neutrophil chemotaxis and 
lymphocyte trafficking (Sy et al 1983). In clinical studies, heparin pre-exposure 
significantly reduced bronchoconstriction in asthmatic patients resulting from exposure to 
house dust mite (Bowler et al 1993) and exercise (Ahmed et al 1993).
Eosinophils
Eosinophils are involved in defence against parasites but the role they are most 
commonly associated with is in allergic disease and asthma. Eosinophilic infiltration of 
the lung is a characteristic of asthma and eosinophilic count is useful for regulating 
steroid dosage (Horn et al 1975). Eosinophilic protein can be detected in the sputum of
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asthmatic patients (Fujimoto et al 1997). The eosinophil granule proteins MBP, ECP, 
eosinophil-derived neurotoxin (EDN) and eosinophil peroxidase are involved in the 
shedding of the epithelium, the degranulation of mast cells and neural stimulation (Frigas 
et al 1991) (Bousquet et al 1990).
Macrophages
Macrophages are derived from blood monocytes and are the most abundant type of 
leukocyte found in the bronchoalveolar lavage fluid of both asthmatic and non-asthmatic 
subjects (Hamid et al 2003). Macrophages can serve as APCs to present the antigen to 
naive T cells. They release a variety of cytokines which induce epithelial cells and 
fibroblasts to release chemoattractants and growth factors. These chemoattractants 
include regulated upon activation, normal T-cell expressed and secreted (RANTES ) and 
monocyte chemotactic protein (MCP)-l which attract further macrophages and 
eosinophils to the site of inflammation.
Neutrophils
Neutrophils contain reactive oxygen species and proteases (neutrophil elastase), both of 
which have the potential to cause damage to the lungs and to cause airways 
inflammation. After allergen challenge in sensitized guinea-pigs, neutrophils appear in 
the lavage fluid after 1 hour, peak at the end of the EAR and subside after 12 hours 
(Toward and Broadley 2004). There is an association between neutrophilic inflammation 
of the airways and severe asthma (Jatakanon et al 1999) and steroid-resistant asthma 
(Pavord et al 1999). Neutrophilia is otherwise more associated with chronic obstructive
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pulmonary disease (COPD) (Cosio et al 2002) where the neutrophil elastase is 
responsible for the degradation of lung parenchyma and the consequent emphysema 
(Fujita et al 1990).
Dendritic cells
Dendritic cells are die primary APCs as they express high levels of major 
histocompatibility complex (MHC) class II molecules compared with macrophages and B 
cells. Those that have the most prominent role in asthma are the myeloid dentritic cells 
(mDC) and plasmacytoid dendritic cells (pDC) (Barnes 2002). Dendritic cells form a 
tightly meshed network throughout the epithelium and are therefore ideally suited to 
sample inhaled air for antigens (Kuipers and Lambrecht 2004). Dendritic cells take up 
antigens, process them to peptides and migrate to the lymph nodes where they present 
them to naive T lymphocytes. In asthma, these develop into Th2 cells due to the release 
of the Th2-favouring cytokines, IL-4 and IL-13 (Barnes and Drazen 2002).
Cytokines
Cytokines are small protein mediators which play a crucial role in the co-ordination of 
inflammation in asthma. In asthma the airway wail is infiltrated by inflammatory cells 
including T lymphocytes of the Th2 phenotype, eosinophils, macrophages/monocytes, 
and mast cells. Th2 lymphocytes produce a wide range of cytokines, including IL-3, IL-4, 
IL-5, IL-9, IL-10, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-
10
CSF) (Barnes et al 1998). Some of the important cytokines in asthma are classified as 
follows:
• Lymphokines: IL-2, 3,4, 5,13, 15, 16 and 17
• Pro inflammatory cytokines: IL-1, 6  and 11, TNF-a, GM-CSF and stem cell factor 
(SCF)
• Inhibitory cytokines: 11-10, 1-ra, 12 and 18 and IFN-y
• Growth factors: Platelet-derived growth factor (PDGF) and tumour growth factor 
(TGF)-p
Histamine
Histamine was the first mediator implicated in the pathogenesis of asthma. Histamine is 
synthesised and released from circulating basophils and mast cells in the airways. Most of 
the effects of histamine in the airways related to asthma are thought to be mediated by 
histamine Hi receptors (Casale et al 1985). Histamine has many effects in the airways 
including contraction or airways smooth muscle, plasma exudation and mucus secretion 
(Barnes 2002). Inhaled histamine is used in asthmatics as a means of testing for airways 
hyperreactivity (AHR) since asthmatics are more sensitive to the bronchoconstrictor 
actions of histamine than non-asthmatics (Whicker et al 1988).
Leukotrienes
In asthmatics elevated levels of cysteinyl-leukotrienes (Cys-LT) have been detected in 
plasma, bronchoalveolar lavage fluid, and sputum samples obtained during spontaneous 
exacerbations of their asthma (Wenzel et al 1997). Cys-LTs are potent contractile agents
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via the Cys-LTi receptor, having a 1000 times greater effect than histamine in human 
bronchi in vitro (Krell et al 1990). Cys-LTs can also increase mucus secretion (Hoffstein 
et al 1990) and in asthmatics causes eosinophilic infiltration (Laitinen et al 1993).
Adenosine
Adenosine is a purine nucleoside formed from 5’- adenosine-monophosphate (AMP) 
when the oxygen demands of a tissue exceed the supply. Adenosine can therefore be 
released under conditions of hypoxia as occurs during an asthma attack and increased 
levels have been detected in the lungs during allergen bronchoconstriction. Raised levels 
have been found in bronchoalveolar lavage fluid (BALF) of asthmatic subjects (Driver at 
al 1983). Inhaled adenosine has no effect in normal subjects but in asthmatics it causes 
bronchoconstriction (Cushley et al 1983). Furthermore, in isolated airways tissue from 
asthmatic subjects, adenosine causes contraction of the bronchi whereas there is no 
response in tissues from non-asthmatics (Bjorck et al 1992). In guinea-pigs, inhaled 
adenosine has no effect but in sensitized animals, there is a bronchoconstriction (Thome 
and Broadley 1994). Also, isolated tracheal and lung preparations from sensitized guinea- 
pigs show a contractile response whereas those from unsensitized animals show a 
bronchodilator effect (Thome et al 1996). Inhalation of adenosine or 5’-AMP in 
sensitized guinea-pigs also causes an influx of inflammatory cells into the lungs 
(Spruntulis and Broadley 2001) and a late asthmatic response (Smith and Broadley 2008). 
It is likely that mast cell degranulation to release histamine is a major source of the 
bronchoconstriction by adenosine as AMP challenge of asthmatics provokes an increase 
in levels of mast cell mediators: histamine, prostaglandin (PG) D2 and tryptase (Polosa et
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al 1995). Adenosine A2A receptors are on the surface of human mast cells and T 
lymphocytes (Fozard and Hannon 1999), and their activation suppresses the release of 
tryptase from human mast cells. Stimulation of adenosine A2 receptors may therefore 
inhibit mast cell-mediated responses. In contrast, A2B receptors are located on eosinophils 
and mast cells and their activation is associated with inflammatory cell influx (Smith and 
Broadley 2008).
Nitric Oxide
Nitric oxide (NO) is generated by the actions of nitric oxide synthase (NOS) which 
converts L-arginine to citrulline. NOS occurs in three forms; two constitutive (cNOS) 
forms (endothelial NOS, eNOS and neuronal NOS, nNOS) and an inducible form (iNOS) 
(Fig 1.4). iNOS is induced or activated by inflammatory stimuli including the cytokines 
IL-lp, TNF-a and IFN-y and bacterial endotoxin (lipopolysaccharide). iNOS is found in 
eosinophils, macrophages, neutrophils and epithelial cells. Unlike cNOS which produces 
only picomolar concentrations of NO, iNOS produces nanomolar concentrations of NO, 
which is long lived and Ca2+/calmodulin independent. NO has a wide spectrum of 
activities that are both pro- and anti-inflammatory. It is a bronchodilator through 
activation in bronchial smooth muscle of soluble guanylyl cyclase to generate cyclic 
guanosine monophosphate (cGMP). NO adversely affects inflammatory cell influx by 
increasing leukocyte chemotaxis and increasing microvascular permeability. It also 
interacts with reactive oxygen species to generate highly toxic peroxynitrite. These 
actions are probably involved in the induction of airways hyperreactivity (Nevin and 
Broadley 2002). Exhaled NO is a marker of asthma and there is a good correlation
13
between sputum eosinophils and airway hyperreactivity to inhaled methacholine 
(Jatakanon et al 1998).
Generation of nitric oxide
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(laactive)
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TISSUE RESPONSE
Figure 1.4
Generation of NO. NOS, nitric oxide; cGMP, cyclic guanosine monophosphate, 
phosphodiesterase (PDE) type 5.
Bradykinin
Bradykinin is a nine amino acid peptide (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg) formed 
from the plasma precursor kininogen during inflammation and tissue injury. Large 
precursor kininogens are cleaved by serine proteinases, known as kininogenases, to 
release the active kinins, bradykinin and kallidin (Lys-BK) (Hall 1992). Bradykinin has
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both direct and indirect actions in the airways. It produces bronchoconstriction, increased 
mucus secretion, stimulates cholinergic and sensory nerve endings, causes oedema due to 
increased microvascular leakage and promotes cough. The stimulation of sensory nerve 
endings causes the release of neuropeptides (SP, NKA and CGRP) resulting in 
neurogenic inflammation (see previously) and cough (Ellis and Fozard 2002). In humans, 
bradykinin-induced bronchoconstriction is inhibited by indomethacin, a non-selective 
cyclo-oxygenase (COX-1 and COX-2) inhibitor although aspirin has no effect (Fuller et 
al 1987). This indicates that it is mediated in part by the prostanoid products of COX, 
such as thromboxane (Tx) A2 (Polosa et al 1990). The bronchoconstriction in humans is 
also due to activation of cholinergic nerves which release acetylcholine onto bronchiolar 
muscarinic M3 receptors, since it is blocked by the muscarinic antagonist, atropine (Fuller 
et al 1987). Bradykinin is also able to release histamine from mast cells. The responses to 
bradykinin of guinea-pigs appear to be closer to those of humans than other species (Ellis 
and Fozard 2002). The actions of bradykinin in the airways is the subject of this thesis 
and its formation, metabolism, responses on the airways and receptors will be discussed 
in more detail later in this introduction and in Chapter 5.
1.6 Treatment of Asthma
Pr-Adrenoceptor agonists
Inhaled fe-adrenoceptor agonists are the best available bronchodilators for asthma. They 
act directly on 0 2  adrenoceptors on airway smooth muscle to dilate the bronchi. p2 
agonists bind to and activate the p2 adrenoceptors, causing the activation of adenylyl 
cyclase and the formation of cyclic adenosine monophosphate (cAMP). cAMP is an
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intracellular mediator, release of which causes smooth muscle relaxation and 
bronchodilatation. There are two types of p2 agonists used in the treatment of asthma, 
short acting and long acting. Salbutamol and terbutaline are short acting drugs which are 
used on an as needed basis to control immediate symptoms of bronchoconstriction. 
Salmeterol and formeterol are long acting (at least 12 hours) and are used for 
maintenance therapy and to control nocturnal symptoms (Ullman and Svedmyr 1988). 
There has been a suggestion that long acting p-adrenoceptor agonists such as salmeterol 
might increase the risk of asthma deaths (Salpeter et al 2006). However, these concerns 
have subsided in the light of newer trials and analysis (Moore 2009; Nelson et al 2009).
Corticosteroids
Corticosteroids are the most effective treatment for controlling chronic asthma. They are 
recommended as the first-line therapy in treating persistent symptoms that derive from 
the inflammatory response of asthma. Fluticasone proprionate, budesonide and 
beclometasone are examples of inhaled corticosteroids. Where asthma is severe and 
resistant to the effects of inhaled corticosteroids, orally administered steroids, such as 
dexamethasone, prednisolone and betametasone are used. Steroids are not regarded as 
bronchodilator agents and therefore do not reduce the EAR following allergen challenge. 
They target the inflammatory process and reduce the numbers of inflammatory cells 
involved in the asthmatic response. Mast cells are reduced (Jeffery et al 1992). 
Corticosteroids reduce the secretion of cytokines and chemokines from lung macrophages 
(John et al 1998). Corticosteroids only reduce neutrophil numbers in asthma rather than 
COPD (Belvisi 2004). Corticosteroids also reduce the number of dentritic cells that serve
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as APCs (Kamei et al 1996). Corticosteroids also inhibit the transcription of a wide range 
of inflammatory mediators, the enzymes that produce them and their receptors. They 
inhibit cytokines, enzymes involved in generating mediators, such as iNOS and COX-2. 
Corticosteroids inhibit mucus production that is elevated in asthma probably by inhibition 
of the mucin genes, MUC2 and MUC5A (Liu et al 2004).
Steroids act on the glucocorticoid receptor (GR), which is highly expressed in airway 
epithelial and vascular endothelial cells. The majority of the actions of steroids are 
mediated through changes in gene transcription. Corticosteroids bind to the GR and this 
homodimer is transported to the nucleus where it undergoes a conformational change and 
binds to a glucocorticoid responsive element (GRE) on the target gene leading to 
increased or decreased gene transcription. The homodimer exerts anti-inflammatory 
effects via two proposed mechanisms, direct and indirect.
Indirect: This mechanism involves an effect on histone acetylation in the DNA/histone 
complex of the DNA. The generation of inflammatory mediators (cytokines, 
inflammatory enzymes, receptors) through increased gene transcription is initiated via 
stimulation of nuclear factor kB  (NF-kB) and activator protein-1 (AP-1) by TNFa, IL-ip. 
Binding of these transcription factors to the DNA/histone complex results in histone 
acetylation of N-terminal lysine residues by intrinsic histone acetyl transferase (HAT). 
This opens out the DNA/histone complex and allows activation of transcription and 
mRNA formation. This generates the inflammatory products. Closing and inactivation of 
this process is via deacetylation by histone deacetylase-2 (HDAC-2). Corticosteroids 
exert their anti-inflammatory effects by inhibition of HAT and stimulation of HDAC-2.
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Direct: The steroid/receptor complex interacts with a number of elements (GREs, cyclic 
adenosine monophosphate response element binding protein (CBP), leading to activation 
of genes encoding ANTI-inflammatory proteins such as MAP kinase phosphatase (MKP- 
1) and IkB -cx (an inhibitor of the pro-inflammatory transcription factor, N F -kB )). This 
pathway is now regarded as less important than the indirect mechanism (Barnes et al 
2005).
Steroids therefore inhibit the transcription of many cytokines that are involved in 
inflammation including IL-1, TNFa, GM-CSF, IL-3, IL-4, IL-5, IL- 6  and IL- 8  (Guyre et 
al 1988). Steroids can also act indirectly by blocking the effects of cytokines. Steroids 
can inhibit the synthesis of cytokine receptors including the IL-2 receptor (Grabstein et al 
1986). Several cytokines produce their effect by activating transcription factors such as 
AP-1 and NFKB. TNFa activates both AP-1 and NFKB and this activation is counteracted 
by steroids through decreased transcription of TNFa (Barnes and Adcock 1997).
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Figure 1.5
Pathways for the action of corticosteroids in inflammation.
Steroid resistance
Resistance to the anti-inflammatory effects of corticosteroids occurs in about 5% of 
asthmatics and in most COPD patients. Smoking asthmatics show a high degree of 
resistance. Steroid-resistance has been shown to be associated with a reduced level of 
HDAC-2 activity (Marwick et al 2007), which normally suppresses the inflammatory 
process. It is thought that oxidative stress, nitration by peroxynitrite and ubiquination 
reduce HDAC-2 activity. Recently, it was reported that phosphorylation of Akt by 
phosphatidylinositide 3-kinase (PI3K) also reduces the activity of HDAC-2 (Fig. 1.5). 
Phosphorylation of Akt is increased in COPD and targeting it may be a useful means of 
limiting exacerbations of COPD (Bozinovski et al 2006). Inhibition of PI3K (specifically
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PI3K6) by IC87114 results in reversal of steroid resistance and attenuates allergic 
inflammation and hyperresponsiveness in mice (Lee et al 2006). Theophylline also 
appears to activate HDAC-2 and restore steroid sensitivity probably by inhibition of 
PBKdelta.
Methylxanthines
Theophylline is the prototypical methylxanthine which has been used for many decades 
and is one of the most widely used drugs for mild to moderate asthma. Despite its long 
history, the molecular mechanism of action remains unclear but several mechanisms have 
been proposed. It is widely held that the bronchodilator effect of theophylline is due to 
inhibition of PDE, which breaks down cAMP. This would result in increased cAMP 
levels, which would cause bronchodilatation and inhibit inflammatory cell migration and 
activation. Other mechanisms may be involved as the degree of inhibition of PDE is 
small at concentrations of theophylline which are clinically relevant (Bergstrand 1980). 
Other mechanisms for the bronchodilator effect include antagonism of adenosine 
receptors. Although inhaled adenosine has little effect on normal human airways, it 
causes bronchoconstriction in asthmatic subjects (Cushley et al 1984). Recent evidence 
suggests that theophylline is an antagonist of A2B adenosine receptors. Like enprofylline, 
a selective A2B antagonist, theophylline inhibits the release of IL- 8  from human mast 
cells (Feoktistov and Biaggioni 1995). This would result in an inhibition of inflammatory 
cell activation and influx into the airways. Theophylline is also receiving a resurgence in 
interest as it may reverse steroid resistance, through activation of histone deacetylases 
(HDAC) (see above and Fig. 1.5) (Barnes 2004).
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Anti-leukotrienes
Cysteinyl leukotrienes are potent bronchoconstrictors and may promote eosinophil 
mediated inflammation. Anti-leukotrienes are drugs that block their synthesis by 
inhibiting the enzyme 5’lipoxygenase (zileuton) or antagonists which block the cysteinyl 
leukotriene receptor (montelukast, pranlukast and zafirlukast). These drugs have been 
shown to reduce allergen, exercise and irritant induced asthma (Drazen et al 1999).
Muscarinic receptor antagonists
The parasympathetic nervous system is the main autonomic innervation of airways 
smooth muscle and reflex bronchoconstriction arises from sensory stimulation by a range 
of agents. There is evidence for enhanced parasympathetic activity in airways disease but 
most particularly in COPD (Roffel and Zaagsma 1995). The bronchoconstrictor actions 
of the parasympathetic innervation are mediated through the release of acetylcholine 
(ACh) onto muscarinic receptors of the M3 subtype. These receptors also mediate an 
increase in mucus secretion from epithelial goblet cells. M2 muscarinic receptors are 
located on the parasympathetic nerve endings where their stimulation causes inhibition of 
transmitter release; that is a negative-feedback effect. Anticholinergic drugs are not 
particularly effective against allergic challenge in asthma, but they do inhibit the 
augmented mucus secretion which occurs in asthma. They are more effective in COPD. 
The main anticholinergic compounds used in the treatment of asthma and COPD are 
ipratropium and tiotropium. The latter is longer acting and licensed for COPD but not 
suitable for relief of acute bronchospasm (British National Formulary 2009). They exert 
their effects by antagonising the M3 muscarinic receptors involved in bronchoconstriction
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resulting in bronchodilatation. Ipratropium does not discriminate between M3 and M2 
receptors and therefore also blocks the negative-feedback which will enhance transmitter 
release and offset the antagonism of M3 receptors on the smooth muscle.
1.7 Brady kinin
Synthesis and metabolism o f bradykinin
Bradykinin is a nonapeptide formed by the cleavage of its precursor, high molecular 
weight kininogen (HMWK) by the kininogenase enzymes, which include tissue and 
plasma kallikrein (Fig 1.6 ). Another kinin, lysyl-BK is a decapeptide, formed by 
kininogenase enzymes, and then rapidly converted to bradykinin by aminopeptidase-N. 
Brasykinin is degraded by a number of kininase enzymes including ACE, NEP and 
carboxypeptidase-N, though not all these enzymes are present in the airways (Bhoola et 
al 1992). ACE has been localized to the endothelium, but it is thought to be present in the 
airways as inhibition of ACE by captopril enhances bradykinin induced 
bronchoconstriction. NEP is localized to the epithelium and is therefore likely to be the 
most important kininase in the airways. Inhibition of NEP by phosphoramidon potentiates 
the bronchoconstriction to bradykinin. Decreased NEP levels due to damage to the 
epithelium as seen in asthma and in viral infections is likely to be a contributory factor to 
the bronchial hyper-responsiveness seen in these conditions. The lack of removal of 
bradykinin by the epithelial enzymes allows its effects to be enhanced. 
Carboxypeptidase-N is not thought to play a role in the airways, as inhibition of this 
enzyme has no effect on bradykinin-induced bronchoconstriction (Ichinose and Barnes 
1990).
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Figure 1.6
A simplified diagram of the synthesis and metabolism of bradykinin in the airways. 
Bradykinin and asthma
Bradykinin is thought to be an important mediator of asthma. Inhalation of bradykinin 
causes bronchoconstriction in asthmatic patients, but has little or no effect in non­
asthmatics (Fuller et al 1987). Kinin levels are increased in BALF of asthmatics after 
allergen challenge (Christiansen et al 1992).
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Allergen challenge in asthmatics in the airways is associated with an immediate 
(<30mins) and a delayed (6-24hours) increase in BALF tissue kallikrein activity 
(Christiansen et al 1987). The source of the immediate increase in tissue kallikrein 
activity is likely to be submucosal cell gland secretions triggered by secretagogue 
mediators including elastase (Scuri et al 2001). Increases in macrophages and neutrophils 
coincide with the delayed increase in kallikrein activity, which is blocked by adhesion 
molecule inhibitors, which also prevented the associated airway hyperreactivity 
(Abraham et al 1999).
Bradykinin receptors
Bradykinin has many different effects in the airways, some of which are mediated 
directly by stimulation of B2 receptors on target cells, others indirectly through the 
release of other mediators or transmitters.
Two types of bradykinin receptor have been cloned, the Bj and B2, which are typical G- 
protein coupled receptors with seven transmembrane segments (Hess et al 1992; Mencke 
et al 1994). Most of the bradykinin receptor-mediated effects in the airways are thought 
to be due to activation of the B2 receptor as selective Bj agonists have little effect (Fuller 
et al 1987). The B2 receptor is widely distributed in the airways. In [3H]bradykinin 
binding experiments in human and guinea-pig lung, dense labelling was found in 
bronchial and pulmonary vessels of all sizes and in the lamina propria immediately below 
the basal epithelial cells in large airways. Smooth muscle in large airways was scarcely 
labelled, but increased in smaller airways. Labelling was also detected over submucosal
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glands and nerve fibres in human intrapulmonary bronchi and over alveolar walls of both 
species (Mak and Barnes 1991).
Effect o f bradykinin on airway smooth muscle
Bradykinin causes contraction of guinea-pig airway smooth muscle in vitro and in 
guinea pig airway in vivo when administered intravenously (Tramontana et al 2001). 
These effects are influenced by the presence of the epithelium and local degrading 
enzymes including NEP, which is expressed in human airway epithelium (Baraniuk et al 
1995). Inhibition of NEP by phosphoramidon and of ACE by captopril increases the 
bronchoconstriction to bradykinin in vivo in guinea-pigs (Ichinose and Barnes 1990). 
Bradykinin causes the release of the bronchodilator PGE2 from the epithelium (Bramley 
et al 1990) and damage to the epithelium would reduce this functional antagonism. NO is 
also thought to modulate the action of bradykinin as the NO synthase inhibitor N°- 
monomethyl-L-arginine (L-NMMA) potentiates bradykinin-induced bronchoconstriction 
in asthmatic patients (Ricciardolo et al 1996).
Effect o f  bradykinin on nerves
An important effect of bradykinin is the ability to activate C-fiber nociceptive sensory 
nerve endings (Barnes 1992). The bronchoconstriction to bradykinin in guinea-pigs is 
thought to involve a cholinergic reflex and release of neuropeptides from sensory nerves 
as it is inhibited by pre-treatment with atropine and capsaicin (which depletes 
neuropeptides from sensory nerves) (Ichinose eta l 1990). Tachykinins are also released
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by bradykinin, in guinea pig perfused lung (Saria et al 1988), and tachykinin antagonists 
have an inhibitory effect on bradykinin-induced bronchoconstriction and plasma 
exudation (Sakamoto et al 1993).
Other airway effects o f bradykinin
Bradykinin induces microvascular leakage, which is at least in part mediated by platelet 
activating factor (PAF), as a PAF antagonist inhibits this prolonged leakage (Rogers et al
1990). The plasma exudation is also blocked by neurokinin and B2 receptor antagonists 
(Sakamoto et al 1993; Ichinose and Barnes 1990) and enhanced by inhibition of NEP and 
ACE (LOtvall et al 1991). Bradykinin stimulates mucus secretion via B2 receptors in 
human submucosal glands in vitro (Nagaki et al 1996).
1.8 Virus infection and asthma
Substantial evidence implicates common respiratory viral infections in the pathogenesis 
of asthma and COPD. Children who experience recurrent virally induced wheezing 
episodes during infancy are at greater risk of developing asthma. In addition, respiratory 
viral infections are a major trigger for acute exacerbations of both asthma and COPD 
(Frick et al 1979). Viral infections lead to enhanced airway inflammation and can cause 
airways hyperresponsiveness. The epithelial cell is the principal site of viral infection in 
the airways and plays a central role in viral modulation of airway inflammation via 
release of a variety of cytokines, chemokines, and growth factors. These induce 
recruitment of inflammatory cells, particularly neutrophils, lymphocytes, and eosinophils 
to the lungs. The epithelium also contributes to the host innate defense response to viral
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infection by releasing products that are antiviral and/or can lead to increased recruitment 
of dendritic cells and lymphocytes. Some evidence supports a role for the epithelial cell 
in specific immunity, although the response of more conventional cells of the immune 
system to viral infections is likely the dominant factor in this regard (Proud and Chow 
2006). A significant fraction of the cost and morbidity of asthma derives from acute care 
for asthma exacerbations. In the United States alone, there are approximately 15 million 
outpatient visits, 2 million emergency room visits, and 500,000 hospitalizations each year 
for management of acute asthma. Common respiratory viruses, especially rhinoviruses, 
cause the majority of exacerbations in children and adults. Having had at least one 
exacerbation is an important risk factor for recurrent exacerbations suggesting an 
’exacerbation-prone’ subset of asthmatics. Factors underlying the ’exacerbation-prone' 
phenotype include extrinsic factors: cigarette smoking, medication non-compliance, 
psychosocial factors, and co-morbidities such as gastroesophageal reflux disease, 
rhinosinusitis, obesity, and intolerance to non-steroidal anti-inflammatory drugs; as well 
as intrinsic factors such as deficient epithelial cell production of the anti-viral type I 
interferons (IFN-alpha and IFN-beta) (Dougherty and Fahy 2009). Evidence is emerging 
that viral infections may alter the inflammatory infiltrate present in chronic asthma with a 
more heterogenous neutrophil/eosinophil composition infiltrate (Wark et al 2001). 
Increased sputum concentrations of cysteinyl leukotrienes have been found in patients 
with parainfluenza virus type 3 (PIV-3) induced asthma exacerbations (Matsuse et al 
2005). Among the respiratory viruses implicated in childhood asthma are respiratory 
syncytial virus (RSV), rhinovirus, PIV-3 and coronovirus.
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Steroid resistance has been attributed to viral and bacterial infection, which lead to 
exacerbations of asthma. Viral infection in guinea-pigs amplifies the inflammatory 
response and induces steroid resistance (Yamada et al 2002). The steroid resistance may 
be explained by a reduction in HDAC activity (see above) by the viral infection (Barnes 
et al 2005). Infection with virus has been implicated in steroid resistance in children with 
asthma (Macek et al 1994). Mycoplasma pneumoniae and Chlamydia are both prevalent 
bacterial infections in asthmatics. These infections reduce mast cell numbers. 
Clarithromycin is used to treat exacerbations.
1.9 Parainfluenza virus
PIV is associated with croup in children. In studies in humans there has been an 
association between virus-induced laryngotracheobronchitis (croup) in children and 
increased reactivity in later years. Loughlin and Taussig (1979) showed that children 
with a history of croup showed hyper-responsiveness after exercise. In a larger study of 
children with croup in the first three years of life, it was found that children who showed 
croup with wheezing were more likely to develop wheezing later in life than those with 
croup without wheezing (Castro-Rodriguez et al 2001). In this study it was found that the 
children who developed croup with wheezing had lower levels of small airway function 
at birth, age 6 and at age 11 compared to those with croup without wheezing, who had 
similar levels to control children at all ages. The virus most commonly isolated in the 
wheezing phenotype was RSV and in croup without wheezing PIV was most common.
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PIV infection induces changes in the airways that are similar to the effects seen in 
asthma, including bronchial hyper-responsiveness, an influx of inflammatory cells, 
epithelial damage and bronchiolar fibrosis.
Anim al studies
There have been several experiments in which PIV infected animals show persistent 
changes in lung morphology and function. Neonatal rats, which were infected with 
Sendai virus (PIV-1), and subsequently developed bronchiolitis still showed decreased 
lung function and hyperreactivity 13-16 weeks later (Sorkness et al 1991). Quan et al 
(1999) showed chronic small airways inflammation and altered lung function during 
growth in canine PIV-2 infected beagle puppies, though there was no long-term 
hyperreactivity to histamine. These animal models suggest that acute PIV infection in the 
lower airways can in some cases lead to long-term changes in the lung.
Characteristics o f parainfluenza viruses
Parainfluenza viruses were first discovered in the late 1950’s. They have been divided 
into subtypes 1 to 4, with PIV-4 being further divided into types a and b. Types 1 to 3, 
along with RS V are major causes of lower respiratory disease in infants, the young, the 
immunocompromised and the elderly (Glezen et al 1984; Glezen et al 2000; Falsey
1991). PIV infection can cause croup, bronchiolitis, and bronchopneumonia, though the 
most common presentation is an upper respiratory tract infection (Belshe et al 1983). The 
pathogenesis of PIV infection is still being studied but the respiratory epithelium appears 
to be the major site of virus binding and subsequent infection. The epithelium is an
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extensive source of inflammatory mediators including chemokines and cytokines, which 
can be released to recruit inflammatory cells after viral infection (Garofalo and Haebere
2000). Little is known about type 4.
PIV belong to the family Paramyxoviridae, which also includes measles, mumps and 
RSV. The virus is spherical and approximately 150-400nm in diameter. They have an 
envelope composed of host cell lipids and viral glycoproteins derived from the plasma 
membrane of the host cell during viral budding. The PIV genome is single stranded, 
negative sense RNA that must be transcribed into message sense RNA before it can be 
translated into protein. The RNA genome is approximately 15,500 nucleotides in length 
and is encapsilated by the viral nucleocapsid protein, forming a helical nucleocapsid. 
(Fig. 1.7) (Lamb et al 1976).
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(shown as trimar)
Figure 1.7
Schematic diagram of the parainfluenza virion, (taken from Moscona 2005).
The first step in infection of a cell by PIV is binding to the target cell, via interaction of 
the viral receptor-binding molecule haemagglutinin-neuraminidase (HN) with sialic acid- 
containing receptor molecules on the cell surface (Fig. 1.8). The viral envelope is then 
thought to fuse directly with the plasma membrane of the cell, mediated by the viral 
fusion (F protein), releasing the nucleocapsid into the cytoplasm (Lamb 1993; Plember et 
al 2003). The nucleocapsid released into the cytoplasm after fusion contains the genome 
RNA in tight association with the viral nucleocapsid protein, and this RNA-protein
complex is the template both for transcription and for replication of the genome RNA that
’ )
is packaged into progeny virions.
The 6 viral replication genes encode the 2 surface glycoproteins HN and F; the matrix 
protein, which is involved in assembly and budding; the RNA polymerase proteins and a
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protein that encapsulates the RNA; and 1 or more proteins that are expressed only in the 
infected cell and whose roles include evasion of the host immune response.
Virions are formed with the full-length viral RNA genome along with the polymerase 
proteins bud out through areas of the plasma membrane that contain the F and HN 
proteins and the matrix protein. In polarised epithelial cells, the viruses bud from the 
apical surface of the cell. The matrix protein binds to the nucleocapsid and with the 
cytoplasmic tails of the HN and F proteins. This aligns the nucleocapsid with the areas of 
the plasma membrane containing viral glycoproteins in readiness for budding (Ali and 
Nayak 2000). The neuraminidase or receptor cleaving activity of the HN molecule 
cleaves sialic acid-containing receptor moieties that would attach the viral HN protein to 
die cell surface and allows the release of newly budded particles from the cell to begin a 
new round of infection (Moscona 2005).
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Figure 1.8
Life cycle of the parainfluenza virus (taken from Moscona 2005).
When PIV infects a cell, the first observable morphologic changes may include focal 
rounding and increase in size of the cytoplasm and nucleus. PIV decreases host cell 
mitotic activity as soon as 24 h after inoculation. Other changes include single or 
multilocular cytoplasmic vacuoles, basophilic or eosinophilic inclusions, and the 
formation of multinucleated giant cells (Craighead and Brennan 1968). These giant cells 
(fusion cells) usually occur late in infection and contain between two and seven nuclei.
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Disease severity has been correlated with PIV shedding in children (Hall et al 1977). The 
parainfluenza viruses generally initiate localised infections in the upper and lower 
respiratory tracts without causing systemic infection. Local and serum antibodies develop 
after primary infection. The resulting immunity is not adequate to prevent re-infection, 
but does not provide some protection against disease.
The parainfluenza viruses replicate in the epithelium of the upper respiratory tract and 
spread from there to the lower respiratory tract. Epithelial cells of the small airways 
become infected, and this is followed by the appearance of inflammatory cell influx. The 
innate immune responses help to clear the virus. Both humoral and cellular components 
of the immune system appear to contribute to both protection and pathogenesis (Smith et 
al 1966). Infection with PIV in immuno-compromised children (e.g. transplant recipients) 
is associated with a range of disease, from mild respiratory symptoms to severe disease 
requiring mechanical ventilation and leading to death (Apalsch et al 1995).
Acute infection of guinea-pigs with PIV increased numbers of airways inflammatory 
cells, histamine levels and airway hyperreactivity (Folkerts et al 1993) and airways 
hyperreactivity of the trachea in vitro (Folkerts et al 1990a) and decreased 
bronchoalveolar cellular superoxide production (Folkerts et al 1990b). PIV-3 infection of 
guinea-pigs also enhanced allergic sensitization (Riedel et al 1996). In addition, PIV-3 
induced peribronchiolar lymphocyte aggregation, bronchiolitis and interstitial pneumonia 
in cotton rats (Porter et al 1991).
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Parainfluenza type 1 (PIV-1)
PIV-1 is reported to cause 50% of all croup cases in children younger than 5 years. It can 
also cause bronchiolitis, pneumonia, febrile and afebrile wheezing during epidemics. The 
majority of infections occur in children between 7 and 36 months with a peak occurrence 
in the second and third year (Denny et al 1983). PIV-1 can cause lower respiratory tract 
infections (LRTI) in children younger than 6 months but is rare in infants under 1 month. 
PIV-1 causes biennial autumn epidemics, resulting in hospitalisation of an estimated 
18000 to 35000 children under 5 years in the US (Belshe et al 1983).
Parainfluenza type 2
PIV also causes croup as well as all the other LRTI diseases seen with PIV infection. 
PIV-2 infection is generally less common than with PIV-1 and 3, though in any particular 
year or location it can be the most prevalent. PIV-2 also causes biennial epidemics, which 
can be in alternate years, or the same years as PIV-1. There can also be yearly outbreaks 
of PIV-2. PIV-2 epidemics usually occur in autumn or early winter. 60% of infections 
occur in children under 5 years with a peak in the second and third years, though many 
infants in their first year are hospitalised (Murphy et al 1980).
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Parainfluenza type 3
PIV-3 infection occurs the earliest and is the most common. It can cause bronchiolitis and 
pneumonia. Around 50% of children are infected in their first year and infants under 6 
months are vulnerable to infection. Only RSV causes more infections at this age. PIV-3 
causes annual spring and summer epidemics though infections occur all year round, with 
the immunocompromised and the chronically ill being particularly at risk (Glezen et al 
1984).
1.10 Influenza
The influenza virus is a negative stranded (-) RNA virus belonging to the family 
Orthomyxoviridae. Influenza types A and B cause seasonal outbreaks whereas type C 
causes only mild respiratory conditions. Influenza types A and C infect many species, 
whereas type B only infects humans. Influenza type A viruses are divided according to 
their surface glycoproteins, termed haemagglutinin (HA or H) and neuraminidase (NA or 
N), also known as sialidase. Three types of HA (HA1, HA2 and HA3) and two NA (NA1 
and NA2) are commonly found in humans, whereas more types are found in avian 
influenza viruses (Richman et al 2002). The first identified influenza virus was H1N1 
which caused the “Spanish flu” epidemic of 1918 which killed more than 20 million 
people (Taubenberger 2006). Genetic rearrangements known as antigenic shift resulted in 
the appearance of two further human viruses; H2N2 and H3N2, which were responsible 
for the “Asian” and “Hong Kong” flu pandemics of 1957 and 1968, respectively 
(Kilboume 2006). The threat of an influenza pandemic has increased dramatically due to 
the emergence in Hong Kong of a new, highly pathogenic avian strain of H5N1 (Webster
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et al 2007). However, this new strain of influenza is not able to transmit between humans. 
Only type A influenza viruses undergo antigenic shift and cause epidemic outbreaks. 
“Swine flu” was first described in the 1918 pandemic and made a recent resurgence in 
April 2009 in the form of a combination of human, swine, and Eurasian avian strains. 
Young adults and children aged < 24 years are the population most affected. The 
pandemic variant influenza A (H1N1) strain is typically susceptible to oseltamivir and 
resistant to adamantanes, unlike the 2008 to 2009 seasonal influenza A (H1N1).
However, 2 cases of oseltamivir-resistant pandemic-variant influenza A (H1N1) were 
reported in late August 2009 and widespread oseltamivir resistance is a possiblity. The 
recent development of a vaccine is therefore important for protection (Scalera and 
Mossad 2009).
The structure and trafficking of the virion is similar to that described for PIV (Whittaker
2001). Influenza types A and B virus bind to the host cell by means of their HAs 
attaching to cell surface 5-V-acetyl neuraminic acids (sialic acids), as for PIV. Human 
influenza viruses preferentially attach to a-(2,6)-linked sialic acids (Rogers et al 1983). 
The virus is then taken up by endocytosis, followed by fusion of the viral envelope with 
the host endosomal membrane for release of viral ribonucleoproteins (vRNPs). This 
process is enhanced by acidification of the interior of the virus via an M2 ion channel.
The vRNPs are then imported into the nucleus, where the influenza type A genome is 
transcripted and replicated by viral RNA-dependent RNA polymerase. The nuclear 
export of viral mRNA is controlled by the viral non-structural protein, NS1. The viral 
constituents are trafficked to the apical surface of the epithelial cell under the influence of 
matrix protein. Budding of the virus occurs at detergent insoluble glycolipid domains of
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the host cell plasma membrane. The mature virus detaches because neuraminidase 
cleaves sialic acid residues from the host cell. After release of virus, the host cell dies.
The influenza virus causes sudden onset of symptoms of fever, aches, fatigue, sore throat 
and nasal congestion about 24-48 hours after infection. Gastrointestinal symptoms of 
vomiting, abdominal pain and diarrhoea can also occur. Infection starts when the virus 
invades the lung epithelial cells. After replication and an innate immune response in these 
cells, the influenza virus infects alveolar macrophages. Peripheral blood neutrophils, T 
cells and macrophages are then activated at the site of infection to release large amounts 
of cytokines. Human airway epithelial cells release RANTES, MCP-1 and IL-8 (Adachi 
et al 1997). IFNa/(3 and the pro-inflammatory cytokines IL-ip, IL-6 and TNFa are 
produced poorly by epithelial cells but large amounts are produced by influenza infected 
monocytes and macrophages (Ronni e ta l 1995,1997).
Influenza in guinea-pigs
Several studies have shown that guinea-pigs are susceptible to infection by influenza. 
Azoulau-Dupouis et al (1984) inoculated guinea-pigs with influenza A/Hong Kong/68 
(H3N2) which caused significant histopathological changes to the whole respiratory tract 
and Lowen et al (2006) demonstrated the spread of influenza between guinea-pigs after 
infection with A/Panama/2007/99 (H3N2).
1.11 Virus recognition and the host innate immune response
Viral genomes are recognized by the host Toll-like receptors (TLRs) and retinoic acid 
inducible protein-I (RIG-like receptors, RLRs). Ten Toll-like receptors have been
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identified in humans. They are transmembrane proteins structurally similar to the IL-1 
receptor which play a crucial role in protecting against viral and bacterial pathogens 
through release of cytokines. TLR1 and TLR2 heterodimers sense bacterial triacylated 
lipopeptides, whereas TLR2 and TLR6 recognise diacetylated lipopeptides. TLR4 detects 
lipopolysaccharide (LPS) or bacterial endotoxin from gram negative bacteria. Polymyxin 
B (PMB) is a cyclic, cationic peptide antibiotic which neutralizes LPS but induces severe 
side effects in the process. Efficient neutralization of endotoxin by PMB is not achieved 
by mere binding to LPS but also requires its sequestration from the membrane (Bhor et al 
2005). TLR3 is found in the endosome of dentritic cells, epithelial cells and 
macrophages, and senses single and double stranded viral RNA and activates the pro- 
inflammatory transcription factor NF-kB (Alexopoulou et al 2001) (see also Fig. 1.5). A 
selective agonist for TLR3 is poly(I-C) (polyinosinic-polycytidylic acid), which is a 
synthetic analogue of viral double stranded RNA which is synthesized during replication 
of single stranded RNA viruses. Poly(I-C) elicits an innate immune response through 
activation of the transcription factors NF-kB or interferon regulatory factor/interferon- 
sensitive response-element pathways. Ultimately, this signal transduction elicits an 
epithelial response that includes the secretion of high levels of pro-inflammatory 
cytokines IL-8, IL-6, RANTES, the antiviral interferon-p and the up-regulation of the 
major adhesion molecule, intercellular adhesion molecule (ICAM)-l (Guillot et al 2005). 
TLR7 recognises single stranded RNA viruses, including influenza (Lund et al 2004). A 
cascade of interactions with kinases results in activation of transcription factor NF-kB 
and type I interferon. Type I interferons (interferon-a/p IFN-a/p) are the key cytokines 
which elicit antiviral responses through activation of IFN stimulated genes by binding to
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IFN-a/p receptor. This ligand-receptor interaction activates a cascade of kinases which in 
the host cell leads to inhibition of viral and cellular protein synthesis and apoptosis 
(Taniguchi and Takaoka 2002). TLR5 is a receptor for flagellin from bacteria (Hayashi et 
al 2001) and TLR9 is a receptor for unmethylated CpG-containing DNA motifs which 
occur in bacterial and viral DNA (Hemmi et al 2000).
1.12 Treatment of PIV and influenza infection
Currently there are no licenced antiviral drugs with proven clinical efficacy against PIV 
infection. Ribavirin has both in vitro and in vivo activity against PIV and influenza 
(Browne 1981; Sidwell et al 1975). Furthermore, there have been anecdotal reports of 
decreased viral shedding and clinical improvement when infected immunocompromised 
patients were treated with aerosolized and oral ribavirin (Chakrabarti et al 2000; 
Malinowski and Hostoffer 2001).
Influenza virus infections can be treated by targeting stages in the life cycle of the virus. 
Amantadine (Symmetrel) and rimantadine (Flumadine) target the pH-dependent 
uncoating of the virus once it is inside the host cell. Amantadine targets the M2 ion 
channel of the virus (Hay et al 1985). Export of nucleoprotein from the nucleus in 
influenza-infected cells is inhibited by the antibiotic leptomycin B (Elton et al 2001). 
Zanamivir (Relenza) and oseltamivir (Tamiflu) are analogues of sialic acid which bind to 
and block the sialic acid residues of the surface HA. There are now reports of resistance 
appearing to amantadine and oseltamivir (Aoki et al 2007). Currently, the use of 
inactivated vaccines is the most effective means of reducing influenza infection.
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Neutralizing antibodies to the haemagglutinin protein can directly block virus entry, but 
protective antibodies to the neuraminidase protein are thought to primarily aggregate 
virus on the cell surface, effectively reducing the amount of virus released from infected 
cells. The neuraminidase protein can be divided into nine distinct antigenic subtypes, 
where there is little cross-protection of antibodies between subtypes. All nine subtypes of 
neuraminidase protein are commonly found in avian influenza viruses, but only selected 
subtypes are routinely found in mammalian influenza viruses; for example, only the N 1 
and N2 subtypes are commonly found in both humans and swine. Even within a subtype, 
the neuraminidase protein can have a high level of antigenic drift, and vaccination has to 
specifically be targeted to the circulating strain to give optimal protection (Sylte and 
Suarez 2009). However, vaccine-induced immunity declines with time and annual flu re­
vaccination is necessary even if the vaccine antigens have remained unaltered.
The use of corticosteroids to treat infectious diseases is counterintuitive since they would 
suppress the immune system of the host which could lead to increased viral replication. 
Meta-analysis of numerous studies has demonstrated that oral or systemic steroids are 
effective at improving symptoms of croup as early as 6 h after treatment (Somani and 
Evans 2001). Other studies, have determined that corticosteroids may be beneficial in 
artificially ventilated patients with severe bronchiolitis, although they had no effect on 
pneumonia (Van Woensel et al 2004). These findings support the idea that corticosteroids 
may be beneficial in virus infections, although further research is required. Combined 
immunotherapy and steroids have been demonstrated to decrease pulmonary virus titre 
and inflammation in a cotton rat model (Prince and Porter 1996).
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1.13 Aims of the study
• The aim of this thesis is to examine the role of bradykinin in airways 
inflammation induced by viral infection in guinea-pigs and the associated 
functional changes.
• The initial objective was to establish models of viral inflammation in guinea-pigs 
inoculated with parainfluenza and influenza virus. Comparative studies were 
undertaken with PIV-2 and PIV-3.
• The effect of inhaled bradykinin in non-inflamed lungs was examined with the 
use of inhibitors of its breakdown (captopril and phosphoramidon) and selective 
bradykinin B2 antagonists (MEN 16132 and icatibant).
• The role of the bradykinin in airways inflammation was studied in the PIV-3 
model by inhibition of its production by the tissue kallikrein inhibitor EE999024 
or with the selective bradykinin B2 receptor antagonist MEN 16132. 
Dexamethasone was used for comparison.
• Guinea-pigs were sensitized and exposed to ovalbumin to produce the asthma 
symptoms of AHR, EAR, LAR and inflammatory cell influx
• The effect of bradykinin inhalation in the ovalbumin model was examined before 
and after ovalbumin exposure to determine whether this model produces AHR to 
bradykinin.
• The ovalbumin model was combined with the PIV-3 model to produce a viral 
exacerbation of allergy model. This exacerbation model was compared to
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ovalbumin alone. The anti-inflammatory effects of dexamethasone were 
compared between both models.
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2.1 Pharmacological Methods
2.1.1 Animal welfare and ethics
Male Dunkin Hartley guinea-pigs were obtained from Harlan UK Ltd (Oxon UK). The 
animals were housed at the laboratory animal facilities of Cardiff University. Controlled 
conditions were imposed on climate and diet and ambient temperature was maintained at 
20°C ± 2°C with 12 hour alternating light/dark cycles at approximately 50% humidity. 
The animals were fed on commercial guinea-pig diet pellets (Harlan UK Ltd, Oxon, UK) 
supplemented with ascorbic acid and water allowed ad libitum. The animals were 
provided with cardboard tubes and received hay every day for environmental enrichment. 
The animals were acclimatised for at least 1 week before the commencement of any 
experiments.
Animal welfare was undertaken in accordance with the Animal Scientific Procedures Act 
1986 under Home Office personnel and project licenses. The guinea-pigs were without 
infections of the respiratory airways as evaluated by the health monitoring quality control 
report by Harlan UK Ltd.
After careful consideration of the ethical issues surrounding use of laboratory animals, it 
was decided that the potential importance of these experiments to improve our 
understanding of viral infections of the airways and their treatment, that the use of live 
animals was justified. In the course of these experiments every care was taken to reduce 
the stress and discomfort of the animals. This was achieved by handling the animals
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regularly and acclimatising them to all the equipment used before starting any 
experiments.
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2.1.2 Measurement o f respiratory function
Specific airways conductance
Whole body plethysmography was used to monitor airway function and was recorded as 
specific airway conductance (sGaw)- This was performed in un-anaesthetised 
spontaneously breathing guinea-pigs based on the methods described previously by 
Griffiths-Johnson et al (1988).
Airway resistance (Raw) is defined as the pressure difference between the alveoli and 
mouth divided by airflow. Raw is dependent upon the volume of air in the lungs, the 
thoracic gas volume (TGV). To correct for TGV, sGaw is often used instead of Raw. sGaw 
is the reciprocal of Raw per unit TGV (Tattersfield and Keeping 1981). The theory 
behind determination of sGaw is described in Appendix 1.
Guinea-pigs were held in a restraining device consisting of a neckpiece to restrain the 
animal, which slotted into a base section that was secured by 2 pins. The animals’ snout 
was covered by a mask with a rubber diaphragm creating an airtight seal around the nose. 
This was attached to a pneumotachograph (Mercury FIL, Glasgow) before the animal and 
restrainer were placed in the plethysmograph chamber, which was then sealed by a plate 
secured to the front of the chamber. Prior to each experiment, the guinea-pigs were 
handled and familiarised with the restrainer and the plethysmograph chamber to reduce 
stress-related factors (Fig. 2.1).
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Pressure transducers (Pioden Type 1, Pioden Controls Ltd. Canterbury, UK), UP1 and 
UP2, attached to the pneumotachograph and plethysmograph chamber, respectively, 
measured changes in respiratory flow and box pressure. These transducers were attached 
to a computerised recording system comprising of AcqKnowledge® software with a 
Biopac® data acquisition system, as previously used by Danahay and Broadley (1997) 
which replaced the original oscilloscope and angle resolver as used by Griffiths-Johnson 
et al (1988). The resulting waveforms were analysed by comparing the gradients of the 
flow and box pressure at a point where flow tended towards zero; - i.e. end tidal volume 
(at the end of expiration and beginning of inspiration). Each recording period was 5 
seconds long, and from this, a minimum of 5 breaths were analysed. Using these values 
and taking into account air pressure and the weight of each guinea pig, resultant values 
for sGaw were determined which were averaged for each time point (see appendix). 
Between recordings, animals were removed from the plethysmograph and placed in a 
holding cage.
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Figure 2.1
A simplified schematic of the whole body plethysmograph and acquisition packs used to 
measure specific airways conductance sGaw, in conscious, restrained guinea-pigs.
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2.1.3 Measurement of airway reactivity
Airway reactivity was measured by testing pulmonary function before and after an 
aerosolised exposure of the brochospastic agent histamine (in one experiment bradykinin 
was used).
Airways reactivity was measured by testing pulmonary function before a 20 second, nose 
only ImM histamine exposure and at 0, 5 and 10 minutes after exposure by whole body 
plethysmography. As mentioned in Chapter 1, histamine activates Hi histamine receptors 
in the airway smooth muscle causing bronchoconstriction. From previous experience in 
these laboratories the selected dose (ImM) of histamine causes minimal 
bronchoconstriction having been found to be a threshold concentration in naive guinea- 
pigs (Toward et al 2003). The effects of viral inoculation and allergen challenge were 
examined on reactivity to inhaled histamine. The appearance of a bronchoconstriction in 
response to the 1 mM of histamine would indicate the presence of airways 
hyperreactivity.
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2.1.4 Bronchoalveolar lavage and removal of lungs
Within 30 minutes of the hyper-reactivity test, the guinea-pigs were sacrificed with a 
lethal overdose of the anaesthetic, pentobarbital sodium (Euthatal 400mg/kg), by bilateral 
intraperitoneal injection. After examination to ensure cessation of breathing and cardiac 
activity a ventral incision was made in the neck and any tissue was moved aside thereby 
exposing the trachea. The trachea was then cannulated by insertion of a nylon intravenous 
cannula (Sims Portex Ltd, Kent, UK). An incision was made below the level of the 
diaphragm upwards to expose the ribcage. The ribcage was then removed exposing the 
lungs and trachea. The trachea and lungs were then removed from the thoracic cavity and 
the heart and any fat and connective tissue were then removed. The right bronchi was 
clamped shut with Spencer-Wells forceps so the lavage could be performed on the left 
lung only.
Saline (0.9%, lOOml/kg) was then injected into the left lung with a syringe, via the 
tracheal cannula. After 3 minutes the fluid was withdrawn, while gently massaging the 
lung. This procedure was repeated and the two recovered BALF samples were combined 
and placed on ice for total and differential cell counts. Only plasticware was used for the 
collection process to minimise adherence of the cells to the surface of the tube.
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2.1.5 Total and differential cell counts
Total cell counts (cells/ml) were determined using a Neubauer haemocytometer 
(Marienfield, Germany) with a light microscope (XI0, Nikon, Tokyo, Japan).
Differential cell counts were then undertaken to determine the levels of alveolar 
macrophages, eosinophils, lymphocytes and neutrophils. A lOOpl sample of the BALF 
was centrifuged using a cytospin (ThermoShandon Ltd. Cheshire, UK) at 1000 r.p.m. for 
7 minutes, onto a glass microscope slide and air-dried. The slides were then stained with 
1.5% Leishman’s stain (Sigma-Aldrich, Dorset, UK) for 7 minutes. Using a light 
microscope (XI00, Nikon, Tokyo, Japan), a minimum of 200 consecutive cells were 
examined, using standard morphological criteria (see leukocyte morphology 2.1.6) to 
determine the cell type and expressed as a percentage. Using the corresponding total cell 
count, cells/ml for the subtypes of leucocytes in each guinea-pig could then be 
determined.
The remainder of the BALF was then centrifuged (Mistral 3000, Fisher Scientific, 
Loughborough, UK) at 2000 r.p.m. for 6 minutes and the cell free supernatant transferred 
into 1ml aliquots and stored at -80°C for further analysis.
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2.1.6 Leukocyte morphology after Leishman’s staining 
Macrophages
Macrophages are around 15 to 20pm in diameter. They have a single, dark bluish purple 
nucleus near the centre o f the cell. The cytoplasm has an irregular appearance and a much 
lighter bluish purple colour (Fig. 2.2).
Eosinophils
Eosinophils are around 10 to 14 pm in diameter. They have a dark blue bi-lobed nucleus. 
The cytoplasm is granular and dark red (Fig. 2.2).
Lymphocytes
Lymphocytes vary in size from around 6 to 10pm or more in diameter. They have a large, 
off centre bluish purple nucleus which almost fills the whole cell, leaving an area of light 
blue cytoplasm at the perimeter of the cell (Fig. 2.2).
Neutrophils
Neutrophils are around 9 to 12pm in diameter. They have dark a blue multi-lobed 
nucleus and light pink granular cytoplasm (Fig. 2.2).
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Lymphocytes
Figure 2.2
Macrophages, eosinophils, lymphocytes and neutrophils after staining with leishman’s 
stain.
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2.1.7 Lung preparation
The smallest of the four lobes of the right lung was used to estimate percentage wet 
weight of the whole lung, while the other three lobes were stored at -80°C for viral 
recovery at a later date.
The four lobes were separated, then cleaned and dried thoroughly by blotting. The weight 
of the whole lung and the weight of the smallest lobe were then measured. The three 
larger lobes were then immediately frozen in liquid nitrogen and stored at -80°C for later 
analysis of viral titre. The smallest lobe was then placed in an oven set at 40°C until it 
had completely dried out to constant weight. Its weight was recorded as ratio of wet 
weight to total weight and recorded as a percentage according to the following equation:
wet weight -  dry weight
Percentage wet weight =   x 100
wet weight
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2.1.8. Data handling and statistical analysis
Baseline sGaw level was determined as the average of two sGaw readings taken before 
each challenge. Subsequent readings taken after challenge with histamine, bradykinin or 
ovalbumen were shown as percentage changes to the baseline value. Statistical 
comparison of histamine or bradykinin responses were determined between the 
percentage changes from baseline before and after treatment (e.g. viral inoculation, 
ovalbumen challenge or drug treatment).
The ovalbumen model of allergy shows distinct early and late phases of airway reactivity, 
however due to natural variation each animal can display these reactions at different time 
points. The average maximum decrease from baseline in each animal between 0 and 6 
hours and between 7 and 12 hours is shown in a separate graph to demonstrate the early 
and late phase respectively alongside the graph showing the time course (e.g. Fig. 5.9).
Statistical comparisons between mean values were made by a two-tailed Student’s t-test. 
A P value of <0.05 was considered significant. All values are presented as mean ± 
standard error of the mean (S.E.M.).
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2.2 Virus experiments
Inoculation o f guinea-pigs with virus
Viral inoculation was performed in a Class II safety cabinet (Captair Madcap 804, Erlab, 
Wiltshire, UK).
The guinea-pigs were held in a supine position with the head firmly supported. The virus 
or virus free medium was then pipetted into the nostrils using a Gilson Pipette. Each 
guinea-pig was given a 250pl inoculation: 125pl in one nostril, which was then repeated 
after 15 minutes in the other nostril. This procedure was then repeated 24 hours later. In 
all experiments a fresh vial of virus (or virus free media) was thawed immediately prior 
to inoculation to ensure no decrease in the viral titre and warmed by hand to 37°C to 
facilitate delivery.
Of the three established techniques for viral inoculation in guinea-pigs: intranasal 
(Hegele et al 1993), intratracheal (Folkerts et al 1992) and aerosolised inhalation 
(Streckert et al 1996), intranasal inoculation was used as it is simple, less invasive and 
causes minimum stress to the animals. Studies using colloidal carbon as a tracer have 
shown that the volume used is sufficient to allow the inoculum to enter all lobes of the 
lower respiratory tract in this weight of guinea-pig used (Dakhama et al 1997).
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2.3 Effects of inhaled bradykinin
Bradykinin exposure experiments
Airway reactivity to bradykinin was measured by recording pulmonary function using 
whole body plethysmography and recorded as sGaw (see pharmacological methods 
2.2.1). Baseline sGaw recordings were taken and then at 0, 5 and 10 minutes after a 20 
second exposure to bradykinin dissolved in saline.
The effects of bradykinin were also examined 1 hour after administration of captopril 
and/or phosporamidon to inhibit the enzymes ACE and NEP respectively. These enzymes 
catalyze the breakdown of bradykinin into inactive metabolites (see chapter 1) and 
therefore inhibitors were used in an attempt to prolong the duration of the inhaled 
bradykinin in the lung. Captopril was administered by i.p. injection (1 mg/kg) and 
phosphoramidon was administered by i.p. injection (0.1 mg/kg) or by inhalation (ImM,
20 minute exposure). The effect of combining captopril (i.p., 1 mg/kg) and 
phosphoramidon (ImM, 20 minute exposure) was also examined.
The effect of the duration of bradykinin exposure was examined by comparing 20, 40, 
and 60 second, 0.3mM bradykinin exposures after captopril (1 mg/kg) treatment.
Bradykinin is thought to produce bronchoconstriction by activation of the B2 bradykinin 
receptor on the airway smooth muscle (Fuller et al, 1987). The selective B2 bradykinin 
antagonists: Icatibant (lOpM inhalation exposure) and MEN 16132 (30, 100 or 
300nM/kg, i.p.) (1 or lOpM, 20 minute inhalation exposure) were administered 1 hour
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before inhalation exposure to ImM bradykinin in guinea-pigs treated with captopril 
(1 mg/kg).
At least 4 days after each experiment with icatibant and MEN16132 the animals were 
treated with an appropriate saline control (i.p. injection or inhalation exposure) before 
further exposure to ImM bradykinin with 1 mg/kg captopril. If a significant 
bronchoconstriction was not produced the animals were left for a further 4 days and the 
control experiment was repeated until a significant bronchoconstriction was seen. This 
was to determine the recovery from B2 receptor blockade.
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2.4 Ovalbumen sensitization and challenge
Ovalbumen sensitization
On days 1 and 5 guinea-pigs were sensitized with a bilateral i.p. injection of a suspension 
containing lOOpg of ovalbumen and lOOmg of aluminium hydroxide (Al(OH)3) which is 
an adjuvant and increases the immune response.
0.0 lg of ovalbumen was dissolved in 10ml sterile saline. 5g of Al(OH)3 was added to 
45ml of sterile saline. 5ml of the ovalbumen solution was added to the Al(OH)3 solution 
and places on a magnetic stirrer for at least 2 hours.
Ovalbumen exposure
On day 15 the animals were placed in a steel exposure chamber (40cm diameter, 15cm 
height) and given a 60 minute inhalation exposure of ovalbumen (0.01%). Any animals 
that looked to be in respiratory distress were immediately removed from the exposure 
chamber and the exposure considered complete. Lung function measurements were taken 
by whole body plethysmography immediately before challenge and at 0, 15, 30, 45 and 
60 minutes after, then hourly up to 12 hours and finally at 24 hours.
Histamine exposure
Animals were given a 20 second, nose only histamine exposure on the day before and the 
day after ovalbumen exposure (see pharmacological methods 2.1.3).
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Dosing with drugs
Animal were dosed twice daily by bilateral subcutaneous injection from day 8 to day 14 
and 1 hour before ovalbumen exposure on day 15 with either saline or lOmg/kg 
deamethasone in saline.
Bronchoalveolar lavage
Within 30 minutes of the histamine exposure the animals were sacrificed with an 
overdose of anaesthetic, pentobarbital sodium, by bilateral intraperitoneal injection and a 
bronchoalveolar lavage was performed (see pharmacological methods 2.1.4).
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2.5 Cell culture and viral growth
Cell Culture
All cell culture and viral growth and detection procedures were performed in a Class II 
microbiological safety cabinet (Envair, Lancashire).
African green monkey kidney epithelial (VERO) cells, provided by Dr Joachim Bugert 
(University of Wales College of Medicine, Medical Microbiology), were obtained from 
the European Collection of Cell Cultures (ECCAC, Wiltshire). The cells were grown in a 
T75 culture flask (Fig. 2.3). The medium (10ml per flask) consisted of Dulbecco’s 
modified essential medium (DMEM), 10% heat inactivated foetal bovine serum (FBS) 
and 1% L-glutamate (the L-glutamate was added to the DMEM). It was decided not to 
use antibiotics, to ensure complete absence of bacterial contamination, the presence of 
antibiotics could mask any low level bacterial contamination, which would become easily 
detectable in the absence of antibiotics. This would avoid the possibility of inoculating 
guinea-pigs with bacterial debris, which could generate inflammatory responses to 
obscure the viral actions. The cells were grown to almost total confluence and then split 
or virally infected. The cells were incubated at 37°C in a humidified incubator (Sanyo, 
Osaka, Japan) maintained at 95% with an atmosphere of 95% O2, 5% CO2
Splitting VERO cells
VERO cells were split when they reached almost total confluence in the T75 culture flask 
(Fig. 2.3). The medium was first removed and the cells were then washed with 1ml of
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trypsin, which was then immediately removed. The cells were then incubated with 1ml of 
trypsin, covering all cells at 37°C for 7minutes. After removal from the incubator the side 
of the culture flask was tapped twice on the side of the bench to ensure all cells had 
detached from the surface of the flask and examined in the light microscope (xlO)
(Nikon, Tokyo, Japan). 1ml of FBS was then added to inactivate the trypsin. DMEM and 
FBS were then added as required. The suspension was pippetted up and down to 
distribute the cells evenly in the medium. 10 ml of the cell suspension was then removed 
and added to each new T75 culture flask.
Growth and harvesting o f virus
Human PIV-3 (Strain:DEL/l39/05) and PIV-2 (Strain: Greer) virus provided by Dr 
Joachim Bugert (University of Wales College of Medicine, Medical Microbiology) was 
obtained from ECCAC (Wiltshire, UK). VERO cells were considered ready for viral 
infection when the monolayer of cells reached almost total confluence in the culture 
flask. The medium was removed and the cells were trypsinized as described above 
(splitting cells) and 1ml of FBS was added to deactivate the trypsin. The cells were then 
transferred to a 50ml bluecap centrifuge tube. The cells were pelleted by centrifugation 
(Jouan CR412, Fisher Scientific, Loughborough, UK) at 1200 r.p.m. for 6 minutes. The 
supernatant was removed and the cells were resuspended in 2ml of DMEM. A previously 
frozen vial of virus was then defrosted by hand and the virus was added to the cells and 
mixed by pipetting up and down three times. The cell/viral suspension was then placed in 
the incubator for 30mins, and swirled by hand every 5mins to ensure the virus has access
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to every cell. 3ml of the cell/viral mix was then added to the T75 flask and topped up 
with 7ml of DMEM and the flask was replaced in the incubator.
After 4 to 5 days the cytopathic effects (CPE) of viral infection became obvious, with 
large syncitia (multi-nuclear cells) and dead cells floating in the medium (Fig. 2.3). The 
virus was then harvested. The cells were frozen at -80°C for 5minutes and allowed to 
thaw at room temperature to break open the cell membranes. This freeze-thaw cycle was 
repeated twice and the resulting suspension was transferred to a 50ml centrifuge tube and 
centrifuged (Jouan CR412, Fisher Scientific, Loughborough, UK) at 4000 r.p.m. for 5 
minutes to remove cellular debris. The supernatant was then transferred into sterile 1ml 
vials and stored at -80°C. For control inoculation uninfected infected VERO cells were 
subjected to the same procedure.
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Figure 2.3
Confluent VERO cells (A and B), infected with PIV-3 (C and D) and PIV-2 (E and F).
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Influenza
All Influenza A H1N1 viruses were grown and provided by Dr Joachim Bugert.
The WSN33 strain was obtained from ECCAC-NCPV (NPCV No.402). It was isolated 
from throat washings of a patient with influenza in London in 1933 (Burnett 1951). The 
virus was grown in Madine-Darby Canine Kidney epithelial cells (MDCK). Media from 
uninfected MDCK cells was used for control inoculation.
The A/PR/8/34 strain was obtained from ECCAC-NCPV (NPCV No.235). It was isolated 
from a patient in Puerto Rico (Francis and Magill 1935). The virus was grown in chicken 
embryos and harvested in the allantoic fluid. Allantoic fluid from uninfected chicken 
embryos was used for control inoculation.
Despite the increasing use of tissue culture, chicken embryos are still the most sensitive 
host mechanism for influenza (Clavijo et al 2002). The amniotic cavity, allantoic cavity, 
yolk sac and chorioallantoic membrane are used for growth of virus. The allantoic cavity 
was used as the yield of virus is greater.
Freshly layed, fertilized specific pathogen free eggs were obtained from the Institute for 
Animal Health (Compton, Newbury, UK). The eggs were stored in the incubator at 37°C 
at relative humidity of 30-40%. The eggs were examined daily with a bright lamp in a 
darkened room to ensure the eggs were still alive. After seven days a small hole was 
made with a sterile drill over the egg sack and a needle was inserted and lOOpl of virus 
was inserted through the chorioallantoic membrane into the allantoic cavity. The hole 
was sealed with candle wax and the eggs were placed in the incubator at 35%, which is
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the best temperature for mammalian influenza growth. After three days the eggs were 
chilled for at 4°C for 18 hours to constrict blood vessels and make harvesting easier. The 
shell over the air over the air sac was broken with sterile forceps, the chorioallantoic 
membrane pushed aside and amniotic and allantoic fluids were collected using a needle 
and syringe. The embryos were then killed by decapitation. The harvested fluid was then 
centrifuged at 4000 r.p.m. for 5 minutes to remove excess blood and tissues. In these 
procedures a Home Office project or personal license was not required as all procedures 
were performed before the halfway point of gestation.
TCIDso
Tissue culture infective dose (TCID50) refers to the quantity of virus that will produce 
cytopathic effects in 50% of wells (for example in a 96 well plate) infected.
450pl of DMEM was added to 10 wells of a 24 well plate, which were marked -1 to 
-10. A vial of the previously frozen virus was thawed by hand and 50pl was removed 
and added to the well marked -1 and pipetted up and down three times. Serial 1 in 10 
dilutions were made up to -10 and the plate was placed on ice. A T75 cell culture flask 
almost confluent with VERO cells was trypsinised as previously described. After the 
addition of the FBS to deactivate the trypsin, the cells were centrifuged (Jouan CR412, 
Fisher Scientific, Loughborough, UK) at 1000 r.p.m. for 6 minutes, the supernatant was 
then removed and the cells were resuspended in 5ml of DMEM. The first 10 columns of a 
96 well plate were labelled -1 to -10 and the last two were left for control. 50pl of each 
viral dilution from the 24 well plate was added to each of the wells of the corresponding
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column of the 96 well plate. 50pl of DMEM was added to each of the wells of the last 
two columns. 50pl of the VERO cell suspension was then added to every well and the 
plate was placed in the 37°C incubator (Fig. 2.4). The cells were then checked every day 
for cytopathic effects. After around 8 to 10 days, when no additional wells had shown 
any sign of infection for two days, the cells were stained. The media was removed and 
50pi of crystal violet was immediately added to each well and left for 30 minutes. The 
crystal violet was then washed off with water and the plate was left to dry. Each well was 
then examined for signs of infection, which were easily determined as there was very 
little staining of the cells that had been destroyed. The uninfected and control wells 
showed complete staining as the cells were intact (Fig. 2.4).
The viral concentration was then determined using the Karber formula (Reed and 
Meunch 1938) (Fig. 2.4).
The final viral concentration for inoculation was determined by tissue culture infective 
dose (TCIDsomf1). Two concentrations of PIV-3 were used. In the initial experiments, 
the viral concentration used was 6.32 x 106 infectious units per ml. In the later 
experiments the viral concentration was 3 x 108 infectious units per ml. The concentration 
of PIV-2 used was 1 x 108.
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2.6 Viral recovery and identification
RNA purification
50jnl of RNA was purified from 200pl samples of BALF using the RNeasy mini kit 
(Qiagen, Crawley, West Sussex).
Synthesis o f cDNA
8pl of each sample of purified RNA, 1 pi of random hexamers and lul of a dNTP mix 
were added to a 0.2ml sterile centrifuge tube and placed in a thermal cycler (PTC-100, 
Biorad, Hemmel Hemsread, UK) heated to 65°C to for 5 mins and then cooled to 4°C. 2pl 
of 10 x RT buffer, 4pl of 25mM MgCl2, 2pl of 0.1M DTT and lpl of RNAse inhibitor 
were then added to each tube then mixed by pippeting and heated to 25°C for 5minutes.
1 pi (50 units) of reverse transcriptase was then added to each tube and after another 10 
minutes at 25°C they were heated to 42°C for 50 minutes then to 72°C for 15 minutes 
then the experiment terminated at 4°C.
Amplification o f cDNA
The amplification of cDNA was performed in a 2 step process. Fig. 2.5 shows a diagram 
of the PIV-3 genome with the haemaglutinin-neuraminidase gene and PCR products with 
the location of the primers used.
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Dilution Infected % Inf
1 0 - 1 8 / 8 1 0 0
1 0 - 2 8 / 8 1 0 0
10-3 8 / 8 1 0 0
10-4 8 / 8 1 0 0
10-5 8 / 8 1 0 0
1 0 - 6 8 / 8 1 0 0
10-7 3/8 37.5
1 0 - 8 0 / 8 0
10-9 0 / 8 0
1 0 - 1 0 0 / 8 0
Figure 2.4
50% endpoint titer = 1 Ologd,lut,on above 50% mfect,on' (I xLog H)
I = 100-50 = 0.8
100-37.5
log Dilution above 50 % Infection =10-6 
dilution factor = 10, Log dilution factor = 1
50% endpoint titer = 10-6 *(0 8x
50% endpoint titer = 10-6 8
= 106 8 TClD50/50pl 
= 6.31 x 106 TCID50/50pl 
= 1.26 x 108 TCID50/ml
A: Diagram of a 96 well plate showing the viral dilution or DMEM added to each 
column. 50|il of VERO cells in DMEM was then added to each well. Red circles show 
infected wells, white non-infected and yellow control. B: Table showing percentage 
infection for each dilution. C: Karber formula calculation where I = interpolated value of 
50% endpoint (percentage of wells infected above 50%)-50 / percentage of wells infected 
above 50% - % of wells infected below 50%) and H = dilution factor.
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Round 1:
For each sample add to PCR tube
•  15 p lo fH 2 0
• 2.5 pi of PCR buffer P2192
• 2 pi of dNTP
• 0.5 pi of Primer PIV-3 forward
• 0.5 pi of Primer PIV-3 reverse
• 0.2 pi of Taq polymerase
• 4pl of cDNA sample
Placed in thermal cycler for:
• 30 minutes at 58°C
• 15 minutes at 94°C
■ 45 cycles of: 30 seconds at 95°C, 30 seconds at 58°C and 30 seconds at 72°C
Round 2 as before but 1 pi of cDNA sample (3pl more H2O), PIV-3 nested forward and
reverse primers and only 32 cycles.
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sRNA genome of :11216 nucleotides, 4 structural, 3 non-structural genes. 
NP C P M F HN L
HN
PIV-3 strain DEL/139/05-EU814626
1719
Figure 2.5
Simplified diagram of RNA genome of PIV-3, showing size of Haemaglutinin- 
neuraminidase gene (HN) and PCR products with primers used (PIV-3 forward and 
reverse and PIV-3 nested forward and reverse).
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Tissue culture
In a class II safety cabinet (Envair, Lancashire) previously frozen guinea-pig lung was 
thawed and a piece (0.1 -  0.2g) was removed and placed in a tube with ceramic beads in 
lml of sterile PBS and placed in a Precellys24 shaker (Bertin technologies, Montigny-le- 
Bretonneux, France) for 40 seconds at 5600rpm to homogenization the tissue. After 
centrifugation (1000 r.p.m., 1 minute) to remove debris serial dilutions of the supernatant 
were made and used to infect VERO cells in a 96 well plate as explained above 
(Methods, cell culture and viral growth, TCID50).
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2.7 Materials
Dulbecco’s modified essential medium, 10% heat inactivated foetal bovine serum, 
histamine diphosphate salt, crystal violet, bradykinin acetate, icatibant, phosphoramidon 
disodium salt, dexamethasone 21-phosphate disodium salt, captopril, Leishman’s, stain, 
PCR buffer P2192, aluminium hydroxide and DMSO were purchased from Sigma- 
Aldrich, Dorset, UK.
Random Hexamers (50ng/pl), lOmM dNTP Mix, 5X cDNA synthesis buffer, 25mM 
MgCU, 2pl of 0.1 M DTT, RNaseOUT RNAse inhibitor and Cloned AMV reverse 
transcriptase (15 U/pl) were purchased from Invitrogen, London, UK as part of the 
Cloned AMV First-Strand cDNA Synthesis Kit.
1% L-glutamate and trypsin were purchased from Invitrogen, London, UK.
Taq DNA polymerase purchased from Roche, Basel, Switzerland.
Euthatal was purchased Genus express, Chepstow, UK 
MEN16132 was donated by Menarini Research, Pomezia, Italy.
FE999024 was donated by Ferring Research, Chilworth, UK
Ovalbumen was purchased from BDH laboratory supplies, Poole, Dorset, UK.
Unless otherwise stated drugs were dissolved in 0.9% sterile saline (for injections) Baxter 
Healthcare, Thetford, Norfolk, UK.
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Chapter 3
Effects of viral inoculation on 
guinea-pig airways
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3.1 Introduction
Viral infection and asthma
Virus infections, including parainfluenza induce changes in the airways that are similar to 
the effects seen in asthma including bronchial hyper-responsiveness, an influx of 
inflammatory cells, epithelial damage and bronchiolar fibrosis (Folkerts et al 1992). Viral 
respiratory infections are the most common cause of asthma exacerbations (Pattemore et 
al 1992). These changes raise the questions of the involvement of PIV in the 
pathogenesis and/or exacerbations of asthma.
Parainfluenza virus
Parainfluenza viruses (PIV) were first discovered in the late 1950’s. They have been 
divided into subtypes 1 to 4, with PIV-4 being further divided into types a and b. Types 1 
to 3, along with Respiratory Syncytial Virus (RSV) are major causes of lower respiratory 
tract disease in infants, the young, the immunocompromised and the elderly (Glezen et al 
1984; Glezen et al 2000; Falsey 1991). PIV infection can cause croup, bronchiolitis, and 
bronchopneumonia, though the most common presentation is an upper respiratory tract 
infection (Belshe et al 1983). The pathogenesis of PIV infection is still being studied but 
respiratory epithelium appears to be the major site of virus binding and subsequent 
infection. The epithelium is an extensive source of inflammatory mediators including 
chemokines and cytokines, which can be released to recruit inflammatory cells after viral 
infection (Garofalo and Haebere 2000). PIV has been shown to cause inflammatory cell 
influx after instillation intranasally to guinea pigs (Toward et al 2005) and rats 
(MeWilliam et al 1997). This was accompanied by airway hyperreactivity to histamine in
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guinea-pigs (Toward et al 2005). In order to examine drug interventions on PIV-induced 
inflammation and AHR, it was first necessary to examine the relative ability of PIV-2 and 
PIV-3 to produce these changes and to confirm that there was viral infection of the lungs 
by recovery of live virus and to identify the virus in the lungs by means of PCR. The 
effects of different inoculation titres were also examined.
Influenza in guinea-pigs
Mice are known to be susceptible to infection with influenza virus (Schulman and 
Kilboume 1963) and several studies have shown that guinea-pigs are susceptible to 
infection by influenza. Azoulau-Dupouis etal (1984) caused significant histopathological 
changes to the whole respiratory tract after infection with influenza A/Hong Kong/68 
(H3N2) and Lowen et al (2006) demonstrated the spread of influenza between guinea- 
pigs after infection with A/Panama/2007/99 (H3N2). Although many studies have shown 
airway hyperreactivity to inhaled histamine after PIV inoculation (Toward et al 2005) no 
studies have shown airway hyperreactivity after influenza inoculation. This study was 
therefore undertaken to establish airways inflammation and AHR in guinea-pigs after 
infection with influenza virus. Type of virus and method of culture were compared to 
obtain optimum levels of AHR for evaluation of drug interventions.
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3.2 Methods
Airway reactivity test
On days 2 and 8, airway reactivity, measured as specific airways conductance (sGaw) was 
tested by whole body plethysmography as described in chapter 2. Baseline readings were 
taken and then at 0, 5 and 10 minutes after a nose only ImM histamine inhalation 
exposure.
Virus inoculation
On days 3 and 4 the guinea-pigs were inoculated intranasally with 250pl of virus in 
different known titres or with virus-free medium.
Bronchoalveolar lavage
Within 30 minutes of the second histamine exposure the animals were killed and a 
bronchoalveolar lavage was performed on the left lung. The total cells in the recovered 
BALF were counted using a haemocytometer. The cells were then centrifuged on to a 
slide, stained with Leishman’s stain so that a differential cell count could be performed. 
Macrophages, eosinophils, lymphocytes and neutrophils were counted.
Viral recovery
Following removal of the lungs, the right lung was immediately placed on ice and then 
stored at -80°C for subsequent viral recovery. A lOOpg section of the right lung was 
homogenized in PBS and after centrifugation the supernatant was used to infect VERO 
cells in a 96 well plate to determine viral titre.
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Experimental Protocol
The experiments performed in this chapter were aimed at establishing the optimum 
conditions for virus-induced airways inflammation and airways hyperreactivity for future 
studies with drug interventions. In preparation for drug intervention studies, these studies 
were performed with vehicle administrations at the proposed drug treatment times. The 
selected vehicles were saline or dimethyl sulphoxide (DMSO) (25 or 50%) in saline all 
delivered by the subcutaneous (s.c.) route. The guinea pigs received bilateral s.c. 
injections every 12 hours of either
• 0.9% sterile saline
• 25 or 50% DMSO in 0.9% sterile saline 
The volume used was lml\kg
Day 1: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline 
Day 2: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline and 
reactivity test to histamine
Day 3: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline and 
inoculation 3 hours later with virus or virus free medium
Day 4: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline and 
inoculation 3 hours later with virus or virus free medium
Day 5: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline 
Day 6: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline 
Day 7: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline
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Day 8: Dosing with 0.9% sterile saline or DMSO (25 or 50%) in 0.9% sterile saline, 
reactivity test to histamine and lavage
Viral identification
Viral identification was undertaken by PCR on the BAL fluid recovered from the left 
lung. RNA was purified using the RNeasy mini kit then cDNA was synthesized using the 
Superscript™ II reverse transcriptase enzyme. The DNA was then amplified using 
primers specific for a section of the haemaglutinin-neuraminidase gene of PIV-3.
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3.3 Results
3.3.1: Effects of parainfluenza on airway inflammation in guinea-pigs 
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 3.1 and 3.2).
After inoculation with 3 x 108 infectious units per ml of PIV-3 there was evidence of 
airway hyperreactivity as there was a 31.5 ± 6.3% reduction in sGaw value at 0 minutes 
after histamine exposure compared to the baseline value. There was a recovery after 5 
and 10 minutes but not to baseline (Fig. 3.1 and 3.2).
There were also significant decreases in sGaw after histamine exposure after inoculation 
with PIV-2 (1 x 108 infectious units per ml) and PIV-3 (6.32 x 106 and 3 x 108 infectious 
units per ml) (Fig. 3.2).
The highest concentration of PIV-3 produced the greatest decrease in sGaw after 
histamine exposure but there was no significant difference in the decrease in sGaw seen 
compared to histamine exposure after inoculation with PIV-2 or the lower concentration 
of PIV-3 (Fig 3.2).
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Figure 3.1
o
Airway function before and after PIV-3 (3x10 infectious units per ml) virus infection in 
saline treated guinea-pigs. Each point represents the mean ± standard error of mean (n=6) 
change in sGaw expressed as a percentage of the baseline sGaw values, shown at 0, 5 and 
10 minutes after a nose only ImM histamine exposure. Negative values represent 
bronchoconstriction. * denotes the significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point, before and after virus inoculation as 
determined by a Student’s t test (paired).
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Figure 3.2
Maximum change in sGaw from baseline in saline treated guinea-pigs after ImM 
histamine exposure recorded at the corresponding time before and after inoculation with 
PIV-2 (1 x 108 infectious units per ml) or PIV-3 (6.32 x 106 or 3 x 108 infectious units per 
ml). Each point represents the mean ± standard error of mean (n=6). * denotes the 
significance (P<0.05) in difference in the maximum decrease in sGaw from baseline 
before and after viral inoculation, as determined by a Student’s t test (paired).
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Bronchoalveolar lavage cell counts
In animals inoculated with medium and treated with saline, the numbers of macrophages, 
lymphocytes, eosinophils and neutrophils in the BALF were as follows; total cells: 1.54 ± 
0.17 (xl06/ml), macrophages: 1.37 ±0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), 
lymphocytes: 0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig. 3.3).
In PIV-2 (1 x 108) inoculated guinea pigs treated with saline, there were significant 
increases in total cells, macrophages, eosinophils and neutrophils compared to the no 
virus control. There was also a modest increase in lymphocytes (Fig. 3.3).
In PIV-3 (6.32 x 106) inoculated guinea pigs treated with saline, there were significant 
increases in total cells, macrophages, eosinophils and lymphocytes compared to the no 
virus control. There was also a modest increase in neutrophils. There was no significant
Q
difference compared to the PIV-2 ( 3 x 1 0 )  inoculated group but modest increases in total 
cells, macrophages, eosinophils and lymphocytes but slightly fewer neutrophils (Fig.
3.3).
In PIV-3 (3 x 108) inoculated guinea-pigs treated with saline, there were significant 
increases in total cells, macrophages, eosinophils, lymphocytes and neutrophils compared 
to the no virus control. There was a significant increase in total cells compared to the 
PIV-2 (1 x 108) inoculated group but only modest increases in each individual cell type.
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There were modest but insignificant increases in all cell types compared to the PIV-3 
(6.32 x 106) inoculated group (Fig. 3.3).
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Figure 3.3
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from virus free medium, PIV-2 (1 x 108 infectious units per ml) or PIV-3 
(6.32 x 106 or 3 x 108 infectious units per ml) inoculated guinea-pigs. Each bar represents 
the mean ± standard error of mean (n=6) of total or differential count of cells per ml/10^. 
* denotes the significance (P<0.05) of difference compared to the corresponding no virus 
control group and + denotes the significance (P<0.05) of difference compared to the 
corresponding PIV-2 group as determined by a Student’s / test (paired).
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Percentage lung wet weight
In animals receiving no virus and treated with saline, the percentage wet weight of the 
lung tissue was 79.0 ± 0.4 (Fig. 3.4).
In the PIV-2 (1 x 108) inoculated guinea-pigs treated with saline the percentage wet 
weight had increased significantly compared to the media control to 81.7 ± 0.3%.
(Fig. 3.4).
In the PIV-3 (6.32 x 106) inoculated guinea-pigs treated with saline the percentage wet 
weight had increased significantly compared to the media control to 81.6 ± 0.5%.
(Fig. 3.4).
o
In the PIV-3 ( 3 x 1 0 )  inoculated guinea-pigs treated with saline the percentage wet 
weight had increased significantly compared to the media control to 82.4 ± 0.8%.
(Fig. 3.4).
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Figure 3.4
Effect on percentage wet lung weight of inoculation with virus free medium, PIV-2 (1 x 
108 infectious units per ml) or PIV-3 (6.32 x 106 or 3 x 108 infectious units per ml) in 
saline treated guinea-pigs. Each bar represents the mean ± standard error of mean (n=6). 
* denotes the significant (P<0.05) difference between the viral inoculated groups and 
their corresponding no virus controls as determined by a Student’s t test (paired).
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Viral recovery
After 25% DMSO treatment and inoculation with 3 x 108 of PIV-3 the average amount of 
virus recovered per gram of lung tissue and grown on VERO cells was 3.62 x 104 ± 2 x 
104 (Fig. 3.5).
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Figure 3.5
Effect of 25% DMSO on PIV-3 recovered from guinea-pig lung tissue after inoculation 
with 3 x 108 of PIV-3. Each point shows the amount of PIV-3 recovered per gram of lung 
tissue and grown in VERO cells and — shows the average (n = 6).
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Virus identification
Two step PCR
Step 1: cDNA amplification using PIV forward and PIV-3 reverse primers with product 
477 base pairs long.
Step 2: cDNA amplification of fragment from within product of step 1 using nested PIV- 
3 forward and nested PIV-3 reverse primers with product 102 base pairs long.
Strong bands are seen at around the 100 base pair ladder size in the standards from 107 
infectious units per ml down to 104, but no band at 103 and 102 (Fig. 3.6).
A strong band was seen at the 100 base pair ladder size in the BALF from the PIV-3 
infected guinea-pig treated with 25% DMSO sample but only a faint band in the guinea- 
pig treated with saline. Comparison with the standards indicates that the BALF samples 
had at least 103 copies of the viral RNA as this was below the detection limit in the 
standards (Fig. 3.6).
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Figure 3.6
PCR with 100 base pair ladder (100 and 200 base pairs shown), PIV-3 standards (107 to 
102 infectious units per ml) and BALF from PIV-3 (3 x 108 infectious units per ml) 
inoculated guinea-pigs treated with 25% DMSO or saline. Strong band are seen at around 
the 100 base pair ladder size in the standards from 107 infectious units per ml down to 
104, but no band at 103 and 102. There is also a strong band at the 100 base pair ladder 
size in the BALF from PIV-3 infected guinea-pig treated with 25% DMSO sample but 
only a faint band in the guinea-pig treated with saline.
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3.3.2: Effects of influenza on airway inflammation in guinea-pigs
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 3.7 and 3.8), since this was a sub-threshold dose 
of histamine.
Effect o f inoculation with WSN33 (9.35x10s) grown in MDCK cells 
In 25% DMSO treated guinea-pigs inoculated with influenza WSN33 virus, there was no 
evidence of airway hyperereactivity as there was only a small -3.1 ± 2.6% decrease in 
sGaw after viral inoculation (Fig. 3.8).
Effect o f  inoculation with A/PR/8/34 (1.1 xlO5) grown in chicken embryos 
In 25% DMSO treated guinea-pigs inoculated with influenza A/PR/8/34 virus, there was 
no evidence of airway hyperereactivity as there was no decrease in sGaw after viral 
inoculation (Fig. 3.8).
Effect o f inoculation with A/PR/8/34 ( l .lx l t f )  grown in chicken embryos 
In 25% DMSO treated guinea-pigs inoculated with a higher titre of A/PR/8/34 virus there 
was evidence of airway hyperreactivity after viral inoculation as there was a -20.4 ± 3.7% 
reduction in sGaw value at 0 minutes after histamine exposure compared to the baseline 
value. sGaw values recovered to -9.7 ± 4.9% after 10 minutes (Fig. 3.7 and 3.8).
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Figure 3.7
Airway response to histamine before and after influenza H1N1 A/PR/8/34 (l.lx lO 6, 
grown in chicken embryos) virus infection in 25% DMSO treated guinea-pigs. Each point 
represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes after a nose only 
ImM histamine exposure. Negative values represent bronchoconstriction.. * denotes the 
significance (P<0.05) in difference between the changes to baseline sGaw values at each 
time point, before and after virus inoculation as determined by a Student’s t test (paired).
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Figure 3.8
Maximum decrease in sGaw from baseline in GPs after ImM histamine exposure before 
and after inoculation with H1N1:WSN33 (9.35x10s) grown in MDCK cells, A/PR/8/34 
(l.lx lO 5) and (l.lx lO 6) grown in chicken embryos and all were treated with 25% 
DMSO. Each bar represents the mean ± standard error of mean (n=6). * denotes the 
significance (P<0.05) in difference in the maximum decrease in sGaw from baseline 
before and after viral inoculation, as determined by a Student’s t test (paired).
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Bronchoalveolar lavage cell counts
In animals inoculated with media, the numbers of macrophages, eosinophils, 
lymphocytes and neutrophils in the BALF were as follows; total cells: 1.96 ± 0.11 
(xl06/ml), macrophages: 1.47 ± 0.08 (xl06/ml), eosinophils: 0.28 ± 0.04 (xl06/ml) 
lymphocytes: 0.07 ± 0.01 (xl06/ml) and neutrophils 0.14 ± 0.02 (xl06/ml) (Fig. 3.9).
In the animals inoculated with H1N1 WSN33 (9.35x105) grown in MDCK cells there 
was a significant increase in macrophages and smaller non-significant rises in 
eosinophils, lymphocytes and neutrophils (Fig 3.9).
In animals inoculated with allantoic fluid from chicken embryo, the numbers of 
macrophages, eosinophils, lymphocytes and neutrophils in the BALF were as follows; 
total cells: 2.39 ±0.1 (xl06/ml), macrophages: 1.95 ±0.11 (xl06/ml), eosinophils: 0.28 ± 
0.08 (xl06/ml) lymphocytes: 0.08 ± 0.02 (xl06/ml) and neutrophils 0.08 ± 0.02 
(xl06/ml). Compared to the media control, the macrophages were significantly increased, 
but there were no increases in eosinophils, lymphocytes or neutrophils (Fig. 3.9).
In the animals inoculated with H1N1 A/PR/8/34 l.lxlO5grown in a chicken embryo 
there were significant increases in macrophages, eosinophils and lymphocytes and a 
smaller but insignificant increase in neutrophils. In the animals inoculated with the higher 
concentration (l.lxlO 6) of the same virus compared to the allantoic fluid no virus control,
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there was a significant increase in macrophages and a smaller increase in eosinophils. 
There was no increase in lymphocytes or neutrophils (Fig. 3.9).
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Figure 3.9
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from virus free medium, H1N1 WSN33 (9.35* 105) grown in MDCK 
cells, allantoic fluid from chicken embryo, and H1N1 A/PR/8/34 grown in chicken 
embryo (l.lxlO 5and l.lx lO 6) all treated with 25% DMSO. The final group were 
inoculated with H1N1 A/PR/8/34 grown in chicken embryo (l.lx lO 6) and treated with 
dexamethasone (10 mg/kg in 25% DMSO. Each bar represents the mean ± standard error 
of mean (n=6) of total or differential count of cells per ml/10 . * denotes the significance 
(P<0.05) of difference compared to the corresponding no virus control and + denotes the 
significance (P<0.05) of difference compared to the egg control group as determined by a 
Student’s t test (paired).
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Percentage wet lung weight
In animals receiving medium only with no virus, the percentage wet weight of the lung 
tissue was 81.0 ± 0.3 (Fig. 3.10).
In the animals inoculated with H1N1 WSN33 (9.35x105) grown in MDCK cells there 
was no increase in wet weight compared to the no virus control.
In animals inoculated with allantoic fluid from chicken embryo there was no significant 
increase in wet weight compared to the no virus control; in fact there was a reduction.
In the animals inoculated with H1N1 A/PR/8/34 l.lxlO5grown in a chicken embryo 
there was a modest increase in wet weight compared to the allantoic fluid control.
In the animals inoculated with the higher concentration (l.lxlO 6) of the same virus there 
was a further increase in wet weight but not a significant increase compared to the 
allantoic fluid control (Fig. 3.10).
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Figure 3.10
Effect on percentage wet lung weight of inoculation with: virus free medium, H1N1 
WSN33 (9.35x105) grown in MDCK cells, allantoic fluid from chicken embryo, and 
H1N1 A/PR/8/34 (1.1x10sand l.lx lO 6), all treated with 25% DMSO. Each bar 
represents the mean ± standard error of mean (n=6). There was no significant (P<0.05) 
difference between the viral inoculated groups and their corresponding no virus controls 
as determined by a Student’s t test (paired).
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3.4 Discussion
Effects o f PIV inoculation on airway hyperreactivity
PIV infection resulted in bronchoconstriction to a dose of inhaled histamine that prior to 
inoculation produced no response. This indicates airway hyperreactivity 4 days after the 
viral infection. Inoculation with a higher concentration of PIV-3 resulted in a greater 
bronchoconstriction than with the lower concentration. Inoculation with a high 
concentration of PIV-2 produced a bronchoconstriction similar to that seen with the lower 
concentration of PIV-3 but much lower than the higher concentration of PIV-3. The 
respiratory epithelium is thought to be the major site of binding and replication of PIV 
(Garofalo and Haebere 2000). The subsequent damage leads to epithelial dysfunction and 
can cause AHR by a variety of mechanisms including increased exposure of airway 
smooth muscle to histamine mediated bronchoconstriction via Hi receptors.
The respiratory epithelium is a source of NO which increases cGMP levels and induces 
bronchodilatation. Damage to the epithelium would reduce the levels of NO and could 
cause AHR in much the same way as NO synthase inhibitors cause AHR in guinea-pigs 
(Nijkamp et al 1993).
Damage to the epithelium can also expose sensory C-fibres, activation of which can 
cause release of tachykinins including NKA and SP which act predominantly on NKj and 
NK2 receptors respectively (Nakanishi 1991). Activation ofNK2 receptors mediates 
contraction of human airways smooth muscle in vitro (Frossard and Barnes 1991). The 
most important effect of tachykinins is possibly the effect on airways blood vessels. SP is
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the tachykinin most potent in causing microvascular leakage in guinea-pigs indicating a 
NKi mediated effect (Lotvall et al 1990).
Tachykinins can also cause the release of acetylcholine (ACh) which causes 
bronchoconstriction by activation of M3 muscarinic receptors. PIV-1 has been shown to 
alter the function of the inhibitory M2 muscarinic receptor in guinea pigs. Release of ACh 
from parasympathetic nerves causes contraction of post-junctional M3 muscarinic 
receptors. Ach also binds to pre-junctional M2 muscarinic receptors, which reduces ACh 
release. Damage to this negative feedback system could lead to increased release of ACh 
(Fryer et al 1990). Thus, viral infection by damaging the airways epithelium could cause 
increased reactivity to inhaled histamine through release of tachykinins and reduced 
levels of NO.
Effects o f P IV  inoculation on inflammatory cell influx
PIV-3 infection produced an increase in inflammatory cell influx. The increases seen 
after PIV-3 inoculation were greater than those seen after PIV-2 inoculation. There was a 
small increase after increasing the concentration of PIV-3 but the change was not as great 
as the effect on the airway hyperreactivity. The pulmonary epithelium is the first site 
where interaction with the virus occurs. The epithelium synthesizes and releases a wide 
range of pro-inflammatory mediators in response to PIV-3 including interleukin (IL)-6 , 
IL- 8  , IL-11, granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
regulated-upon-activation normal-T cell-expressed and secreted (RANTES) (Barnes et al
1998). The release of these mediators from the epithelium would lead to a complex series
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of events including, activation of resident leukocytes, further release of cytokines and 
chemokines and the migration to the lungs of additional leukocytes as seen in this study.
Effect o f PIV-3 inoculation on pulmonary oedema
PIV infection appears to cause pulmonary oedema as there was an increase in the 
percentage wet weight of the lung tissue. There was an increase in wet weight after 
increasing the concentration of PIV-3. PIV-2 inoculation produced a similar increase to 
that seen with the lower dose of PIV-3. The increase in wet weight may be due to an 
increase in mucus production but the most likely cause is pulmonary oedema (Hwang et 
al 2001). Pulmonary oedema can be caused by increased blood pressure in the pulmonary 
capillaries or increased permeability of the capillary wall. PIV-3 infection can lead to a 
release in pro-inflammatory mediators which increase blood pressure in pulmonary 
capilliaries (thromboxane, 5-lipoxygenase and leukotrienes C4, D4 and E4) and increase 
permeability of the capillary wall (tachykinins, reactive oxygen species (ROS), mast cell- 
derived histamine, excess NO and ROS-activated proteolytic enzymes) (Barnes et al
1999).
Viral recovery and identification o f PIV-3
Recovery of live virus 4 days after inoculation confirms infection. As the respiratory 
epithelium is the main site of adhesion and replication of PIV-3 this would be the most 
likely location of the virus in the lung tissue. The most likely binding site is the ICAM 
receptors on the respiratory epithelium, ICAM-1 is the receptor for most rhinoviruses 
(Suzuki et al 2000). Viruses can also activate toll-like receptors (TLR) which leads to
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secretion of type 1 interferons (Samuel 2001). The inflammation seen in mice after 
exposure to inactivated H5N1 influenza virus was reduced in TLR-4 mutant mice (Imai 
et al 2008). The virus recovered was identified as PIV-3 by PCR.
Effect o f influenza on airway hyperreactivity
There was no evidence of airway hyperreactivity after inoculation with H1N1 WSN33 
(9.35x103) grown in MDCK cells as there was no bronchoconstriction after histamine 
exposure. There was no increase in wet lung weight. There was no evidence of airway 
hyperreactivity after inoculation with H1N1 A/PR/8/34 (l.lxlO 5) grown in a chicken 
embryo as there was no bronchoconstriction after histamine exposure. The increased 
concentration of this virus (l.lx lO 6) did produce a bronchoconstriction indicating airway 
hyper-reactivity. This would appear to show that this virus can cause airway reactivity in 
guinea-pigs dependant on the concentration of virus in the inoculum. This concentration- 
dependant effect has also been seen in other studies. Lowen et al (2006) saw an increase 
in infection of guinea-pigs by increasing the concentration of influenza 
A/Panama/2007/99 (Pan/99) (H3N2) in the inoculum and an increase in the 
concentration of the 1918 influenza strain increased the severity of the symptoms in 
mice.
Effect o f influenza on inflammatory cell influx
There was only a small rise in inflammatory cells after inoculation with H1N1 WSN33 
(9.35x10s) grown in MDCK cells. After inoculation with H1N1 A/PR/8/34 (l.lxlO 5)
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grown in chicken embryos there was a large rise in inflammatory cells compared to the 
no virus control. There was also a rise in inflammatory cells after inoculation with the 
increased concentration, compared to control, though not to the same level as the lower 
concentration of the virus. This is contrary to expectations and the reason for this is 
unknown. It is notable that the lower concentration of H1N1 A/PR/8/34 produced an 
increase in inflammatory cells but there was no AHR. It is possible that different 
mediators are involved in these two effects or that the respiratory epithelium was still 
largely intact and therefore the sensory C-fibers would not be exposed to activation 
causing bronchoconstriction.
Effect o f influenza on pulmonary oedema
There was no increase in wet lung weight after inoculation with H1N1 WSN33 
(9.35x105) grown in MDCK cells. The wet lung weight increased after inoculation with 
H1N1 A/PR/8/34 (l.lx lO 5) grown in a chicken embryo compared to control. In the 
group inoculated with the higher concentration of the virus there was an additional rise 
in wet lung weight but not significantly compared to control.
Inoculation with H1N1 A/PR/8/34 grown in a chicken embryo induces AHR, 
inflammatory cell influx and a small rise in wet lung weight in the guinea- pig. 
Inoculation with H1N1 WSN33 grown in MDCK cells only induces a small rise in 
inflammatory cells. Of the influenza viruses tested H1N1 A/PR/8/34 grown in a chicken 
embryo appears to be more pathogenic in guinea-pigs. The virulence of influenza is
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influenced by the heamagglutinin (HA) molecule, which is involved in entry of the virus 
into the host cell (White et al 1982). In cell culture altered posttranslational modification 
of the HA molecule can lead to a lack of pathogenicity compared to in vivo growth (Li et 
al 1990). This may account for the differences seen in this study although it must be 
noted that we were comparing two different influenza virus strains.
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Chapter 4
Drug interventions
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4.1 Introduction
The role o f Brady kinin in airway inflammation
Bradykinin is thought to be an important mediator of asthma. Inhalation of bradykinin 
causes bronchoconstriction in asthmatic patients, but has little or no effect in non­
asthmatics (Fuller et al 1987). Kinin levels are increased in BALF of asthmatics after 
allergen challenge (Christiansen et al 1992). Most of the bradykinin receptor-mediated 
effects in the airways are thought to be due to activation of the bradykinin B2 receptor as 
selective Bi agonists have little effect (Fuller et al 1987). The selective bradykinin B2 
receptor antagonist icatibant (also known as HOE 140) blocked PIV-3 induced AHR but 
not the inflammatory cell influx (Folkerts et al 2000). The non peptide, selective 
bradykinin B2 receptor antagonist MEN 16132 prevented the bronchoconstriction and 
plasma extravasation produced by dextran sulfate-induced contact activation of the kinin- 
kallikrein cascade, whereas icatibant had a 3-30 less potent inhibitory effect (Valenti et al 
2007).
Despite the lack of effect of bradykinin B2 antagonist icatibant on inflammatory cell 
influx seen by Folkerts et al (2000), bradykinin is thought to play a role in the 
recruitment of inflammatory cells to the airways. Selective bradykinin B2 antagonists 
have been shown to inhibit the antigen-induced eosinophilia and neutrophilia as well as 
the airway hyperresponsiveness in rats (Bandeira-Melo et al 1999) and guinea-pigs 
(Farmer et al 1992).
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Bradykinin is a nonapeptide formed by the cleavage of its precursor, high molecular 
weight kinninogen (HMWK) by the kinninogenase enzymes, which include tissue and 
plasma kallikrein (Bhoola et al 1992). In this study we used the tissue kallikrein inhibitor 
FE999024 (Evans et al 1996) in an attempt to reduce bradykinin levels in the lung and 
therefore inhibit the bradykinin-mediated effects of the PIV induced airway inflammation 
in guinea-pigs.
Dexamethasone is a corticosteroid which binds to cytosolic glucocorticoid receptors, this 
dimer then migrates to the nucleus, binds to target DNA and reduces the transcription and 
expression of a wide range of pro-inflammatory mediators (Barnes and Adcock 1993). 
Dexamethasone has been shown to inhibit AHR and leukocyte influx in rats after sendai 
virus (PIV-1) inoculation (Mehta et al 1997) and in guinea-pigs after PIV-3 inoculation 
(Toward et al 2005). In this study we tried to recreate the inhibitory effect of 
dexamethasone on PIV-3 induced AHR and inflammatory cell influx. We also looked at 
the effect of dexamethasone on increased lung wet weight.
Various studies have shown contradictory results on the ability of corticosteroids to 
inhibit the replication of viruses. Domachowske et al (2001) increased titres of 
pneumonia virus in mice with hydrocortisone but Moreno et al (2003) have shown that 
dexamethasone reduced the titres of virus recovered from the lung after sendai virus 
(PIV-1) infection in guinea-pigs.
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4.2 Methods
The methods in this section are the same as in chapter 3.2 with the exception of the 
treatment with FE999024 and dexamethasone. The guinea-pigs received bilateral sub­
cutaneous injections every 12 hours of either
• 0.9% sterile saline (vehicle for FE999024)
• FE999024 (1, 3 or lOmg/kg) in 0.9% sterile saline
• 25 or 50% DMSO in 0.9% sterile saline (vehicle for dexamethasone)
• Dexamethasone (lOmg/kg) in 25 or 50% DMSO in 0.9% sterile saline 
The volume used was lml\kg
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4.3 Results
4.3.1 Effects of FE999024 and dexamethasone on inoculation of guinea-pigs with a 
viral concentration of 6.32 x 106 infectious units per ml of PIV-3
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 4.1 and 4.2)
In the saline control there was evidence of airway hyperreactivity after viral inoculation 
with significant reductions in sGawat 5 (-10.0 ± 2.7%) and 10 (-13.5 ± 3.5%) minutes 
after histamine exposure compared to the baseline values (Figs. 4.1 and 4.2).
After treatment with FE999024 (1 mg/kg) there was evidence of airway hyperreactivity 
after viral inoculation with a -19.5 ± 4.2% reduction in sGaw value at 0 minutes after 
histamine exposure compared to the baseline sGaw values (Fig. 4.2). There was a gradual 
recovery to -12.4 ± 8.8% after 10 minutes
After treatment with FE999024 (3mg/kg) there was still some evidence of airway 
hyperreactivity after viral inoculation as there was a -4.8 ± 4.6% reduction in sGaw value 
at 0 minutes, which peaks at -7.5 ± 3.2% at 5 minutes after histamine exposure compared 
to the baseline sGaw values. sGaw values recovered after 10 minutes (Fig. 4.2).
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After treatment with FE999024 (lOmg/kg) there was no evidence of airway 
hyperreactivity after viral inoculation as there was no decrease in sGaw values compared 
to baseline (Fig. 4.2).
After treatment with 50% DMSO (dexamethasone vehicle) there was no evidence of 
airway hyperreactivity after viral inoculation as the -8.2 ± 6.6% reduction in sGaw value 
at 0 minutes after histamine exposure was not significantly different compared to 
baseline. There was complete recovery after 5 minutes (Fig. 4.2).
After treatment with dexamethasone (lOmg/kg) in 50% DMSO there was no evidence of 
airway hyperreactivity after viral inoculation as there is no reduction in sGaw values after 
histamine exposure compare to baseline. In fact there was an increase in sGaw reaching a 
peak of 19.2 ± 10.4%, indicating a bronchodilator response. Before viral inoculation there 
was a small decrease in sGaw to -5.6 ± 8.8% at 5 minutes after histamine exposure, which 
returned to baseline value after 5 minutes (Fig. 4.2).
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Figure 4.1
Effect of saline treatment on airway function before and after PIV-3 (6.32 x 106) 
infection. Each point represents the mean ± standard error of mean (n=6) change in sGaw 
expressed as a percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes after 
a nose only ImM histamine exposure. Negative values represent bronchoconstriction. 
(P<0.05) difference between the changes to baseline sGaw values at each time point, 
before and after virus inoculation as determined by a Student’s t test (paired).
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Figure 4.2
Maximum change in sGaw from baseline in GPs after ImM histamine exposure after 
inoculation with 6.32 x 106 infectious units per ml of PIV-3 compared with the 
corresponding time after histamine obtained before inoculation. Guinea-pigs were treated 
with either saline, FE999024 (1, 3, or 10 mg/kg), 50% DMSO or dexamethasone 
(lOmg/kg) in 50% DMSO. Each point represents the mean ± standard error of mean 
(n=6). * denotes the significance (P<0.05) in difference in the maximum decrease in sGaw 
from baseline before and after viral inoculation, as determined by a Student’s t test 
(paired).
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Bronchoalveolar lavage cell counts
In animals receiving no virus (medium controls), the numbers of macrophages, 
lymphocytes, eosinophils and neutrophils in the BALF were as follows; total cells: 1.54 ± 
0.17 (xl06/ml), macrophages: 1.37 ± 0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), 
lymphocytes: 0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig. 4.3).
In PIV-3 virus inoculated guinea-pigs treated with saline vehicle, there were significant 
increases in total cells, macrophages eosinophils and lymphocytes. There was also an 
increase in neutrophils (Fig. 4.3).
The increases in macrophages, eosinophils and lymphocytes were inhibited in a dose- 
dependant manner by FE999024. The increase in neutrophils was inhibited by the 
maximum dose of FE999024 (Fig. 4.3).
In 50% DMSO treated guinea-pigs inoculated with PIV-3, there were modest increases in 
total cells, macrophages and eosinophils compared with no virus controls but 
significantly less than the virus and saline group in the case of total cells and 
macrophages.
The increases in cell numbers were restored to baseline values by dexamethasone 
treatment in the case of total cells, macrophages and lymphocytes. Total cell numbers and 
macrophages were significantly less than the 50% DMSO controls (Fig. 4.3).
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Figure 4.3
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from PIV-3 or virus free medium inoculated GPs treated with saline 
(PIV-3 and virus free medium inoculated), FE999024 (1, 3, and 10 mg/kg) 50% DMSO 
and dexamethasone (lOmg/kg) in 50% DMSO. Each point represents the mean ± 
standard error of mean (n=6) of total or differential count of cells per ml/106. * denotes 
the significance (P<0.05) of difference compared to the corresponding no virus control, 
+ denotes the significance (P<0.05) of difference as compared to the corresponding saline 
control, f  denotes the significance (P<0.05) of difference in the 50% DMSO group as 
compared to the corresponding saline group and # denotes the significance (P<0.05) of 
difference in the dexamethasone group as compared to the corresponding 50% DMSO 
control as determined by a Student’s t test (paired).
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Percentage wet lung weight
In animals receiving no virus, the percentage wet weight of the lung tissue was 79.0 ± 0.4 
(Fig. 4.4).
In the PIV-3 inoculated guinea-pigs treated with saline the percentage wet weight had 
increased significantly to 81.4 ± 0.5. In the FE999024 1 mg/kg and 3mg/kg treated groups 
there was no significant decrease in the percentage wet weight, in fact there is a small 
increase in the FE999024 1 mg/kg group. The increase seen in the saline group was 
significantly reduced to 80.0 ± 0.4% by the lOmg/kg dose of FE999024 (Fig.4.4).
In the PIV-3 inoculated guinea-pigs treated with 50% DMSO the percentage wet weight 
had increased significantly to 81.6 ± 0.4 compared to the media control. In the 
dexamethasone (lOmg/kg) treated group there was no significant decrease (Fig. 4.4).
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Figure 4.4 -Virus inoculated-
Effect of PIV-3 infection on percentage wet weight after treatment with saline, 
FE999024, 50% DMSO (dexamethasone vehicle) and dexamethasone. Each point 
represents the mean ± standard error of mean (n=6). * denotes the significance (P<0.05) 
in difference compared to the media control, + denotes the significance (P<0.05) in 
difference compared to the saline group as determined by a Student’s / test (paired).
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4.3.2: Effects of increasing PIV-3 viral concentration to 3 x 108 infectious units per 
ml
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 4.5. and 4.6)
In the saline control there was evidence of airway hyperreactivity after viral inoculation 
as there was a -31.5 ± 6.3% reduction in sGaw value at 0 minutes after histamine exposure 
compared to the baseline value. There was a recovery after 5 and 10 minutes but not to 
baseline (Figs. 4.5 and 4.6).
After treatment with FE999024 (lOmg/kg) there was no evidence of airway 
hyperreactivity after viral inoculation as there was only a -2.4 ± 6.2% decrease in sGaw 
values compared to baseline (Fig. 4.6).
Because of the effects of 50% DMSO on cells seen previously, further experiments were 
conducted with 25% DMSO.
After treatment with 25% DMSO there was evidence of airway hyperreactivity after viral 
inoculation as there was a -22.5 ±6.1% reduction in sGaw value at 0 minutes after 
histamine exposure compared to baseline. There was complete recovery after 5 minutes 
(Fig.4.6).
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After treatment with dexamethasone (lOmg/kg) there was no evidence of airway 
hyperreactivity after viral inoculation as there was only a 1.2 ± 6.9% reduction in sGaw 
values after histamine exposure compared to baseline (Fig.4.6).
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Figure 4.5
Effect of saline treatment on airway function before and after PIV-3 virus infection. Each 
point represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes after a nose only 
ImM histamine exposure. Negative values represent bronchoconstriction. * denotes the 
significance (P<0.05) in difference between the changes to baseline sGaw values at each 
time point, before and after virus inoculation as determined by a Student’s t test (paired).
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Figure 4.6
Maximum change in sGaw from baseline in guinea-pigs after ImM histamine exposure 
after inoculation with 3 x 10s infectious units per ml o f PIV-3 compared with the 
corresponding time after histamine obtained before inoculation. Guinea-pigs were treated 
with either saline, FE999024 (10 mg/kg), 25% DMSO or dexamethasone (1 Omg/kg) in 
25% DMSO. Each point represents the mean ± standard error o f  mean (n=6). * denotes 
the significance (P<0.05) in difference in the maximum decrease in sGaw from baseline 
before and after viral inoculation, as determined by a Student’s t test (paired).
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Bronchoalveolar lavage cell counts
In animals receiving no virus, the numbers of macrophages, lymphocytes, eosinophils 
and neutrophils in the BALF were as follows; total cells: 1.54 ± 0.17 (xl06/ml), 
macrophages: 1.37 ± 0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), lymphocytes: 
0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig 4.7).
In PIV-3 virus inoculated guinea-pigs treated with saline, there were significant increases 
in total cells, macrophages, eosinophils, lymphocytes and neutrophils. FE999024 
(1 Omg/kg) had little effect on the cell counts compared to the saline control (Fig. 4.7).
In 25% DMSO treated guinea pigs inoculated with PIV-3, there were significant 
increases in total cells, macrophages, eosinophils, lymphocytes and neutrophils compared 
with the no virus control. They were not significantly different from the saline controls. 
The increases in cell numbers were significantly reduced, but not to baseline values by 
dexamethasone treatment in the case of total cells, macrophages and neutrophils 
(Fig. 4.7).
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Figure 4.7
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from virus free medium inoculated animals or PIV-3 inoculated animals 
treated with saline, FE999024 10 (mg/kg), 25 % DMSO or dexamethasone (1 Omg/kg). 
Each point represents the mean ± standard error of mean (n=6) of total or differential 
count of cells per ml/10^. * denotes the significance (P<0.05) of difference compared to 
the corresponding no virus control. + denotes the significance (P<0.05) of difference 
compared to the corresponding DMSO group, as determined by a Student’s t test 
(paired).
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Percentage wet lung weight
In animals receiving no virus, the percentage wet weight of the lung tissue was
79.0 ± 0.4 (Fig. 4.8).
In the PIV-3 inoculated guinea-pigs treated with vehicle (saline) the percentage wet 
weight had increased significantly to 82.8 ± 0.8. In the FE999024 (1 Omg/kg) treated 
group this increase was significantly reduced to 80.1 ± 0.5% (Fig. 4.8).
In the PIV-3 inoculated guinea-pigs treated with 25% DMSO the percentage wet weight 
had increased significantly to 83.3 ± 0.3. In the dexamethasone (1 Omg/kg) treated group 
this increase was significantly reduced to 79.9 ± 0.5 (Fig. 4.8).
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Figure 4.8
Effect on percentage wet lung weight of PIV-3 infection after treatment with saline, 
FE999024 (1 Omg/kg), 25% DMSO and dexamethasone (1 Omg/kg). Each bar represents 
the mean ± standard error of mean (n=6). * denotes the significance (P<0.05) in 
difference compared to the media control, + denotes the significance (P<0.05) in 
difference compared to the saline group and # denotes the significance (P<0.05) in 
difference compared to the DMSO group as determined by a Student’s t test (paired).
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4.3.3 Effects of FE999024 and dexamethasone on PIV-2 (1 x 108) inoculation in
guinea-pigs
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 4.9 and 4.10).
In the saline control there was evidence of airway hyperreactivity after viral inoculation 
as there was a significant -16.9 ± 4.4% reduction in sGaw value at 0 minutes after 
histamine exposure compared to the baseline value. There was no recovery after 5 
minutes and only a small recovery after 10 minutes (Figs. 4.9 and 4.10).
After treatment with FE999024 (1 mg/kg), there was still evidence of airway 
hyperreactivity after viral inoculation as there was a -23.1 ± 7.6% reduction in sGaw value 
at 0 minutes after histamine exposure compared to the baseline sGaw values. There was a 
recovery to -9.7 ± 4.6% after 10 minutes (Fig. 4.10)
After treatment with FE999024 (3mg/kg), there was no evidence of airway 
hyperreactivity after viral inoculation as there was almost no decrease in sGaw values at 0 
and 5 minutes although a non significant reduction of -13 ± 4.6% in sGaw occurred 10 
minutes after histamine exposure (Fig. 4.10).
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After treatment with FE999024 (1 Omg/kg), there was no evidence of airway 
hyperreactivity after viral inoculation as there was no decrease in sGaw values compared 
to baseline (Fig. 4.10).
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Figure 4.9
Effect of saline treatment on airway function before and after PIV-2 virus infection. Each 
point represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes after a nose only 
ImM histamine exposure. Negative values represent bronchoconstriction. * denotes the 
significance (P<0.05) in difference between the changes to baseline sGaw values at each 
time point, before and after virus inoculation as determined by a Student’s t test (paired).
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Figure 4.10
Maximum change in sGaw from baseline in guinea-pigs after ImM histamine exposure 
after inoculation with 1 x 108 infectious units per ml of PIV-2 compared with the 
corresponding time after histamine obtained before inoculation. Guinea pigs were treated 
with either saline, FE999024 (1, 3, or 10 mg/kg), or dexamethasone (1 Omg/kg) in 50% 
DMSO. Each bar represents the mean ± standard error of mean (n=6). * denotes the 
significance (P<0.05) in difference in the maximum decrease in sGaw from baseline 
before and after viral inoculation, as determined by a Student’s t test (paired).
129
Bronchoalveolar lavage
In animals receiving no virus, the numbers of macrophages, lymphocytes, eosinophils 
and neutrophils in the BALF were as follows; total cells: 1.54 ±0.17 (xl06/ml), 
macrophages: 1.37 + 0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), lymphocytes: 
0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig. 4.11).
In PIV-2 virus inoculated guinea-pigs treated with saline, there were significant increases 
in total cells, macrophages, eosinophils and neutrophils. The increases in macrophages 
were inhibited in a dose-dependant manner by FE999024. Similar trends were observed 
for lymphocytes, eosinophils and neutrophils (Fig. 4.11).
In 50% DMSO treated guinea-pigs inoculated with PIV-2, there was a significant 
increase in eosinophils and modest increases in total cells and macrophages, lymphocytes 
and neutrophils compared with the no virus control. The increases seen were reduced as 
compared to the saline control though not significantly. The increases in cell numbers 
were restored to baseline values by dexamethasone treatment in the case of total cells, 
macrophages, eosinophils, lymphocytes and neutrophils (Fig. 4.11).
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Figure 4.11
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from virus free medium inoculated animals or PIV-2 inoculated animals 
treated with saline, FE999024, 50 % DMSO or dexamethasone (1 Omg/kg). Each bar 
represents the mean ± standard error of mean (n=6) of total or differential count of cells 
per ml/1 0 6 . * denotes the significance (P<0.05) of difference compared to the 
corresponding no virus control. + denotes the significance (P<0.05) of difference 
compared to the corresponding DMSO group, as determined by a Student’s t test 
(paired).
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Percentage wet lung weight
In animals receiving no virus, the percentage wet weight of the lung tissue was
79.0 + 0.4 (Fig. 4.12).
In the PIV-2 inoculated guinea-pigs treated with saline the percentage wet weight had 
increased significantly compared to the media control to 82.5 ± 0.8%. In the FE999024 
treated groups there was a decrease in wet weight though not significantly and not dose 
dependency (Fig. 4.12).
In the PIV-2 inoculated guinea-pigs treated with 50% DMSO the percentage wet weight 
had increased significantly compared to the media control. In the dexamethasone treated 
group the percentage wet weight had significantly decreased (Fig. 4.12).
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Effect on percentage wet lung weight of PIV-2 infection after treatment with saline, 
FE999024, 50% DMSO and dexamethasone (1 Omg/kg). Each bar represents the mean ± 
standard error of mean (n=6). * denotes the significance (P<0.05) in difference compared 
to the media control and # denotes the significance (P<0.05) in difference compared to 
the DMSO group as determined by Student’s t test (paired).
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4.3.4 Effect of dexamethasone on viral recovery
After 25% treatment and inoculation with 3 x 108 of PIV-3, the average amount of virus 
recovered per gram of lung tissue and grown on VERO cells was 3.62 x 104 ± 2 x 104 
(Fig. 4.13).
After treatment with dexamethasone (1 Omg/kg) in 25% DMSO there was a small but 
insignificant reduction in virus recovered (Fig. 4.13).
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Figure 4.13
Effect of 25% DMSO and dexamethasone (lOmg/kg) on PIV-3 recovery in guinea-pig 
lung tissue after inoculation with 3 x 108 of PIV-3. Each point shows the amount of PIV- 
3 recovered per gram of lung tissue and grown in VERO cells and — shows the average 
(n = 6). There was no significant (P<0.05) difference between the saline and 
dexamethasone treated groups as determined by a Student’s t test (paired).
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4.3.5 Effects of dexamethasone on influenza-induced airway inflammation in
guinea-pigs
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Fig 4.14)
Effect o f inoculation with A/PR/8/34 (l.lxlC f) grown in chicken embryos 
In 25% DMSO treated guinea-pigs inoculated with influenza type A/PR/8/34 there was 
evidence of airway hyperreactivity after viral inoculation as there was a -20.4 ± 3.7% 
reduction in sGaw value at 0 minutes after histamine exposure compared to the baseline 
value (Fig.4.14). sGaw values recovered to -9.7 ± 4.9% after 10 minutes (Fig.4.14).
After 1 Omg/kg dexamethasone in 25% DMSO treatment the decrease in sGaw seen at 
0 minutes was reduced to -4.6% but peaked at -8.3% after 5 minutes, which was not 
significantly different from pre-histamine baseline (Fig. 4.14).
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Figure 4.14
Maximum decrease in sGaw from baseline in guinea-pigs after 1 mM histamine exposure 
before and after inoculation with (l.lxlO 6) grown in chicken embryos and treated with 
25% DMSO or dexamethasone (1 Omg/kg in) 25% DMSO. Each bar represents the mean 
± standard error of mean (n=6). * denotes the significance (P<0.05) in difference in the 
maximum decrease in sGaw from baseline before and after viral inoculation, as 
determined by a Student’s t test (paired).
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Bronchoalveolar lavage cell counts
In animals inoculated with allantoic fluid from chicken embryo and treated with 25% 
DMSO, the numbers of macrophages, eosinophils, lymphocytes and neutrophils in the 
BALF were as follows; total cells: 2.39 ±0.1 (xl06/ml), macrophages: 1.95 ± 0.11 
(xl06/ml), eosinophils: 0.28 ± 0.08 (xl06/ml) lymphocytes: 0.08 ± 0.02 (xl06/ml) and 
neutrophils 0.08 ± 0.02 (xl06/ml) (Fig. 4.15).
In the animals inoculated with H1N1 A/PR/8/34 l.lxlO6grown in a chicken embryo and 
treated with 25% DMSO, there were significant increases in macrophages and a smaller 
increase in eosinophils. There was no increase in lymphocytes or neutrophils (Fig. 4.15).
In dexamethasone (1 Omg/kg) in 25% DMSO treated animals inoculated with H1N1 
A/PR/8/34 l.lxlO6 grown in a chicken embryo there were significant reductions total 
cells, macrophages, eosinophils and neutrophils and a modest decrease in lymphocytes 
(Fig 4.15).
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Figure 4.15
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from guinea-pigs inoculated with allantoic fluid from chicken embryos 
and treated with 25% DMSO or inoculated with H1N1 A/PR/8/34 grown in chicken 
embryo (l.lxlO 6) and treated with 25% DMSO or dexamethasone (1 Omg/kg in 25% 
DMSO). Each bar represents the mean ± standard error of mean (n=6) of total or 
differential count of cells per ml/10^. * denotes the significance (P<0.05) of difference 
compared to the corresponding no virus control and + denotes the significance (P<0.05) 
of difference compared to the H1N1 A/PR/8/34 grown in chicken embryo (l.lx lO 6) 
group as determined by a Student’s / test (paired).
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Percentage wet lung weight
In animals inoculated with allantoic fluid from chicken embryo and treated with 25% 
DMSO the percentage wet lung weight was 79.9 ± 0.5 (Fig. 4.16).
In the animals inoculated with H1N1 A/PR/8/34 l.lxlO6grown in a chicken embryo and 
treated with 25% DMSO there was an increase in wet weight but not significantly 
compared to the allantoic fluid control (Fig. 4.16).
In dexamethasone (1 Omg/kg in 25% DMSO) treated animals inoculated with H1N1 
A/PR/8/34 l.lxlO6grown in a chicken embryo there was a non significant reduction in 
wet weight (Fig. 4.16).
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Figure 4.16
Effect on percentage wet lung weight guinea-pigs inoculated with allantoic fluid from 
chicken embryos and treated with 25% DMSO or inoculated with H1N1 A/PR/8/34 
grown in chicken embryo (l.lxlO 6) and treated with 25% DMSO or dexamethasone 
(1 Omg/kg in 25% DMSO). Each bar represents the mean ± standard error of mean (n=6). 
There was no significant (P<0.05) difference between any of the groups as determined by 
a Student’s t test (paired).
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4.4 Discussion
Effects o f FE999024 on PIV-3 and PIV-2 induced airway inflammation 
PIV-3 and PIV-2 infection resulted in bronchoconstriction to an inhaled dose of 
histamine that before inoculation produced no response. This indicates airway 
hyperreactivity 4 days after the viral infection. The lowest dose of FE999024 used 
(1 mg/kg) had no inhibitory effect, compared to control, as there was no decrease in the 
post-viral bronchoconstriction, in fact there was an increase in brochoconstriction. The 
3mg/kg dose appeared to have had some effect as there was a small, but incomplete 
decrease in the histamine-induced bronchoconstriction. The maximum dose of 
FE999024 (lOmg/kg) completely inhibited the airway hyper-reactivity to inhaled 
histamine seen in the saline control.
Bradykinin relaxes guinea-pig trachea in vitro but if the epithelium is removed it causes 
bronchoconstriction (Bramley et al 1990). Similar effects are seen in humans with 
inhaled bradykinin causing little or no effect in normal patients but causing 
bronchoconstriction in asthmatics (Simonsson et al 1973). This indicates that the 
presence of an intact epithelium would have an inhibitory effect on the ability of 
bradykinin to cause bronchoconstriction in the airways.
Damage to the epithelium would enable bradykinin to cause bronchoconstriction via 
several different possible mechanisms. NEP is the principal enzyme which metabolizes 
bradykinin in the airways. NEP is strongly expressed in the airway epithelium, so damage
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to the epithelium would therefore prolong the presence of bradykinin in the airways 
(Nadel 1991). Bradykinin causes the release of the bronchodilator PGE2 from the 
epithelium therefore damage to the epithelium would reduce this inhibitory effect on the 
ability of bradykinin to cause bronchoconstriction (Bramley et al 1990). NOS inhibitors 
potentiate the bronchoconstrictor effect of inhaled bradykinin in guinea-pigs (Ricciardolo 
et al 1994) and in asthmatic patients (Ricciardolo et al 1996). The likely source of the 
NO is the epithelium which expresses both constitutive (Robbins et al 1994) and 
inducible NOS (Asano et al 1994). This potentiating effect of NOS inhibitors is not seen 
in more severe asthma, possibly due to more extensive damage to the epithelium and the 
loss of this source of NO (Ricciardolo et al 1997).
Bradykinin can also cause bronchoconstriction through activation of bradykinin B2 
receptors on airway smooth muscle and through the release of tachykinins by the 
activation of C fibre nociceptive sensory nerve endings. Tachykinins can also cause 
bronchoconstriction through cholinergic nerve activation (C fibre and cholinergic 
mediated bronchoconstriction explained in chapter 3.4.2).
The effects of this reduced availability of bradykinin due to inhibition of tissue kallikrein 
by FE999024 would appear to complement previous studies which show that inhaled 
bradykinin causes bronchoconstriction in inflamed airways (Fuller et al 1987).
After inoculation with PIV-2 and the lower concentration of PIV-3, FE999024 appears to 
reduce influx of macrophages, lymphocytes, eosinophils and neutrophils in a
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concentration-dependent manner. At the higher concentration of PIV-3, FE999024 
(lOmg/kg) was unable to reduce the influx of inflammatory cells.
Although bradykinin is not thought to have much direct effect on activation and 
recruitment of inflammatory cells, it is thought to work indirectly through the release of 
monocyte and neutrophil chemotactic activity from the airway epithelial cells (Koyama et 
al 1995), to cause release of neutrophil, monocyte and eosinophilic factors from alveolar 
macrophages (Sato et al 1996) and also to stimulate eotaxin release from human lung 
fibroblasts (Sato et al 2000). This is reflected in this study as we have seen reduced levels 
of macrophages, eosinophils and neutrophils by the kallikrein inhibitor FE999024. This 
supports a role for bradykinin in the inflammatory response and subsequent airway 
hyper-reactivity following viral infection of the airways with parainfluenza virus.
The highest dose of FE999024 significantly reduced the increase in wet weight after PIV 
inoculation. The bradykinin induced microvascular leakage, which could contribute to the 
increased lung wet weight in guinea-pigs can be inhibited by a PAF inhibitor (Rogers et 
al 1990) and a thromboxane A2 antagonist (Kawikova et al 1993) indicating an indirect 
effect.
Effect o f dexamethasone on P IV  induced airway inflammation
Dexamethasone completely inhibited the AHR seen after PIV-3 and PIV-2 inoculation. 
Dexamethasone works through the decreased transcription and translation of a wide
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range of pro-inflammatory mediators including those released by the pulmonary 
epithelium in response to PIV infection such as IL-6, IL-8, IL-11, granulocyte- 
macrophage colony-stimulating factor (GM-CSF) and RANTES (Barnes and Adcock 
1993). Suppression of the release of these inflammatory mediators by dexamethasone 
would also reduce the release of further mediators and the activation of resident 
macrophages, lymphocytes, granulocytes, mast cells and basophils (Folkerts and Nijkamp 
1995) and therefore reduce inflammation and further damage to the epithelium and the 
subsequent AHR. PIV has been shown to alter the function of the inhibitory M2 
muscarinic receptor in guinea pigs which leads to increased ACh release and 
bronchoconstriction (Fryer et al 1990). Moreno et al (2003) have shown that 
dexamethasone can reverse the PIV-induced M2 receptor dysfunction in guinea-pigs.
Dexamethasone reduced the PIV induced inflammatory cell influx, in some cases to 
baseline levels. Dexamethasone reduces the transcription and translation of IL-3,
IL-4, IL-5, IL-6, IL-8, TNF-a, RANTES and GMCSF, which are responsible for the PIV 
induced migration of inflammatory cells to the airways (Barnes and Adcock 1993).
Dexamethasone reduced the PIV-induced increase in lung wet weight. The increase in 
wet weight may be due to an increase in mucus production but the most likely cause is 
pulmonary oedema (Hwang et al 2001). Dexamethasone may reduce pulmonary oedema 
by decreasing expression of pro-inflammatory mediators which increase blood pressure 
in pulmonary capilliaries (thromboxane, 5-lipoxygenase and leukotrienes C4, D4 and E4) 
or increase permeability of the capillary wall (tachykinins, reactive oxygen species
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(ROS), mast cell-derived histamine, excess NO and ROS-activated proteolytic enzymes 
(Barnes et al 1999).
Effect o f dexamethasone on viral recovery
Dexamethasone reduced the amount of virus recovered from the lung tissue though not 
significantly. The reason for this reduction could be decreased viral receptors on the 
pulmonary epithelium as dexamethasone reduced the infectability of rhinovirus on 
cultured epithelial cells by decreasing expression of ICAM-1 (Suzuki et al 2000).
Effect o f dexamethasone on influenza induced airway inflammation
Dexamethasone reduced the AHR and abolished the leukocyte influx and increased wet 
weight seen after inoculation with H1N1 A/PR/8/34. The mechanism for the reduced 
influenza-induced inflammation is likely to be similar to the inhibition of the PIV- 
induced inflammation by dexamethasone explained above.
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Chapter 5
The role of bradykinin in airway
function
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5.1 Introduction
Bradykinin-induced bronchoconstriction
In healthy humans, inhalation of bradykinin has little or no effect, but in asthmatics it 
produces a bronchoconstriction (Fuller et al 1987; Polosa et al 1990). Asthmatic subjects 
show a greater degree of airways hyperreactivity to bradykinin than to methacholine after 
allergen challenge (Berman et al 1995). Kinins exert their pharmacological effects 
through two main bradykinin receptor subtypes, bradykinin Bj and B2 receptors (Hall 
1992). Bi receptors, which are characterized by binding of [des-Arg9]-bradykinin, are 
absent in the lungs under normal conditions but their expression is induced by 
inflammation (Regoli et al 1978; Christiansen et al 2002). Bradykinin B2 receptors show 
high affinity for bradykinin and are constitutively expressed in the airways (Hall 1992).
In guinea-pigs, inhaled bradykinin has been shown to produce bronchoconstriction which 
can be blocked by the bradykinin B2 receptor antagonist icatibant (Sakamoto et al 1994; 
Wirth et al 1993). To date the effects of bradykinin on the airways have been largely 
examined after intravenous, inhalation or intratracheal administration to anaesthetized 
animals such as guinea-pigs (Wirth et al 1993; Miura et al 1994; Sakamoto et al 1994; 
Valenti et al 2005) and rats (Ellis et al 2004). In these earlier studies there are a number 
of discrepancies in the role of bradykinin in allergic responses (Ricciardolo et al 1994; 
Sakamoto et al 1996). A possible reason for the variable effects of bradykinin in the lung 
is its rapid breakdown by NEP and/or ACE. There do not appear to have been any studies 
on the airways effects of bradykinin in conscious guinea-pigs or rats, where the effect of 
anaesthetic is eliminated. In this study, we therefore attempted to identify a
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bronchoconstriction with inhaled bradykinin and to examine the effects of 
phosphoramidon and captopril, inhibitors of NEP and ACE, respectively. As bradykinin 
is thought to act on B2 receptors in the airways (Ellis and Fozard 2002), we also 
examined blockade of the bradykinin-induced bronchoconstriction with the bradykinin B2 
receptor antagonists icatibant and MEN16132. Icatibant is a peptide antagonist of B2 
receptors (Leeb-Lundberg et al 2005). Intravenous, intratracheal or aerosol administered 
icatibant has been shown to inhibit the bronchoconstriction to intravenously administered 
bradykinin in anaesthetized guinea-pigs (Tramonana et al 2001; Valenti et al 2005). 
Inhaled icatibant also inhibited the bronchoconstriction and microvascular leakage after 
inhaled bradykinin in anaesthetized guinea-pigs (Sakamoto et al 1994). MEN 16132 is a 
nonpeptide selective antagonist of bradykinin B2 receptors which has been shown to 
block bronchoconstriction to intravenous bradykinin (Valenti et al 2005) and endogenous 
Bradykinin released by dextran sulphate infusion (Valenti et al 2007) in anaesthetized 
guinea-pigs.
Airway hyperreactivity to bradykinin
Kinin levels are increased in BALF of asthmatics after allergen challenge (Christiansen et 
al 1992) and inhalation of bradykinin causes bronchoconstriction in asthmatic patients, 
but has little or no effect in non-asthmatics (Fuller et al 1987; Polosa and Holgate 1990). 
Bradykinin receptor expression is up-regulated in sensitized rat lungs (Huang et al 1999), 
in asthmatic airways inflammation (Christiansen et al 2002) and in murine airways under 
interleukin-4 (IL-4) stimulation (Brybom et al 2004). IL-lp and TNF-a induced 
transcriptional up-regulation of bradykinin Bj and B2 receptors in vitro in murine airways
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(Zhang et al 2004,2007), which was inhibited by the corticosteroid, dexamethasone 
(Zhang et al 2005). Allergen sensitization and challenge has been repeatedly shown to 
cause airways hyperreactivity in guinea-pigs to a range of spasmogens, including 
histamine and methacholine (Toward and Broadley 2004; Smith and Broadley 2007). 
AHR to intravenous bradykinin has been demonstrated in anaesthetized rats after allergen 
challenge (Ellis et al 2004), but there are few studies examining AHR to inhaled 
bradykinin in conscious animals. In this study, we therefore determined whether 
ovalbumen exposure in ovalbumen-sensitized guinea-pigs produced airways 
hyperreactivity to inhaled bradsykinin.
Bradykinin in PIV-3-induced airway inflammation
In previous experiments we have show that the tissue kallikrein inhibitor F999024 
inhibits PIV-induced airway inflammation by reducing the levels of bradykinin in the 
lung (Chapter 4). Previous studies have shown contradictory effects of bradykinin B2 
antagonists in airway inflammation. Folkerts et al (2000) have shown that the bradykinin 
B2 antagonist icatibant can inhibit the PIV-3 induced AHR but not the inflammatory cell 
influx. Bandeira-Melo et al (1999) were able to inhibit the ovalbumen-induced 
eosinophilia and neutrophilia in rats with icatibant. We attempted to determine whether 
bradykinin was involved in the PIV-3-induced AHR and inflammatory cell influx and 
whether it was mediated by the bradykinin B2 receptor by treating PIV-3 inoculated 
guinea-pigs with the bradykinin B2 receptor antagonist MEN16132.
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5.2 Methods
Bradykinin exposure experiments
Airway reactivity to bradykinin was measured by recording pulmonary function using 
whole body plethysmography and recorded as sGaw. Baseline sGaw recordings were 
taken and then at 0, 5 and 10 minutes after a 20 second box exposure to bradykinin 
dissolved in saline.
The effects of bradykinin were also examined 1 hour after administration of captopril 
(1 mg/kg i.p.) and/or phosporamidon (0.1 mg/kg i.p. or ImM, 20 minute inhalation 
exposure) to inhibit the enzymes ACE and NEP respectively. These enzymes catalyze the 
breakdown of bradykinin into inactive metabolites (see Chapter 1) and therefore 
inhibitors were used in an attempt to prolong the duration of the inhaled bradykinin in the 
lung.
The effect of the duration of bradykinin exposure was examined by comparing 20, 40, 
and 60 second, 0.3mM bradykinin exposures after captopril (1 mg/kg) treatment.
The selective B2 bradykinin antagonists: icatibant (lOpM inhalation exposure) and 
MEN16132 (30, 100 or 300nM/kg, i.p.) (1 or lOpM, 20 minute inhalation exposure) were 
administered 1 hour before inhalation exposure to ImM bradykinin in guinea-pigs treated 
with captopril (1 mg/kg).
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At least 4 days after each experiment with icatibant and MEN16132, the animals were 
treated with an appropriate saline control (i.p. injection or inhalation exposure) before 
further exposure to ImM bradykinin with 1 mg/kg captopril to determine the recovery 
from B2 receptor blockade.
Ovalbumen sensitization/exposure experiments
The methods in this section are the same as in 2.4 Ovalbumen methods with the 
exception that in one experiment AHR was tested with bradykinin (ImM, 20 second 
inhalation exposure) rather than histamine. AHR was tested 24 hours before and after 
ovabumen challenge.
Virus experiments
The methods in this section are described in detail in Chapter 2 (General Methods, 2.1. 
and 2.2 Virus experiments), with the exception of the drug treatments. Guinea-pigs were 
treated with a daily 20 minute inhalation exposure of the B2 bradykinin receptor 
antagonist, MEN 16132 (lOpM in saline) or control (saline).
Protocol fo r  virus experiments
Day 1: Dosing with 0.9% sterile saline or MEN16132 (lOpM) in 0.9% sterile saline 
Day 2: Dosing with 0.9% sterile saline or MEN16132 (lOpM) in 0.9% sterile saline and 
reactivity test to histamine
Day 3: Dosing with 0.9% sterile saline or MEN16132 (lOpM) in 0.9% sterile saline and 
inoculation 3 hours later with virus or virus free medium
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Day 4: Dosing with 0.9% sterile saline or MEN16132 (IOjiM) in 0.9% sterile saline and 
inoculation 3 hours later with virus or virus free medium 
Day 5: Dosing with 0.9% sterile saline or MEN16132 (IOjiM) in 0.9% sterile saline 
Day 6: Dosing with 0.9% sterile saline or MEN 16132 (IOjiM) in 0.9% sterile saline 
Day 7: Dosing with 0.9% sterile saline or MEN16132 (lOfiM) in 0.9% sterile saline 
Day 8: Dosing with 0.9% sterile saline or MEN16132 (10jiM) in 0.9% sterile saline, 
reactivity test to histamine and lavage
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5.3 Results
5.3.1 Bradykinin exposures 
Bronchoconstrictor effect
After 20 second, nose only 0.01,0.1 and ImM bradykinin exposures in guinea-pigs there 
was no significant decrease in sGaw from baseline (Fig. 5.1).
After captopril (1 mg/kg, i.p.) treatment there was no significant reduction in sGaw after
0.01 and O.lmM bradykinin exposure but a significant decrease after a ImM exposure 
(Fig. 5.2).
After captopril (1 mg/kg) treatment, a 0.3mM bradykinin exposure produced modest 
decreases in sGaw after 20 (-8.7 ± 7.0 %) and 40 (-5.9 ± 6.3 %) second exposures and a 
significant decrease after a 60 second (-17.9 ± 6.4 %) exposure (Fig. 5.3).
After phosphoramidon (0.1 mg/kg, i.p.) there was no significant decrease (-3.8 ± 4.4%) in 
sGaw after a ImM bradykinin exposure, but after a 10mM, 20 minute inhalation exposure 
there was a significant decrease (21.7 ± 4.4%) after a ImM bradykinin exposure (Fig. 
5.4).
After combined phosphoramidon (10mM, 20 minute inhalation exposure) and captopril 
(lmg/kg i.p.) there was a significant 22.3 ± 3.2% decrease in sGaw after a ImM 
bradykinin exposure. However, this response was no greater than with the same doses of 
phosphoramidon or captopril alone (Fig. 5.4).
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After i.p.injections of MEN16132 (30,100 and 300nM/kg) there was no blockade of the 
decrease in sGaw seen after a ImM bradykinin exposure after captopril (1 mg/kg, i.p.) 
treatment (Fig. 5.5). The bronchoconstrictor responses (-11.1 ± 4.3, -13.6 ± 4.3 and 
-11.2 ± 7.1%) were not significantly different from baseline or from the saline control 
(-17.3 ±2.4%).
After MEN16132 (1 and lOpM) by a 20 minute inhalation exposure, there was complete 
blockade of the decrease in sGaw seen after a ImM bradykinin exposure with captopril 
(1 mg/kg, i.p.) treatment (Fig. 5.6).
Icatibant (lOpM) by 20 minute inhalation exposure had no effect on the decrease in sGaw 
seen after a ImM bradykinin exposure with captopril (lmg/kg, i.p.) (Fig. 5.7).
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Figure 5.1
Effect of 0.01, 0.1 and ImM bradykinin exposures (20 seconds). Each point represents 
the mean ± standard error of mean (n=6) change in sGaw expressed as a percentage of the 
baseline sGaw values, shown at 0, 5 and 10 minutes. Negative values represent 
bronchoconstriction. There was no significance (P<0.05) in difference between the 
baseline sGaw values at each time point after bradykinin exposure as determined by a 
Student’s t test (paired).
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Figure 5.2
Effect of 0.1, 0.3 and ImM bradykinin exposures (20 seconds) after captopril treatment. 
Each point represents the mean ± standard error of mean (n=6) change in sGaw expressed 
as a percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes. Negative 
values represent bronchoconstriction. * indicates the significance (P<0.05) in difference 
between the changes from baseline sGaw after bradykinin exposure as determined by a 
Student’s t test (paired).
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Figure 5.3
Effect o f  20, 40 and 60 second, 0.3mM bradykinin exposures after captopril (1 mg/kg,
i.p.) treatment. Each point represents the mean ± standard error o f mean (n=6) change in 
sGaw expressed as a percentage o f  the baseline sGaw values, shown at 0, 5 and 10 minutes. 
Negative values represent bronchoconstriction. There was no significance (P<0.05) in 
difference between the changes to baseline sGaw values at each time point, before and 
after bradykinin exposure as determined by a Student’s t test (paired).
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Figure 5.4
Effect of phosphoramidon (lOpM, 20 minute exposure or 0.1 mg/kg) and combining 
phosphoramidon (lOfiM, 20 minute exposure) with captopril (1 mg/kg, i.p.) on 
bradykinin (ImM, 20 second exposure). Each point represents the mean ± standard error 
of mean (n=6) change in sGaw expressed as a percentage of the baseline sGaw values, 
shown at 0, 5 and 10 minutes. Negative values represent bronchoconstriction. * denotes 
the significance (P<0.05) in difference between the changes to baseline sGaw values at 
each time point, with and without phosphoramidon or captopril treatment as determined 
by a Student’s t test (paired).
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Figure 5.5
Effect of MEN6132 (30, 100 and 300nmol/kg, i.p.) and saline on bradykinin (ImM, 20 
second) exposure with captopril (1 mg/kg, i.p.). Each point represents the mean ± standard 
error of mean (n=6) change in s G aw expressed as a percentage of the baseline s G aw values, 
shown at 0, 5 and 10 minutes. Negative values represent bronchoconstriction.. There was 
no significance (P<0.05) in difference between the changes to baseline s G aw values at 
each time point, between the saline and MEN16132 treated groups as determined by a 
Student’s t test (paired).
160
Captopril 1 mg/kg with saline 
-■ -C aptopril 1 mg/kg with MEN16132 1uM 
-A - Captopril 1 mg/kg with MEN16132 10uM
30
20
10
55m
O
CO
b ase lin e
-10
-20 J
-30
Tim e (mins)
Figure 5.6
Effects of 20 minute inhalation exposures of MEN6132 (1 and lOpM) and saline on 
bradykinin (ImM, 20 second) exposure with captopril (1 mg/kg, i.p.). Each point 
represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes. Negative values 
represent bronchoconstriction.. * denotes the significance (P<0.05) in difference between 
the changes to baseline sGaw values at each time point, with and without MEN 16132 
treatment as determined by a Student’s t test (paired).
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Figure 5.7
Effects of 20 minute exposures of icatibant (lOpM) and saline on bradykinin (ImM, 20 
second) exposures with captopril (lmg/kg, i.p.). Each point represents the mean ± 
standard error of mean (n=6) change in sGaw expressed as a percentage of the baseline 
sGaw values, shown at 0, 5 and 10 minutes. Negative values represent 
bronchoconstriction. There was no significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point, between the saline and icatibant 
treated groups as determined by a Student’s t test (paired).
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Bronchoalveolar lavage
In animals receiving no treatment, the numbers of macrophages, eosinophils, neutrophils 
and lymphocytes in the BALF were as follows; total cells: 1.95 ± 0.09 (xl06/ml), 
macrophages: 1.68 ± 0.09 (xl06/ml), eosinophils: 0.20 ± 0.04 (xl06/ml), neutrophils 0.04 
± 0.03 (xl06/ml) and lymphocytes: 0.03 ± 0.01 (xl06/ml) (Fig. 5.8).
In animals which received ImM bradykinin with captopril (1 mg/kg, i.p.) prior to lavage 
there was no significant increase to any of the cell types (Fig.5.8).
In animals which received a ImM bradykinin, captopril (1 mg/kg, i.p.) and 
phosphoramidon (lOmM, 20 minute inhalation exposure) prior to lavage there were 
significant increases in total cells, macrophages, eosinophils and neutrophils compared to 
the same experiment without phosphoramidon. There was no increase in lymphocytes 
(Fig. 5.8).
In animals which received a ImM bradykinin, captopril (1 mg/kg, i.p.), phosphoramidon 
(lOmM, 20 minute inhalation exposure) and MEN16132 (lOpM, 20 minute inhalation 
exposure) prior to lavage, there were significant decreases in total cells, eosinophils, 
neutrophils and lymphocytes and a modest decrease in macrophages compared to the 
same experiment without MEN16132 (Fig. 5.8).
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Figure 5.8
Total and differential cell (macrophage, eosinophil, neutrophil and lymphocyte) count of 
BALF removed from animals receiving no treatment, all other groups received ImM 
bradykinin exposure with captopril (1 mg/kg, i.p.) with or without phosphoramidon. The 
final group received phosphoramidon (lOmM inhalation exposure) and MEN 16132 
(lOpM inhalation exposure). Each bar represents the mean ± standard error o f mean 
(n=6) o f total or differential count o f  cells per ml/lO^. * denotes the significance 
(P<0.05) o f  difference compared to the corresponding group without phosphoramidon 
and + denotes the significance (P<0.05) o f  difference compared to the group without 
MEN 16132 as determined by a Student’s t test (paired).
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5.3.2 Ovalbumen sensitization experiments
Effect o f ovalbumen exposure
In the 50% DMSO (i.p.) treated group there was an immediate 25.5 ± 4.5% decrease in 
sGaw from baseline following ovalbumen exposure. After 4 hours there was a recovery 
but not to baseline levels. This was followed by a secondary 19.6 ± 8.3% decrease in 
sGaw at 8 hours (Fig. 5.9).
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Figure 5.9
Effect o f  ovalbumen sensitization and exposure on airway function after treatment with 
50% DMSO ( i.p.). Each point represents the mean ± standard error o f  mean (n=6) 
change in sGaw expressed as a percentage o f the baseline sGaw values, shown up to 24 
hours after ovalbumen exposure. Negative values represent bronchoconstriction.
* denotes the significance (P<0.05) in difference between the changes from baseline sGaw 
values at each time point as determined by a Student’s t test (paired).
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Bradykinin exposures
After ovalbumen sensitization but before ovalbumen exposure, there was no significant 
decrease in sGaw from baseline levels after a ImM bradykinin exposure (Fig. 5.10).
24h after ovalbumen exposure of sensitized guinea-pigs, there was a significant decrease 
in sGaw after a ImM bradykinin exposure (Fig. 5.10).
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Figure 5.10
Effect of ImM bradykinin exposure on ovalbumen sensitized guinea-pigs treated with 
50% DMSO (i.p.) before and after ovalbumen exposure. Each point represents the mean ± 
standard error of mean (n=6) change in sGaw expressed as a percentage of the baseline 
sGaw values, shown at 0, 5 and 10 minutes. Negative values represent 
bronchoconstriction. * denotes the significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point, before and after ovalbumen exposure 
as determined by a Student’s t test (paired).
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Bronchoalveolar lavage
In ovalbumen sensitized, saline challenged, histamine exposed and 50% DMSO treated 
guinea-pigs the numbers of macrophages, eosinophils, neutrophils and lymphocytes in 
the BALF were as follows; total cells: 4.38 ± 0.42 (xl06/ml), macrophages: 2.31 ± 0.22 
(x 106/ml), eosinophils: 1.95 ± 0.34 (x 106/ml), neutrophils 0.03 ± 0.01 (x 106/ml) and 
lymphocytes: 0.1 ± 0.02 (xl06/ml) (Fig. 5.11).
In the ovalubumen sensitized and challenged, histamine exposed group treated with 50% 
DMSO there were significant increases in total cells, macrophages, eosinophils and 
neutrophils and a modest in lymphocytes (Fig. 5.11).
In the ovalubumen sensitized and challenged, bradykinin exposed group treated with 50% 
DMSO there were significant increases in total cells, macrophages, eosinophils, 
neutrophils and lymphocytes compared to the saline challenged group. Compared to the 
ovalbumen sensitized and challenged, histamine exposed group there was a significant 
decrease in macrophages, modest decreases in total cells and eosinophils and small 
increases in neutrophils and lymphocytes (Fig. 5.11).
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Figure 5.11
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from ovalbumen sensitized animals treated with 50% DMSO (i.p.), 
challenged with saline and exposed to histamine, challenged with ovalbumen and 
exposed to histamine or challenged with ovalbumen and exposed to bradykinin. Each bar 
represents the mean ± standard error of mean (n=6) of total or differential count of cells
per ml/10 . * denotes the significance (P<0.05) of difference compared to the 
corresponding saline challenged and histamine exposed group and + denotes the 
significance (P<0.05) of difference compared to the ovalbumen challenged and histamine 
exposed group as determined by a Student’s t test (paired).
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5.3.3 PIV-3 (3 x 108) inoculated animals
Airway reactivity to histamine
Prior to inoculation with virus there was no significant decrease in sGaw following 
inhalation exposure to histamine (Figs. 5.12 and 5.13)
In the saline control there was evidence of airway hyperreactivity after viral inoculation 
as there was a 31.5 ± 6.3% reduction in sGaw value at 0 minutes after histamine exposure 
compared to the baseline value. There was a recovery after 5 and 10 minutes (Fig. 5.12).
After treatment with MEN 16132 (lOpM, 20 minute inhalation exposure) there was no 
evidence of airway hyperreactivity after viral inoculation as there was only a 5.6 ± 4.6% 
reduction in sGaw after histamine exposure (Fig. 5.13).
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Figure 5.12
Effect of saline (20 minute inhalation exposure) treatment on airway function before and 
after PIV-3 virus infection. Each point represents the mean ± standard error of mean 
(n=6) change in sGaw expressed as a percentage of the baseline sGaw values, shown at 0, 5 
and 10 minutes after a nose only ImM histamine exposure. Negative values represent 
bronchoconstriction. * denotes the significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point, before and after virus inoculation as 
determined by a Student’s t test (paired).
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Figure 5.13
Effect of MEN16132 (lOpM, 20 minute inhalation exposure) treatment on airway 
function before and after PIV-3 virus inoculation. Each point represents the mean ± 
standard error of mean (n=6) change in sGaw expressed as a percentage of the baseline 
sGaw values, shown at 0, 5 and 10 minutes after a nose only ImM histamine exposure. 
Negative values represent bronchoconstriction. There was no significance (P<0.05) in 
difference between the changes to baseline sGaw values at each time point, before and 
after virus inoculation as determined by a Student’s t test (paired).
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Bronchoalveolar lavage cell counts
In animals receiving no virus, but the medium only, the numbers of macrophages, 
lymphocytes, eosinophils and neutrophils in the BALF were as follows; total cells: 1.54 ± 
0.17 (xl06/ml), macrophages: 1.37 ± 0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), 
lymphocytes: 0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig. 5.14).
In PIV-3 virus inoculated guinea-pigs treated with saline (20 minute exposure) there were 
significant increases in total cells, macrophages, eosinophils and neutrophils and a 
modest increase in lymphocytes. After MEN 16132 (lOpM, 20 minute exposure) there 
were significant decreases in total cells, macrophages, neutrophils and eosinophils and a 
modest decrease in eosinophils (Fig. 5.14).
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Figure 5.14
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from virus free medium inoculated animals or PIV-3 inoculated animals 
treated with saline or MEN 16132 (lOpM, 20 minute inhalation exposure). Each point 
represents the mean ± standard error of mean (n=6) of total or differential count of cells 
per ml/10 . * denotes the significance (P<0.05) of difference compared to the 
corresponding no virus control. + denotes the significance (P<0.05) of difference 
compared to the corresponding saline group, as determined by a Student’s t test (paired).
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5.4 Discussion
Bradykinin exposures
After bradykinin exposures up to ImM there was no significant bronchoconstriction in 
guinea-pigs. This contrasts with observations made in anaesthetized guinea-pigs where 
intravenous (Wirth et al 1993; Tramontana et al 2001; Ichinose and Barnes 1990b), 
intratracheal (Ichinose and Barnes 1990a) or inhaled (Sakamoto et al 1994) bradykinin 
exerted bronchoconstriction. The lack of effect of inhaled bradykinin in conscious 
guinea-pigs appears to be due to the rapid breakdown of bradykinin as there was a 
significant bronchoconstriction after treatment with captopril, an inhibitor of ACE. ACE 
(also known as kininase II) and NEP catalyse the breakdown of bradykinin into inactive 
metabolites, while kininase I produces the active metabolite [des-Arg9] bradykinin 
(Decarie et al 1996). [des-Arg9]-bradykinin binds to Bj receptors (Leeb-Lundberg et al 
2005) and but does not cause any bronchoconstriction in asthmatic or normal subjects 
(Polosa and Holgate 1990), suggesting that Bi receptors are not involved in the 
bronchoconstriction. Contrary to this clinical finding, isolate murine tracheae have been 
shown to express both Bi and B2 receptors and display contractile responses to both 
bradykinin and [des-Arg9]-bradykinin which are upregulated by culture with TNF-a 
(Zhang et al 2004). ACE mediates the breakdown of bradykinin in the circulation but 
may also be present in the lungs (Dusser et al 1988). bradykinin-induced sensitization of 
airways sensory nerves is thought to be responsible for cough which is a major side effect 
of ACE inhibitors (Fox et al 1996). Bradykinin increases the excitatory nonadrenergic 
noncholinergic neural bronchoconstriction in anaesthetized guinea-pigs via B2 receptors
176
(Miura et al 1994). Chronic ACE inhibitor treatment causes spontaneous coughing which 
can be inhibited with the bradykinin B2 antagonist icatibant (Fox et al 1996). 
Phosphoramidon (i.p.) treatment had no effect but after inhalation exposure there was a 
bronchoconstriction similar to that seen after captopril treatment. NEP is expressed in the 
respiratory epithelium (Baraniuk et al 1995), so inhalation exposure would enable 
phosphoramidon to have an instant effect, whereas after i.p. injection the drug may not be 
reaching the lung in a concentration sufficient to have an effect. Captopril and 
phosphoramidon, both by instillation into the lungs, were shown to potentiate the 
bronchoconstriction by airways-instilled bradykinin in aneasthetized guinea-pigs, 
although the kininase 1 inhibitor, DL-2-mercaptomethyl-3-guanidinoethylthiopropionic 
acid, failed to alter the bronchoconstriction (Ichinose and Barnes 1990a). This suggested 
that both ACE and NEP degrade bradykinin but kininase 1 is not involved. In the present 
study, when capropril and phosphoramidon treatment were combined, the 
boronchoconstriction by bradykinin was similar to that seen with treatment with each 
drug individually. A similar observation was made by Ichinose et al (1990). This could 
be because this was the maximum bronchoconstriction to bradykinin. It was interesting, 
however, that there was also no prolongation of the bronchoconstriction when the two 
inhibitors were combined.
Thus, either ACE or NEP had to be inhibited to prevent its breakdown before a 
bronchoconstriction to inhaled bradykinin could be observed in conscious guinea-pigs. 
Kininase I is probably not involved in the metabolism of inhaled bradykinin as this 
enzyme is localized to the blood (Proud and Kaplan 1988). The mechanism of this
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bronchoconstriction by the inhaled route is probably via a neural mechanism. Atropine, to 
block parasympathetic muscarinic pathways and capsaicin, to deplete sensory neurone 
tachykinins, blocked the responses in anaesthetized guinea-pigs to instilled bradykinin 
but not intravenous bradykinin (Ichinose et al 1990). Intravenous bradykinin mediates 
bronchoconstriction mainly by release of cyclooxygenase products, since it was 
attenuated by indomethacin (Ichinose et al 1990).
The bradykinin B2 receptor antagonist MEN16132 (1 and lOpM inhalation exposure) 
blocked the bronchoconstriction to ImM bradykinin exposure but icatibant (lOpM 
inhalation exposure) had no effect. These results are similar to those by Valenti et al 
(2005), who have shown that MEN16132 is more potent and longer lasing than icatibant 
in inhibiting the bradykinin induced bronchoconstriction and microvascular leakage in 
anaesthetized guinea-pigs. MEN16132 administered i.p. had no effect in our study, 
possibly because the drug was not absorbed by this route and did not reach the lungs in 
enough concentration to have an effect, although in the study of Valenti et al (2005) it 
was effective by intravenous administration.
After bradykinin inhalation exposure with captopril treatment there was no significant 
increase in inflammatory cells in the lung but after inhalation exposure with both 
captopril and phosphoramidon there was significant increases in total cells, macrophages, 
eosinophils and neutrophils. This suggests that the threshold for leukocyte influx was 
higher than for bronchoconstriction, since both degradative enzymes were required to be 
blocked. After treatment with the B2 receptor antagonist MEN16132 (lOpM inhalation
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exposure) the increases in total cells, eosinophils, neutrophils and lymphocytes were 
significantly inhibited and there was a modest inhibition of the macrophage increase.
This study shows that bradykinin can produce an influx of inflammatory cell influx but 
only by prolonging the duration of bradykinin in the lung by inhibition of both ACE and 
NEP. Although bradykinin is not thought to have much direct effect on activation and 
recruitment of inflammatory cells, it is thought to work indirectly through the release of 
monocyte and neutrophil chemotactic activity from the airway epithelial cells (Koyama et 
al 1995), to cause release of neutrophil, monocyte and eosinophilic factors from alveolar 
macrophages (Sato et al 1996) and also to stimulate eotaxin release from human lung 
fibroblasts (Sato et al 2000). The inhibition of the bradykinin-induced inflammatory cell 
influx by MEN161 indicates that it is mediated through the bradykinin B2 receptor.
Airway hyperreactivity to inhaled bradykinin
Bradykinin exposure had no effect in sensitized guinea-pigs in the absence of enzyme 
inhibitors. Thus, sensitization alone is not sufficient to induce a bronchoconstriction to 
bradykinin. This contrasts with another indirect bronchoconstrictor adenosine, which 
shows no bronchoconstriction in normal subjects (Cushley et al 1983) and unsensitized 
guinea pigs (Smith and Broadley 2008) but produces a bronchoconstriction in asthmatic 
subjects and sensitized guinea-pigs. However, in sensitized guinea-pigs, 24 hours after 
ovalbumen exposure there was a significant bronchoconstrictor response to bradykinin. 
This was achieved without inhibition of ACE or NEP. This indicates that ovalbumen 
induces airway hyperreactivity to bradykinin. Since ovalbumen challenge causes airway 
hyperreactivity to other directly acting spasmogens, including histamine and
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methacholine (Toward and Broadley 2004; Smith and Broadley 2007), these results 
demonstrate that the hyperreactivity is extended to the indirect spasmogen bradykinin. 
Whether this is because of a common mechanism cannot be deduced from the present 
study. It is likely due to epithelial damage caused by the ovalbumen challenge. This 
would expose the sensory nerves through which bradykinin acts after inhalation (Ichinose 
et al 1990) or result in loss of the epithelium-derived NEP. Allergen-induced airways 
hyperreactivity to bradykinin does not appear to have been demonstrated previously in 
guinea-pigs and these results provide a basis for the appearance of bronchoconstriction in 
asthmatics but not in normal subjects after bradykinin inhalation (Fuller et al 1987;
Polosa and Holgate 1990).
Effect o f MEN16132 on PIV-3 induced airway inflammation
PIV-3 inoculation of guinea-pigs caused AHR to inhaled histamine and inflammatory cell 
influx in the BALF. The bradykinin B2 antagonist abolished these effects after PIV-3 
inoculation. Previously we have shown that the PIV induced inflammation can be 
reduced by decreasing bradykinin levels by inhibition of the enzyme tissue kallikrein 
with FE999024 (chapter 4). The inhibition of the PIV-3 induced inflammation with 
MEN16132 shows that the bradykinin-induced inflammation is mediated through the 
bradykinin B2 receptor. Folkerts et al (2000) also showed that the B2 receptor antagonist, 
icatibant, administered subcutaneously inhibited the AHR to intravenously administered 
histamine in anaesthetized guinea-pigs treated with PIV-3. However, they did not show 
any reduction in cell influx after icatibant. In their study, there was a tendency for an
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increase in bradykinin levels in BALF after PIV-3 infection, which supports the idea that 
bradykinin is involved in the AHR and cell influx caused by PIV-3 infection.
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Chapter 6
Viral exacerbations in ovalbumen
allergic model
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6.1 Introduction
Asthma is a chronic inflammatory disease of the airways which is characterized by 
bronchial hyper-responsiveness, an influx of inflammatory cells, epithelial damage and 
bronchiolar fibrosis (Cohn et al 2005). Inhalation of antigen in patients with atopic 
asthma results in an early and late phase brochoconstrictions and AHR (Payne and 
DeNucci 1987). Various groups have reproduced these asthmatic effects in animal 
studies. Smith and Broadley (2007) have shown that in ovalbumen sensitized guinea- 
pigs, ovalbumen exposure results in early and late phase bronchoconstrictions, AHR to 
inhaled histamine and an influx of inflammatory cells.
Viral respiratory infections are the most common cause of asthma exacerbations. Along 
with respiratory syncytial virus and rhinovirus, PIV has been implicated in the 
pathogenesis and exacerbations of asthma (Frick et al 1979). In this study we attempted 
to produce a model of viral exacerbation of asthma by combining the ovalbumen guinea- 
pig model of allergy with the PIV-3 inoculation model (chapter3).
Glucocorticoids are widely used for the management of asthma (Spahn and Leung 
1996).Glucocorticoids have many anti-inflammatory actions including inhibition of 
cytokine production and release, reduction of circulating inflammatory cells and 
inhibition of the production and release of arachidonic acid metabolites (Schleimer 1988). 
Toward and Broadley (2004) have shown that dexamethasone inhibits the late 
bronchoconstriction, AHR, and leukocyte influx induced by ovalbumen exposure in 
ovalbumen sensitized guinea-pigs. In this study we attempted to confirm this
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dexamethasone induced inhibition of the inflammation seen in the ovalbumen allergic 
model of allergy in the guinea-pig. We also attempted to establish an exacerbation of the 
ovalbumen-induced responses by PIV-3 virus inoculation in the guinea-pig and to 
determine the effectiveness of dexamethasone in this model.
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6.2 Methods
Ovalbumen sensitization and exposure
On days 1 and 5 guinea-pigs were sensitized with a bilateral i.p. injection of a suspension 
containing lOOpg of ovalbumen and lOOmg of aluminium hydroxide, which is an 
adjuvant and increases the immune response. On day 15 the animals were placed in a 
steel exposure chamber and given a 60 minute inhalation exposure of ovalbumen 
(0.01%). Lung function measurements were taken by whole body plethysmography 
immediately before challenge and at 0, 15, 30,45 and 60 minutes after, then hourly up to 
12 hours and finally at 24 hours.
Histamine exposure
Animals were given a 20 second, nose only histamine exposure on the day before and the 
day after ovalbumen exposure (see pharmacological methods: measurement of airway 
reactivity).
Treatment with dexamethasone
Animal were treated twice daily with dexamethasone (lOmg/kg in saline) or saline 
control by bilateral subcutaneous injection from day 8 to day 14 and 1 hour before 
ovalbumen exposure on day 15.
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Bronchoalveolar lavage
Within 30 minutes of the final histamine exposure the animals were sacrificed with an 
overdose of anaesthetic, pentobarbital sodium, by bilateral intraperitoneal injection and a 
bronchoalveolar lavage was performed (see general methods 2.1.4).
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6.3 Results
6.3.1 Ovalbumen exposure without virus 
Effect o f ovalbumen exposure
In the saline treated group there was a 68.3 ± 5.3 % decrease in sGaw from baseline 
following ovalbumen exposure. After 6 hours sGaw had returned to baseline levels. This 
was followed by a secondary 26.8 ± 3.3% decrease in sGaw which began at 8 hours and 
peaked at 10 hours (Fig 6.1).
In the dexamethasone treated group there was also an immediate decrease in sGaw from 
baseline (45.4 ± 6.6%) following ovalbumen exposure. This decrease was less than seen 
in the saline treated group and sGaw levels returned to baseline levels more quickly (3 
hours). There was no secondary decrease in sGaw levels (Fig 6.1).
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Figure 6.1
Effect of ovalbumen sensitization and exposure on airway function after treatment with 
saline or dexamethasone (lOmg/kg, s.c.). Each point represents the mean ± standard error 
of mean (n=6) change in sGaw expressed as a percentage of the baseline sGaw values, 
shown up to 24 hours after ovalbumen exposure. Negative values represent 
bronchoconstriction. * denotes the significance ( P < 0 .0 5 )  in difference between the 
changes to baseline sGaw values at each time point between the saline and dexamethasone 
treated groups as determined by a Student’s t test (paired).
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Airway reactivity to histamine
After ovalbumen sensitization but before ovalbumen exposure, there was no significant 
decrease in sGaw following inhalation exposure to histamine (Fig. 6.2 and 6.3).
24 hours after ovalbumen exposure in the saline treated group there was a significant 
16.5% reduction in sGaw from baseline levels (Fig 6.2).
In the dexamethasone (lOmg/kg) treated group there was no reduction in sGaw after 
ovalbumen exposure (Fig 6.3).
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Figure 6.2
Effect of saline treatment on airway function in ovalbumen sensitized (i.p., 0.1 mg/kg) 
guinea-pigs before and after ovalbumen exposure (0.01% nebulised, 1 hour). Each point 
represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown at 0, 5 and 10 minutes after a nose only 
ImM histamine exposure. Negative values represent bronchoconstriction. * denotes the 
significance (P<0.05) in difference between the changes to baseline sGaw values at each 
time point, before and after ovalbumen exposure as determined by a Student’s t test 
(paired).
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Figure 6.3
Effect of dexamethasone (lOmg/kg) treatment on airway function in ovalbumen 
sensitized (i.p., 0.1 mg/kg) guinea-pigs before and after ovalbumen exposure (0.01% 
nebulised, 1 hour). Each point represents the mean ± standard error of mean (n=6) change 
in sGaw expressed as a percentage of the baseline sGaw values, shown at 0, 5 and 10 
minutes after a nose only ImM histamine exposure. Negative values represent 
bronchoconstriction. There was no significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point, before and after ovalbumen exposure 
as determined by a Student’s t test (paired).
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Bronchoalveolar lavage
In ovalbumen sensitized, saline challenged and saline treated guinea pigs the numbers of 
macrophages, eosinophils, neutrophils and lymphocytes in the BALF were as follows; 
total cells: 4.38 ± 0.42 (xl06/ml), macrophages: 2.31 ± 0.22 (xl06/ml), eosinophils:
1.95 ± 0.34 (xl06/ml), neutrophils 0.03 ± 0.01 (xl06/ml) and lymphocytes:
0.1 ± 0.02 (xl06/ml) (Fig. 6.4).
In the ovalubumen sensitized and challenged group treated with saline there were 
significant increases in total cells (12.60 ± 1.07 xl06/ml), macrophages (6.13 ± 0.61 
xl06/ml), eosinophils (4.95 ± 0.58x106/ml) and neutrophils (1.32 ± 0.19xl06/ml) and a 
modest in lymphocytes (0.20 ± 0.06x106/ml). After treatment with dexamethasone 
(lOmg/kg, s.c.) these increases in total cells, macrophages, eosinophils and neutrophils 
were significantly reduced though not to baseline levels (5.11 ± 0.27, 2.74 ±0.14, 2.05 ± 
0.12 and 0.24 ± 0.04 xl06/ml respectively). There was also a modest decrease in 
lymphocytes (0.07 ± 0.01 x l06/ml) (Fig. 6.4).
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Figure 6.4
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from ovalbumen sensitized animals challenged and treated with saline, 
challenged with ovalbumen and treated with saline or dexamethasone (10 mg/kg). Each 
bar represents the mean ± standard error of mean (n=6) of total or differential count of 
cells per ml/10 . * denotes the significance (P<0.05) of difference compared to the 
corresponding saline challenged/ saline treated group and + denotes the significance 
(P<0.05) of difference compared to the OA challenged/saline treated group as determined 
by a Student’s t test (paired).
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6.3.2 Effect of combining PIV-3 (3.16 x 108) inoculation with ovalbumen
sensitization and exposure in guinea-pigs
Effect o f ovalbumen exposure
Compared to the ovalbumen sensitized and exposed group without viral inoculation there 
was a significantly smaller reduction in sGaw at 0, 15 and 30 minutes after ovalbumen 
exposure compared to the PIV-3 inoculated group. However the virus free group 
recovered more quickly, significantly so at 7 and 8 hours. The secondary reduction in 
sGaw in the virus free group became significantly different at 11 hours (Fig.6.5).
In the saline treated group with PIV-3 inoculation there was a 28.3 ± 4.8 % decrease in 
sGaw from baseline immediately following ovalbumen exposure. The average maximum 
decrease in sGaw from baseline in the first 6 hours was 44.1 ± 6.5%. There was no clear 
secondary decrease as sGaw levels did not completely return to baseline levels until 11 
hours after exposure (Fig. 6.6).
In the dexamethasone treated group there was also an immediate decrease in sGaw from 
baseline (27.5 ± 5.2%) following ovalbumen exposure. The average maximum decrease 
in sGaw from baseline in the first 6 hours was 36.2 ± 63.3%. sGaw values did not recover 
completely until 24 hours. The only significant difference from the saline group was a 
better recovery at 8 hours (Fig 6.6).
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Figure 6.5
The effect on airway function of saline treatment and ovalbumen sensitization and 
challenge with and without PIV-3 inoculation. Each point represents the mean ± standard 
error of mean (n=6) change in sGaw expressed as a percentage of the baseline sGaw values, 
shown up to 24 hours after ovalbumen exposure. Negative values represent 
bronchoconstriction. * denotes the significance (P<0.05) in difference between the 
changes to baseline sGaw values at each time point with and without virus as determined 
by a Student’s t test (paired).
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Figure 6.6
Effect of combining PIV-3 inoculation with ovalbumen sensitization and exposure on 
airway function after treatment with saline or dexamethasone (lOmg/kg). Each point 
represents the mean ± standard error of mean (n=6) change in sGaw expressed as a 
percentage of the baseline sGaw values, shown up to 24 hours after ovalbumen exposure 
Negative values represent bronchoconstriction. * denotes the significance (P<0.05) in 
difference between the changes to baseline sGaw values at each time point between the 
saline and dexamethasone treated groups as determined by a Student’s t test (paired).
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Airway reactivity to histamine
After ovalbumen sensitization but before exposure and PIV-3 there was no significant 
decrease in sGaw following inhalation exposure to histamine (Figures 6.7 and 6.8).
After ovalbumen exposure and PIV-3 inoculation in the saline treated group there was a 
significant (16.9 ± 4.6 %) reduction in sGaw from baseline levels. Dexamethasone 
(lOmg/kg) treatment had no effect as there was still a significant (15.0 ± 4.8%) decrease 
in sGaw (Figures 6.7 and 6.8).
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Figure 6.7
Effect of saline treatment on airway function in ovalbumen sensitized guinea-pigs before 
and after PIV-3 inoculation and ovalbumen exposure. Each point represents the mean ± 
standard error of mean (n=6) change in sGaw expressed as a percentage of the baseline 
sGaw values, shown at 0, 5 and 10 minutes after a nose only ImM histamine exposure. 
Negative values represent bronchoconstriction.. * denotes the significance (P<0.05) in 
difference between the changes to baseline sGaw values at each time point, before and 
after ovalbumen exposure as determined by a Student’s t test (paired).
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Figure 6.8
Effect of dexamethasone treatment on airway function in ovalbumen sensitized guinea- 
pigs before and after PIV-3 inoculation and ovalbumen exposure. Each point represents 
the mean ± standard error of mean (n=6) change in sGaw expressed as a percentage of the 
baseline sGaw values, shown at 0, 5 and 10 minutes after a nose only ImM histamine 
exposure. Negative values represent bronchoconstriction.. * denotes the significance 
(P<0.05) in difference between the changes to baseline sGaw values at each time point, 
before and after ovalbumen exposure as determined by a Student’s t test (paired).
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Bronchoalveolar lavage
In animals receiving no virus (medium controls), the numbers of macrophages, 
lymphocytes, eosinophils and neutrophils in the BALF were as follows; total cells: 1.54 ± 
0.17 (xl06/ml), macrophages: 1.37 ±0.15 (xl06/ml), eosinophils: 0.12 ± 0.01 (xl06/ml), 
lymphocytes: 0.06 ± 0.02 (xl06/ml) and neutrophils 0.03 ± 0.01 (xl06/ml) (Fig. 6.9).
In the PIV-3 inoculated and ovalubumen sensitized and challenged group treated with 
saline there were significant increases to all cell types as follows: total cells 10.39 ± 1.00, 
macrophages: 4.96 ± 0.44 (xl06/ml), eosinophils: 4.36 ± 0.43 (xl06/ml), lymphocytes: 
0.39 ±0.13 (xl06/ml) and neutrophils 0.69 ± 0.21 (xl06/ml). After treatment with 
dexamethasone (10 mg/kg) all these increases were reduced significantly to the following 
levels: total cells 6.29 ± 0.99, macrophages: 3.69 ± 0.49 (xl06/ml), eosinophils: 2.23 ± 
0.46 (xl06/ml), lymphocytes: 0.14 ± 0.05 (xl06/ml) and neutrophils 0.22 ± 0.08 
(xl06/ml) but not to baseline levels (Fig. 6.9).
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Figure 6.9
Total and differential cell (macrophage, eosinophil, lymphocyte and neutrophil) count of 
BALF removed from media inoculated animals treated with saline and also PIV-3 
inoculated animals, sensitized and challenged with ovalbumen and treated with saline or 
dexamethasone (10 mg/kg). Each bar represents the mean ± standard error of mean (n=6) 
of total or differential count of cells per ml/10 . * denotes the significance (P<0.05) of 
difference compared to the corresponding media inoculated/saline treated group and + 
denotes the significance (P<0.05) of difference compared to the PIV-3/ovalbumen saline 
treated group as determined by a Student’s t test (paired).
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6.4 Discussion
Ovalbumen sensitization and exposure without virus
Immediately following ovalbumen exposure there was a significant bronchoconstriction 
in ovalbumen sensitized and saline treated guinea-pigs. After 6 hours there was a 
recovery to baseline levels then a secondary bronchoconstriction at around 9 hours. These 
are the early and late asthmatic responses. These responses are also seen in asthmatics 
(Inman et al 1995). Antigen challenge in sensitized animals causes the release of 
histamine, leukotrienes, prostaglandin and PAF from mast cells and macrophages causing 
bronchoconstriction via airways smooth muscle (Brocklehurst, 1960; Piper and Vane 
1969). The EAR is thought to be mediated by mast cells as mast cell derived mediators 
including histamine, cysteine-leukotriens PGD2, and tryptase are found in the lavage fluid 
of asthmatics at this time (Lui et al 1991, Casale et al 1987). After dexamethasone 
treatment there was also an immediate bronchoconstriction after ovalbumen exposure in 
ovalbumen sensitized animals. Dexamethasone treatment reduced the immediate 
bronchoconstriction and also the duration as there was complete recovery after 3 hours. 
Corticosteroids do not usually inhibit the EAR in guinea-pig experimental models 
(Toward and Broadley 2004) or clinically (Cockcroft and Murdock 1987).
Dexamethasone treatment abolished the secondary bronchoconstriction. The LAR is 
usually susceptible to corticosteroids clinically (Paggiaro et al 1994) and in guinea-pigs 
(Toward and Broadley 2004). Eosinophils are thought to play an important role in the 
LAR. Katoh et al (1991) have shown that eosinophil infiltration in the lungs is required 
for the development of the LAR in passively sensitized guinea pigs. In patients who
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developed a LAR increased eosinophilia was found compared to patients who did not 
show this late response (Durham and Kay 1985).
In ovalbumen sensitized and exposed guinea-pigs there were significant increases in total 
cells, macrophages, eosinophils and neutrophils and a modest increase in lymphocytes 
after saline treatment. After dexamethasone treatment the increases in total cells, 
macrophages, eosinophils and neutrophils were significantly reduced though not to 
baseline levels. There was also a modest decrease in lymphocytes. Allergen can cause the 
release of cytokines including IL-3, IL-5, IL-8, GM-CSF, TNF and eotaxin from T cells 
causing the migration of eosinophils into the airways and their activation (Corrigan and 
Kay 1992).
After ovalbumen sensitization but before ovalbumen exposure there was no 
bronchoconstriction to a ImM exposure to histamine. After ovalbumen sensitization and 
exposure there was a significant bronchoconstriction after histamine exposure indicating 
AHR. After dexamethasone treatment the AHR was abolished as there was no 
bronchoconstriction after histamine exposure in ovalbumen sensitized and exposed 
animals. Eosinophil accumulation in the bronchial wall is a characteristic feature of 
asthma (Gleich et al 2000). Release of eosiniphilic products including major basic 
protein, eosinophilic cationic protein and eosinophilic peroxidase can lead to tissue 
damage and are thought to play a role in the AHR seen in asthma (Pease and Williams 
2001).
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Ovalbumen sensitization and exposure in PIV-3 inoculated guinea-pigs
Immediately following ovalbumen exposure there was a significant bronchoconstriction 
in ovalbumen sensitized and saline treated guinea-pigs inoculated with PIV-3. The 
secondary bronchoconstriction seen after ovalbumen exposure in ovalbumen sensitized 
animals without virus was absent as there was a prolonged bronchoconstiction which did 
not recover fully for 11 hours. This represents an exacerbation of the bronchoconstrictor 
response to ovalbumen. This model could help with the understanding of asthma as viral 
respiratory infections are the most common cause of asthma exacerbations (Pattemore et 
al 1992). Dexamethasone treatment had little effect on the initial bronchoconstriction or 
the rate of recovery. This represents steroid resistance as this dose of dexamethasone was 
enough to inhibit the LAR, AHR and cell influx without virus and the cell influx in this 
experiment. Steroid resistance is important clinically as a small proportion of asthmatics 
fail to respond to even high doses of oral glucocorticocoids (Cypcar and Busse 1993). 
Steroid resistance can be caused by abnormalities of the steroid receptor (Lamberts et al
1992) or a resistance to the anti-inflammatory actions of steroids (Barnes and Adcock 
1995). In COPD, HDAC2 activity and expression are reduced in the peripheral lung. 
Corticosteroid resistance in COPD occurs because corticosteroids use HDAC2 to switch 
off activated inflammatory genes (Barnes 2009).
After ovalbumen sensitization but before ovalbumen exposure and PIV-3 inoculation 
there was no bronchoconstriction to a ImM exposure of histamine in saline treated 
guinea-pigs. After ovalbumen sensitization and exposure there was a significant 
bronchoconstriction after histamine exposure in PIV-3 inoculated animals indicating
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AHR. Dexamethasone treatment had no effect on AHR as there was still a significant 
bronchoconstriction after histamine exposure.
In ovalbumen sensitized and exposed guinea-pigs inoculated with PIV-3 there were 
significant increases in total cells, macrophages, eosinophils, neutrophils and 
lymphocytes after saline treatment. After dexamethasone treatment the increases in total 
cells, macrophages, eosinophils, neutrophils and lymphocytes were significantly reduced 
though not to baseline levels. So the cellular component is not steroid resistant. The other 
responses (EAR, LAR and AHR) are therefore independent of cell influx.
The addition of PIV-3 to the ovalbumen model of allergy in the guinea-pig produced, in 
addition to the AHR and inflammatory cell influx, a prolonged bronchoconstriction as 
opposed to the distinct early and late phases seen without virus. The allergen induced 
bronchoconstriction and the AHR appear to be resistant to dexamethasone. It seems that 
the allergen induced bronchconstriction and the AHR are not mediated by inflammatory 
cells as dexamethasone inhibited the leukocyte influx but not the bronchonstriction or the 
AHR. It should be noted that although dexamethasone did inhibit the cell influx it was 
not to baseline levels.
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Chapter 7
General discussion
206
Viral model of inflammation
One of the primary aims of this study was to develop a model of virus-induced airway 
inflammation in the guinea-pig which demonstrated airway hyperreactivity, inflammatory 
cell influx and pulmonary oedema in the form of increased wet lung weight. We used a 
number of different virus types, strains and titres in order to compare the effects of these 
different inoculums on airway inflammation and to produce sufficient inflammation to 
enable us to show significant inhibition after later drug intervention experiments.
A concentration of 1 x 108 infectious units per ml of PIV-2 produced significant 
inflammation in the form of airway hyperreactivity, inflammatory cell influx and 
increased wet lung weight. A smaller concentration of PIV-3 (6.32 x 106 infectious units 
per ml) produced a similar or slight increase in the level of inflammation. After 
inoculation with a higher concentration of the same strain of PIV-3 (3 x 108 infectious 
units per ml) there was an increase in airway hyperreactivity and wet lung weight but 
similar levels of inflammatory cell influx. PIV-3 appears to be more pathogenic than 
PIV-2 in the guinea-pig and the effects of PIV-3 appear to be concentration-dependent 
with the exception of inflammatory cell influx. It must be noted thiat in this experiment 
we were comparing two specific strains of PIV-2 and PIV-3 so the conclusions reached 
here may not apply to all strains of these viruses. The reason for the lack of increase in 
inflammatory cell influx after increasing the concentration of PIV-3 is unknown but 
could be due to reaching the maximum effect with this virus.
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Inoculation with the WSN33 strain of influenza H1N1 grown in MDCK cells produced a 
small increase in inflammatory cells but no airway hyperreactivity or increased wet lung 
weight. After inoculation with a similar concentration of die A/PR/8/34 strain of H1N1 
influenza grown in chicken embryos there was a significant increase in inflammatory 
cells, a small increase in wet lung weight but still no airway hyperreactivity. Inoculation 
with an increased concentration of the A/PR/8/34 strain did produce airway 
hyperreactivity and a further small increase in wet lung weight. The inflammatory cells 
were increased compared to control but decreased compared to the lower concentration of 
the same virus. The reason for these contradictory results on inflammatory cell influx is 
unknown but it is interesting to note that there was a similar lack of effect with the 
increased concentration of PIV-3. In this experiment the virus grown in chicken embryos 
appears to be more pathogenic in guinea-pigs but once more it must be noted that we 
were comparing two different strains of virus. An interesting additional experiment 
would be to further increase the concentration in the inoculum of the A/PR/8/34 strain of 
H1N1 influenza grown in chicken embryos to determine whether the level of airway 
hyperreactivity increased and clarify the effects on inflammatory cell influx.
Steroid intervention
Dexamethasone (lOmg/kg in all experiments) abolished the airway hyperreactivity after 
PIV inoculation in all experiments. Dexamethasone reduced the inflammatory cell influx 
after all PIV inoculation, significantly with PIV-3 but to a lesser extent after PIV-2. The 
reason for the lack of significance in the PIV-2 experiment is likely due to the smaller 
inflammatory cell influx seen in the 50% DMSO control. Dexamethasone also reduced
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the increase in wet weight seen after PIV inoculation. In the PIV-2 and PIV-3 (lower 
concentration) experiments dexamethasone was administered in 50% DMSO so the 
control was also 50% DMSO. In most of these control experiments DMSO appeared to 
have an inhibitory effect on the PIV induced inflammation compared to the saline control 
(for the FE999024 experiments). Due to this effect we reduced the DMSO concentration 
in the control and dexamethasone experiments to 25%. In subsequent experiments this 
inhibitory effect of DMSO effect was not seen. Anti-inflammatory effects of DMSO have 
been reported previously (Santos et al 2003). It has been shown to inhibit IL-8 production 
by human whole blood and decreases NF-kB activation in a macrophage cell line and 
TNF-a activity (Kelly et al 1994).
Dexamethasone reduced the airway hyperreactivity seen after inoculation with the 
A/PR/8/34 strain of influenza H1N1 grown in chicken embiyo. Dexamethasone also 
significantly reduced the inflammatory cell influx and reduced the small increase in wet 
lung weight to baseline levels. These actions of dexamethasone can be attributed to its 
inhibitory effects on transcription of pro-inflammatory cytokines (Barnes and Adcock 
1993).
Dexamethasone also reduced the amount of live PIV-3 recovered from the lung tissue 
and subsequently re-grown in VERO cells. Dexamethasone did not have a significant 
effect due to the large amount of variation in virus recovered from each animal. This is 
confirmed by a previous study which shows that dexamethasone reduced the titres of 
virus recovered from the lung after sendai virus (PIV-1) infection in guinea pigs (Moreno
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et al 2003). The mechanism of this antiviral action of dexamethasone may be on die 
epithelial cells which are the primary target for viral entry to the lungs. Dexamethasone 
may inhibit key molecules involved in viral entry and replication (Moscona 2005).
Effects of bradykfnin on the airways
Bradykinin exposure (ImM) with inhibition of ACE by captopril and/or NEP with 
phophoramidon (inhalation but not i.p.) produced a significant bronchoconstriction in 
conscious guinea-pigs. Captopril alone, phosphoramidon alone and both phophoramidon 
together all produced similar sized bronchoconstrictions after bradykinin exposure. This 
bronchoconstriction was blocked with the selective bradykinin B2 antagonist MEN16132 
(inhalation but not i.p.) but not by icatibant (inhalation). This confirms previous reports 
that showed bronchoconstriction was mediated via bradykinin B2 receptors (Fuller et al 
1987).
There was no significant increase in inflammatory cells after bradykinin exposure after 
captopril treatment alone but after both captopril and phosphoramidon there was a 
significant increase. This appears to indicate that inhibition of both ACE and NEP are 
required to prolong the duration of bradykinin in the lung long enough to have an effect 
on inflammatory cell influx. To confirm this conclusion an additional experiment would 
be required with phosphoramidon but without captopril as phosphoramidon may be 
having the dominant effect. Therefore under the right conditions, inhaled bradykinin 
increases cell influx and bronchoconstriction in conscious guinea-pigs. This finding of 
inflammatory cell influx does not appear to have been made before. The mechanism may
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involve release of neurokinins from sensory nerve endings since SP and NKA are known 
to cause leakage of inflammatory cells (N&iana et al 2001). It would be interesting to 
examine whether neurokinin inhibitors block the inflammatory cell influx induced by 
bradykinin.
The role of bradykinin in airway inflammation
The lowest dose (1 mg/kg) of tissue kallikrein inhibitor FE999024 had little effect on the 
PIV-3 induced airway inflammation in the guinea pigs. In fact the level of airway 
hyperreactivity was increased slightly. The 3mg/kg dose generally had a small but 
incomplete inhibitory effect on the PIV induced inflammation. The highest dose 
(lOmg/kg) completely abolished the airway hyperreactivity but had variable effects on 
inflammatory cell influx and wet lung weight. There was inhibition of the cell influx in 
the PIV-2 and the lower concentration of PIV-3 by the lOmg/kg dose but no effect after 
inoculation with the higher concentration of PIV-3. This lack of effect could be due to the 
effect of the increased inflammation induced by the higher concentration of PIV-3 
overcoming the inhibitory effect of FE999024 even at the 10 mg/kg dose. In the PIV-3 
experiments only the highest dose of FE999024 had a significant inhibitory effect on the 
increase in wet lung weight. In the PIV-2 experiments no dose of FE999024 had a 
significant effect on wet lung weight. In these experiments the lowest dose of FE999024 
had the strongest inhibitory effect and the highest dose had the weakest effect. The reason 
for this is unknown. Inhibition suggests that bradykinin has a role in inflammation arising 
from viral infection. Christiansen et al (1992) have shown that kinin levels are increased 
in BALF of asthmatics after allergen challenge.
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In PIV-3 (high concentration) inoculated guinea-pigs the bradykinin B2 antagonist 
MEN 16132 abolished the airway hyperreactivity and reduced the inflammatory cell 
influx seen in the control. Previous studies have shown that icatibant can inhibit PIV-3 
induced inflammation (Folkerts et al 1997) but this may be the first study to use 
MEN 16132. The inhibition of the PIV-3 induced inflammatory cell influx with 
MEN16132 appears to contradict the previous result in this study where even at the 
highest dose used the tissue kallikrein inhibitor FE999024 failed to block the cell influx 
induced by inoculation with the same concentration of PIV-3. FE999024 has its effect by 
reducing bradykinin levels and MEN16132 acts through blocking bradykinin B2 receptors 
so it is interesting that only MEN16132 can block this bradykinin mediated cell influx. 
This indicates that even after treatment with FE999024 there may still be some residual 
bradykinin activity at the B2 receptors. B2 receptor expression can be up-regulated in 
airway inflammation (Huang et al 1999; Christiansen et al 2002) and this could be an 
important factor.
Ovalbumen allergic model
After ovalbumen exposure in ovalbumen sensitized guinea-pigs there was an immediate 
bronchoconstriction followed by recovery and a secondary bronchoconstriction peaking 
at 8 hours which mimics the EAR and LAR seen in asthma. These are the well 
established responses of conscious guinea-pigs to ovalbumen challenge (Smith and 
Broadley 2007). There was also airway hyperreactivity to histamine and inflammatory 
cell influx. Bradykinin also displayed airway hyperreactivity to its bronchoconstrictor
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the increase in wet weight seen after PIV inoculation. In the PIV-2 and PIV-3 (lower 
concentration) experiments dexamethasone was administered in 50% DMSO so the 
control was also 50% DMSO. In most of these control experiments DMSO appeared to 
have an inhibitory effect on the PIV induced inflammation compared to the saline control 
(for the FE999024 experiments). Due to this effect we reduced the DMSO concentration 
in the control and dexamethasone experiments to 25%. In subsequent experiments this 
inhibitory effect of DMSO effect was not seen. Anti-inflammatory effects of DMSO have 
been reported previously (Santos et al 2003). It has been shown to inhibit IL-8 production 
by human whole blood and decreases NF-kB activation in a macrophage cell line and 
TNF-a activity (Kelly et al 1994).
Dexamethasone reduced the airway hyperreactivity seen after inoculation with the 
A/PR/8/34 strain of influenza H1N1 grown in chicken embryo. Dexamethasone also 
significantly reduced the inflammatory cell influx and reduced the small increase in wet 
lung weight to baseline levels. These actions of dexamethasone can be attributed to its 
inhibitory effects on transcription of pro-inflammatory cytokines (Barnes and Adcock
1993).
Dexamethasone also reduced the amount of live PIV-3 recovered from the lung tissue 
and subsequently re-grown in VERO cells. Dexamethasone did not have a significant 
effect due to the large amount of variation in virus recovered from each animal. This is 
confirmed by a previous study which shows that dexamethasone reduced the titres of 
virus recovered from the lung after sendai virus (PIV-1) infection in guinea pigs (Moreno
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et al 2003). The mechanism of this antiviral action of dexamethasone may be on the 
epithelial cells which are the primary target for viral entry to the lungs. Dexamethasone 
may inhibit key molecules involved in viral entry and replication (Moscona 2005).
Effects of bradykinin on the airways
Bradykinin exposure (ImM) with inhibition of ACE by captopril and/or NEP with 
phophoramidon (inhalation but not i.p.) produced a significant bronchoconstriction in 
conscious guinea-pigs. Captopril alone, phosphoramidon alone and both phophoramidon 
together all produced similar sized bronchoconstrictions after bradykinin exposure. This 
bronchoconstriction was blocked with the selective bradykinin B2 antagonist MEN 16132 
(inhalation but not i.p.) but not by icatibant (inhalation). This confirms previous reports 
that showed bronchoconstriction was mediated via bradykinin B2 receptors (Fuller et al 
1987).
There was no significant increase in inflammatory cells after bradykinin exposure after 
captopril treatment alone but after both captopril and phosphoramidon there was a 
significant increase. This appears to indicate that inhibition of both ACE and NEP are 
required to prolong the duration of bradykinin in the lung long enough to have an effect 
on inflammatory cell influx. To confirm this conclusion an additional experiment would 
be required with phosphoramidon but without captopril as phosphoramidon may be 
having the dominant effect. Therefore under the right conditions, inhaled bradykinin 
increases cell influx and bronchoconstriction in conscious guinea-pigs. This finding of 
inflammatory cell influx does not appear to have been made before. The mechanism may
214
involve release of neurokinins from sensory nerve endings since SP and NKA are known 
to cause leakage of inflammatory cells (Ndnana et al 2001). It would be interesting to 
examine whether neurokinin inhibitors block die inflammatory cell influx induced by 
bradykinin.
The role of bradykinin in airway inflammation
The lowest dose (1 mg/kg) of tissue kallikrein inhibitor FE999024 had little effect on the 
PIV-3 induced airway inflammation in the guinea pigs. In fact the level of airway 
hyperreactivity was increased slightly. The 3mg/kg dose generally had a small but 
incomplete inhibitory effect on the PIV induced inflammation. The highest dose 
(lOmg/kg) completely abolished die airway hyperreactivity but had variable effects on 
inflammatory cell influx and wet lung weight. There was inhibition of the cell influx in 
the PIV-2 and the lower concentration of PIV-3 by the lOmg/kg dose but no effect after 
inoculation with the higher concentration of PIV-3. This lack of effect could be due to the 
effect of the increased inflammation induced by the higher concentration of PIV-3 
overcoming the inhibitory effect of FE999024 even at the 10 mg/kg dose. In the PIV-3 
experiments only the highest dose of FE999024 had a significant inhibitory effect on the 
increase in wet lung weight. In the PIV-2 experiments no dose of FE999024 had a 
significant effect on wet lung weight. In these experiments the lowest dose of FE999024 
had the strongest inhibitory effect and the highest dose had the weakest effect. The reason 
for this is unknown. Inhibition suggests that bradykinin has a role in inflammation arising 
from viral infection. Christiansen et al (1992) have shown that kinin levels are increased 
in BALF of asthmatics after allergen challenge.
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In PIV-3 (high concentration) inoculated guinea-pigs the bradykinin B2 antagonist 
MEN16132 abolished the airway hyperreactivity and reduced the inflammatory cell 
influx seen in the control. Previous studies have shown that icatibant can inhibit PIV-3 
induced inflammation (Folkerts et al 1997) but this may be the first study to use 
MEN16132. The inhibition of the PIV-3 induced inflammatory cell influx with 
MEN16132 appears to contradict the previous result in this study where even at the 
highest dose used the tissue kallikrein inhibitor FE999024 failed to block the cell influx 
induced by inoculation with the same concentration of PIV-3. FE999024 has its effect by 
reducing bradykinin levels and MEN16132 acts through blocking bradykinin B2 receptors 
so it is interesting that only MEN16132 can block this bradykinin mediated cell influx. 
This indicates that even after treatment with FE999024 there may still be some residual 
bradykinin activity at the B2 receptors. B2 receptor expression can be up-regulated in 
airway inflammation (Huang et al 1999; Christiansen et al 2002) and this could be an 
important factor.
Ovalbumin allergic model
After ovalbumin exposure in ovalbumin sensitized guinea-pigs there was an immediate 
bronchoconstriction followed by recovery and a secondary bronchoconstriction peaking 
at 8 hours which mimics the EAR and LAR seen in asthma. These are the well 
established responses of conscious guinea-pigs to ovalbumin challenge (Smith and 
Broadley 2007). There was also airway hyperreactivity to histamine and inflammatory 
cell influx. Bradykinin also displayed airway hyperreactivity to its bronchoconstrictor
216
effect which represents a novel finding. This was achieved in the absence of any 
metabolism inhibitors. This is similar to the effect seen in asthmatics where inhalation of 
bradykinin causes bronchoconstriction, but has little or no effect in non-asthmatics 
(Fuller et al 1987). The LAR and the airway hyperreactivity were blocked with 
dexamethasone and the inflammatory cell influx was also reduced.
Viral exacerbations in ovalbumin allergic model
After ovalbumin exposure in ovalbumin sensitized guinea-pigs inoculated with PIV-3 
there was an immediate prolonged bronchoconstriction which did not fully recover until 
11 hours. There was airway hyperreactivity and inflammatory cell influx. This represents 
an exacerbation of the response to allergen exposure and mimics the exacerbations of 
asthma that occur with viral infection (Frick et al 1979). Dexamethasone had little effect 
on the immediate prolonged bronchconstriction, or the airway hyperreactivity but did 
reduce the inflammatory cell influx. This indicates steroid resistance in a guinea-pig 
model of viral exacerbations of allergy and is novel to this study. This is therefore a 
model for steroid resistance in humans which is known to be brought about by viral 
infections (Macek et al 1994).
Future experiments
In this study we inhibited PIV-induced inflammation with the bradykinin inhibitors 
FE999024 and MEN 16132 and also dexamethasone and treated the influenza-induced 
inflammation with dexamethasone. We have also shown a role for bradykinin in virus 
induced inflammation. It would be interesting to attempt to treat the ovalbumin and
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influenza induced inflammation with the bradykinin inhibitors. If successful in treating 
the allergic model with either of the bradykinin inhibitors then a further experiment 
would be to treat the viral exacerbation of allergy model with this drug. Having 
established the model of steroid resistance it would be beneficial to determine the 
underlying mechanisms of steroid resistance in human asthma. For example, are the 
levels of HD AC-2 altered and does this serve as a marker of steroid resistance. The 
present studies therefore provide the first steps in establishing the underlying mechanisms 
for steroid resistant asthma and possible ways in the future for developing new treatments 
for overcoming this major problem in asthma management.
Conclusions
This study confirms the role of bradykinin in viral inflammation. In this study we used 
virus models but B2 antagonists and kallikrein inhibitors may also have application in 
other forms of airway inflammation such as asthma.
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Appendix
Poiseulle’s Law:
(1) AP = 81|iv/ n r where AP = drop in pressure due to friction
L = length of tube 
p = viscosity 
v = flow rate 
r = radius
Poiseulle’s law describes laminar flow in smooth walled vessels where there is no 
appreciable turbulence. This equation can also be used to describe the changes in pressure 
in the airways in response to changes in airway length and radius.
Flow through the airway is driven by the pressure difference (Pd) between the upper 
airway pressure at the mouth (P m) and the peripheral airway pressure at the alveoli (Paiv).
Pd — Pm — Palv
Airway resistance (Raw) is defined as the relationship between instantaneous flow (v) and 
the pressure difference (Pd) between the mouth and the alveoli
. Raw = Pd/v
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Airway conductance (Gaw) is describes as the reciprocal of resistance 
Gaw RaW -1 — v/P j
To allow comparison between differences in thoracic gas volume (TGV) in individuals 
sGaw is often used.
(2) sGaw = v/Pd xTGV
Boyle’s law states that in a sealed box, at constant temperature, changes in pressure are 
inversely related to changes in gas volume. Therefore at constant temperature:
PI x VI =P2 x V2
or
P x  V + (P + 5 P ) x ( V - 5 V )
By multiplying the two brackets:
P x V  = p x V - P x 8 V  + V x 8 P - 5 P x 5 V
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As 5P x 8V is negligible
V x 8P = P x 5V
In a sealed plethysmography chamber, changes in box pressure result from the difference 
in chest volume (Vc) and respired air volume changes (Vr) at atmospheric pressure (Patm), 
corrected for saturated water vapour pressure (Psvp).
(3) 8Pd x TGV = 5 (Vc -V r) x (Patm - Psvp)
For Poiseulle’s law to be true, flow must be laminar and so v must tend towards zero. 
This occurs at end during end expiration and end inspiration. In this study measurements 
were taken at the end of expiration
By substitution equation (2) into (3) gives
sGaw 5v/ 5(Vchest” Vrespir) x (Patm " Psvp)
Use of the Biopac data acquisition system allows measurement of 5(VChest- Vrespir) as the 
slope of the change in box volume, where flow tends towards zero. It is then possible to 
record the simultaneous change in flow.
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Atmospheric pressure (Patm) = 1010 cm H2O 
Saturated vapour pressure (Psvp) = 63 cm H2O
Therefore sGaw can be calculated from the following equation
sGaw = 8v/ 5(Vbox) x 947 x cf s 1 cm H20
cf is the correction factor to allow for the displacement of air by each guinea pig.
The net volume of the plethysmography chamber after displacement by the guinea pig is:
Vn (litres) =Vbox-Vgp
Therefore:
cf= (V box-V gp)
cf = 1 - (Vgp/Vbox) 
cf= 1 - Wgp/PgpXPb  ^
cf = 1 - Wgp/5.885
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Therefore sGaw can be calculated by the following equation: 
sGaw= 5(flow)/ 6(box volume) x 947 x (1 -  Wgp/5.885) s 1 cm H2O
